<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Screen Them All: High-Throughput Pan-Cancer Genetic and Phenotypic Biomarker Screening from H&amp;E Whole Slide Images</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability  status="unknown">
					<licence/>
				</availability>
				<date type="published" when="2025-07-14">14 Jul 2025</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Yi</forename><forename type="middle">Kan</forename><surname>Wang</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution">NYC</orgName>
								<address>
									<settlement>Paige</settlement>
									<region>NY</region>
									<country key="US">United States</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ludmila</forename><surname>Tydlitatova</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution">NYC</orgName>
								<address>
									<settlement>Paige</settlement>
									<region>NY</region>
									<country key="US">United States</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jeremy</forename><forename type="middle">D</forename><surname>Kunz</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution">NYC</orgName>
								<address>
									<settlement>Paige</settlement>
									<region>NY</region>
									<country key="US">United States</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gerard</forename><surname>Oakley</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution">NYC</orgName>
								<address>
									<settlement>Paige</settlement>
									<region>NY</region>
									<country key="US">United States</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Bonnie</forename><surname>Kar</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Bo</forename><surname>Chow</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution">NYC</orgName>
								<address>
									<settlement>Paige</settlement>
									<region>NY</region>
									<country key="US">United States</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ran</forename><forename type="middle">A</forename><surname>Godrich</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution">NYC</orgName>
								<address>
									<settlement>Paige</settlement>
									<region>NY</region>
									<country key="US">United States</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Matthew</forename><forename type="middle">C H</forename><surname>Lee</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution">NYC</orgName>
								<address>
									<settlement>Paige</settlement>
									<region>NY</region>
									<country key="US">United States</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hamed</forename><surname>Aghdam</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution">NYC</orgName>
								<address>
									<settlement>Paige</settlement>
									<region>NY</region>
									<country key="US">United States</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Alican</forename><surname>Bozkurt</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution">NYC</orgName>
								<address>
									<settlement>Paige</settlement>
									<region>NY</region>
									<country key="US">United States</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Michal</forename><surname>Zelechowski</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution">NYC</orgName>
								<address>
									<settlement>Paige</settlement>
									<region>NY</region>
									<country key="US">United States</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Chad</forename><surname>Vanderbilt</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution" key="instit1">Memorial Sloan Kettering Cancer Center</orgName>
								<orgName type="institution" key="instit2">NYC</orgName>
								<address>
									<region>NY</region>
									<country key="US">United States</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christopher</forename><surname>Kanan</surname></persName>
							<affiliation key="aff2">
								<orgName type="institution">University of Rochester</orgName>
								<address>
									<settlement>Rochester</settlement>
									<region>NY</region>
									<country key="US">United States</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Juan</forename><forename type="middle">A</forename><surname>Retamero</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution">NYC</orgName>
								<address>
									<settlement>Paige</settlement>
									<region>NY</region>
									<country key="US">United States</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Peter</forename><surname>Hamilton</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution">NYC</orgName>
								<address>
									<settlement>Paige</settlement>
									<region>NY</region>
									<country key="US">United States</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Razik</forename><surname>Yousfi</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution">NYC</orgName>
								<address>
									<settlement>Paige</settlement>
									<region>NY</region>
									<country key="US">United States</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Thomas</forename><forename type="middle">J</forename><surname>Fuchs</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution">NYC</orgName>
								<address>
									<settlement>Paige</settlement>
									<region>NY</region>
									<country key="US">United States</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">David</forename><forename type="middle">S</forename><surname>Klimstra</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution">NYC</orgName>
								<address>
									<settlement>Paige</settlement>
									<region>NY</region>
									<country key="US">United States</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Siqi</forename><surname>Liu</surname></persName>
							<email>siqi.liu@paige.ai</email>
							<affiliation key="aff0">
								<orgName type="institution">NYC</orgName>
								<address>
									<settlement>Paige</settlement>
									<region>NY</region>
									<country key="US">United States</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Screen Them All: High-Throughput Pan-Cancer Genetic and Phenotypic Biomarker Screening from H&amp;E Whole Slide Images</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2025-07-14">14 Jul 2025</date>
						</imprint>
					</monogr>
					<idno type="MD5">E332E615EDB9A249A39CC9D89686E977</idno>
					<idno type="arXiv">arXiv:2408.09554v4[q-bio.QM]</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-09-28T13:56+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">a91ee48</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=0, consolidateHeader=0, consolidateFunders=0, includeRawAffiliations=false, includeRawCitations=false, includeRawCopyrights=false, generateTeiIds=false, generateTeiCoordinates=[], sentenceSegmentation=false, flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Molecular assays are standard of care for detecting genomic alterations in cancer prognosis and therapy selection but are costly, tissue-destructive and time-consuming. Artificial intelligence (AI) applied to routine hematoxylin and eosin (H&amp;E)-stained whole slide images (WSIs) offers a fast and economical alternative for screening molecular biomarkers. We introduce OmniScreen, a high-throughput AI-based system leveraging Vir-chow2 embeddings extracted from 60,529 cancer patients with paired 489gene MSK-IMPACT targeted biomarker panel and WSIs. Unlike conventional approaches that train separate models for each biomarker, Om-niScreen employs a unified model to predict a broad range of clinically relevant biomarkers across cancers, including low-prevalence targets impractical to model individually. OmniScreen reliably identifies therapeutic targets and shared phenotypic features across common and rare tumors. We investigate the biomarker prediction probabilities and accuracies of OmniScreen in relation to tumor area, cohort size, histologic subtype alignment, and pathway-level morphological patterns. These findings underscore the potential of OmniScreen for routine clinical screening.</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1">Introduction</head><p>Single and multi-gene assays have revolutionized personalized cancer treatments by identifying targetable genomic alterations <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref>. For example, androgen receptor (AR) variants predict endocrine versus chemotherapy resistance in metastatic castrate resistant prostate cancer (mCRPC) <ref type="bibr" target="#b3">[4]</ref>, while BRCA1/2 germline mutations guide poly(ADP-ribose) polymerase (PARP) inhibitor use in the treatment of high-risk early stage HER2-negative breast cancer <ref type="bibr" target="#b4">[5]</ref>. Commercial assays such as Oncotype DX, MammaPrint and Decipher provide valuable prognostic insights but are costly, time-consuming, and require substantial tissue samples, limiting their utility in cases with scarce tumor material <ref type="bibr" target="#b5">[6]</ref>. Minimally invasive approaches, such as liquid biopsies, have emerged to address these issues but face challenges including low sample yield, variability in cell collection and stabilization procedures, and reduced sensitivity and specificity due to the presence of non-tumor mutated clones in the blood of patients without cancer <ref type="bibr" target="#b6">[7,</ref><ref type="bibr" target="#b7">8]</ref> Digital biomarkers derived from routine H&amp;E WSIs may sidestep many of these limitations. By leveraging widely available WSIs and digital image analysis, such biomarkers could enable rapid, cost-effective and tissue-sparing screening, especially if clinically important genomic biomarkers can be identified. Such applications could complement existing workflows by prioritizing cases for definitive genomic testing while excluding those unlikely to yield actionable results, thereby improving efficiency in both cost and turnaround time. Beyond clinical applications, digital biomarkers could accelerate drug development and clinical trials by facilitating novel target discovery, optimizing patient stratification, and improving the cost efficiency and success rates of clinical studies <ref type="bibr" target="#b8">[9,</ref><ref type="bibr" target="#b9">10]</ref>. Moreover, robust digital biomarkers could eventually serve as companion diagnostics in clinical practice, integrating seamlessly into precision oncology workflows.</p><p>Recent studies have demonstrated the ability of machine learning methods to identify morphological features in routine H&amp;E histopathology images that are associated with genomic abnormalities across various cancer types, enabling the prediction of clinically actionable genomic alterations directly from WSI analysis <ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref>. However, most of these efforts focused on single biomarkers for specific tissues or cancer types, limiting their generalizability due to restricted training data and overlooking shared morphological patterns across cancers. Additionally, developing separate models for each biomarker is both resourceintensive and inefficient. Despite advances in digital pathology, the simultaneous identification of multiple biomarkers across diverse tumor types remains limited, largely due to insufficient access to genomically characterized WSIs. Existing datasets, such as The Cancer Genome Atlas (TCGA), have been widely used for multi-biomarker studies but were primarily designed for genomic research, with digital image submission as a secondary priority <ref type="bibr" target="#b16">[17]</ref>. Variability in image quality and sequencing methods may impact model performance and introduce biases in predictive accuracy <ref type="bibr" target="#b17">[18,</ref><ref type="bibr" target="#b18">19]</ref>.</p><p>Here, we present an approach to high-throughput screening for clinically relevant genomic abnormalities applicable to all cancer types using routine H&amp;E-stained whole slide images (Figure <ref type="figure" target="#fig_0">1</ref>). By leveraging image representations from Virchow2, a foundation model pre-trained on 3 million slides <ref type="bibr" target="#b19">[20,</ref><ref type="bibr" target="#b20">21]</ref>, we develop OmniScreen, a model capable of simultaneously predicting 1,637 biomarkers across 71 human cancers. OmniScreen was trained and tested on a cohort of 75,383 WSIs obtained from 60,529 patients, sourced from Memorial Sloan Kettering Cancer Center (MSKCC) and TCGA. MSKCC is a large cohort of WSIs with associated comprehensive molecular characterization, with single institution control of tissue processing, image generation, and molecular characterization using the Food and Drug Administration (FDA)-approved Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Targets (MSK-IMPACT) next-generation sequencing (NGS) panel. This eliminates many of the limitations of other public databases. Inclusion of TCGA ensures generalizability to other tissue processing methods, staining procedures, and molecular characterization methods.</p><p>We evaluated our model across diverse tumor types, identifying clinically relevant biomarkers associated with driver genomic alteration, histologic phenotypes, actionable targets for FDA-approved therapies, molecular pathways and genome instability. We further examined the impact of training sample size and tumor area within WSIs on biomarker prediction. Finally, we compared OmniScreen to the conventional methods that involve training separate models for individual biomarkers. By enabling scalable and accurate predictions from H&amp;E-stained WSIs, our model demonstrates the potential to complement molecular assays, refine prognostic assessments, guide therapeutic strategies, and address challenges in integrating image-based biomarkers into clinical oncology.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2">Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1">OmniScreen enables high-throughput pan-cancer biomarker screening</head><p>Our model, OmniScreen, simultaneously predicts the likelihood of 1,637 biomarkers, representing genomic features derived from the MSK-IMPACT panel of 489 cancer-related genes. These biomarkers include pathogenic alterations, measures of genomic instability, and alterations in groups of genes involved in shared signaling pathways (Figures S1, S2, Methods 4.2). We evaluated biomarker performance across tumor types in both primary and metastatic sites (Figures <ref type="figure">S3A-B</ref>). To address different use cases, we defined filtering criteria to categorize biomarkers into tiers, as outlined in Table <ref type="table">S3</ref> (see Methods 8.1.2). The baseline criteria identified 739 genetic alteration biomarkers (AUC &gt; 0.5), spanning 346 genes in 43 cancer types, exceeding the threshold expected by chance. Notably, the accuracy of biomarker predictions varied across cancer types (Figure <ref type="figure" target="#fig_1">2A</ref>).</p><p>Using high-performing biomarker criteria, we further refined this set to include genomic alterations with strong screening potential for the 15 most com-mon cancer types treated at MSK. From 8,178 samples (5,260 primary and 2,918 metastatic samples), we identified 427 biomarkers with a mean AUC of 0.84 (mean sensitivity=0.92 and mean specificity=0.55). This refined set highlights the promise for screening 235 genes in at least one cancer type (Table <ref type="table">S9</ref>). We observed higher AUCs when evaluating WSIs obtained from primary tumors (mean AUC 0.86; range 0.76-0.96) compared to those from metastatic lesions (mean AUC 0.82; range 0.77-0.95) (Figure <ref type="figure">S3C</ref>-D, Table <ref type="table">S9</ref>). Notably, strong predictive performance was evident for genomic alterations in well-established oncogenes and tumor suppressors, such as TP53, CDKN2B, TERT, CDKN2A, RB1, MYC, PTEN (Figure <ref type="figure">S3E</ref>). Among tumor types, colorectal cancers (CRCs) demonstrated the broadest range of biomarkers with strong screening potential, achieving AUC &gt; 0.75 for 80 genes in primary CRCs and 29 genes in metastatic CRCs. Endometrial cancers followed, exhibiting similar robust performance, with AUC &gt; 0.75 for 50 different genes in primary tumors and 28 genes in metastatic samples (Figure <ref type="figure">S3F</ref>).</p><p>Top-performing biomarkers, defined as those with prevalence &gt; 5% and AUC &gt; 0.85 (Table <ref type="table">S3</ref>), comprise 93 genomic alterations among 55 genes. These biomarkers achieved a mean AUC of 0.90 (range: 0.85-0.99), with a mean sensitivity of 0.93, and a mean specificity of 0.66 (Figure <ref type="figure" target="#fig_1">2B</ref>). Of these, 29 genomic alterations which were sufficiently represented in the TCGA evaluation cohort (N=1,868; Methods 4.1.2), were validated and replicated as top-performing screening biomarkers, achieving a mean AUC of 0.88 (95% CI: 0.87-0.90). Their performance in TCGA was comparable to that observed in MSK samples, with a mean AUC of 0.9 (95% CI: 0.89-0.91; P-value = 0.41) (Tables S5, S9, S10).</p><p>We next evaluated OmniScreen's predictions of genomic alterations linked to therapeutic targets of FDA-approved drugs across various cancer types, focusing on 54 treatment-associated genes with actionable hotspot mutations reported in My Cancer Genome (MCG) <ref type="bibr" target="#b21">[22,</ref><ref type="bibr" target="#b22">23]</ref> and OncoKB <ref type="bibr" target="#b23">[24,</ref><ref type="bibr" target="#b24">25]</ref> OmniScreen demonstrated strong predictive performance in identifying actionable targets that are routinely screened in clinical practice for therapy selection and response prediction (Figure <ref type="figure" target="#fig_7">S4A</ref>, Table <ref type="table">S7</ref>; Supplementary Note 8.1.4). For example, it accurately predicted BRAF V600E mutations, achieving AUCs of 0.93 and 0.89 in primary and metastatic thyroid cancers respectively, and performed well in primary cancers such as CRC (AUC=0.91), glioma (AUC=0.88) and melanoma (AUC=0.76). Additionally, it effectively identified rare BRAF V600E carriers in NSCLC (N=11/903, 1.2%; AUC=0.77). Other notable examples include the prediction of FGFR3 hotspot mutations (R248C, S249C, G370C, Y373C), which are associated with response to drugs such as erdafitinib, demonstrating high accuracy in bladder cancer (AUC=0.93 in primary samples and AUC=0.82 in metastatic samples). It also predicted ERBB2 amplification, associated with response to trastuzumab, with an AUC of 0.81 in primary breast and metastatic gastric cancers. In metastatic non-small cell lung cancer (NSCLC), the model achieved an AUC of 0.79 and demonstrated 100% negative predictive value (NPV), highlighting its potential to reliably identify patients unlikely to benefit from HER2-targeted therapy. In addition to ERBB2, OmniScreen showed robust performance in detecting tyrosine kinase inhibitor (TKI)-targetable hotspot mutations in primary NSCLC, including EGFR (p.L858R, p.T790M, exon 19 deletions, and exon 20 insertions; AUC=0.87), KRAS p.G12C (AUC=0.83), MET exon 14 deletion/splicing mutations (AUC=0.79), and rarer RET fusion (N=12/903, 1.3%; AUC=0.77). With an NPV of 100% for RET fusions, it enables the reliable exclusion of patients unlikely to harbor these alterations, supporting effective screening of both common and rare actionable mutations.</p><p>To evaluate phenotypes indicative of genomic instability, OmniScreen was examined on three key metrics: high tumor mutation burden (TMB-H), microsatellite instability or deficient mismatch repair (MSI-H/dMMR), and chromosomal instability (CIN) (Figure <ref type="figure" target="#fig_7">S4C</ref>; Supplementary Note 8.1.5). OmniScreen demonstrated strong performance in predicting TMB-H across nine cancer types (mean AUC = 0.88), with notable accuracy in primary CRC and endometrial cancers (AUC = 0.90) and metastatic esophagogastric cancer (AUC = 0.87). Rare TMB-H cases in soft tissue sarcoma were also detected (N=8/346, 2.3%; AUC = 0.89). The model demonstrated robust prediction of MSI-H/dMMR phenotypes across CRC (AUC = 0.97), endometrial (AUC = 0.87), esophagogastric (AUC = 0.96), and bladder cancers (AUC = 0.97), characterized by histopathological features such as poorly differentiated, medullary-like patterns of tumor growth with "pushing" borders, tumor infiltrating lymphocytes (TILs), and mucin production. OmniScreen also achieved high accuracy (AUC = 0.85 in primary CRC) in identifying individuals with Lynch Syndrome (LS), a hereditary condition linked to MSI-H/dMMR-associated cancers <ref type="bibr" target="#b25">[26]</ref>. For CIN, a distinct form of genomic instability characterized by large-scale chromosomal alterations, OmniScreen showed a mean AUC of 0.84 in primary breast and ovarian cancers, with comparable performance in metastatic lesions.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2">Tumor area and cohort size influence biomarker prediction performance</head><p>To assess the impact of tumor area within WSIs (Figure <ref type="figure" target="#fig_1">2C</ref>; Methods 4.3) on biomarker predictions, we evaluated the AUC on samples with slides filtered by varying minimum tumor area thresholds. While certain biomarkers, such as MSI-H/dMMR (primary CRC), TMB-H (primary endometrial cancer), and DNAJB1 fusion (metastatic hepatobiliary cancer), exhibited performance invariant to tumor area filtering, the average AUC of the high-performing biomarkers showed a modest improvement after excluding slides with very small tumor areas (≤ 10.05 mm 2 , corresponding to the 35th percentile of tumor area in the tune set slides) (Figure <ref type="figure" target="#fig_1">2D</ref>). However, this trend reversed, with a decline observed when slides with tumor areas ≤ 27.31 mm 2 (the 50th percentile in the tune set) were excluded, coinciding with an increase in the false negative rate. False negative slides with tumor area &gt; 139.68 mm 2 (at 80th percentile) were found to be enriched for uncommon cancer types compared to slides with smaller tumor areas, based on pathologist's review.</p><p>In addition to tumor area, we evaluated the impact of training sample size on biomarker predictions by re-training our model on randomly sampled subsets of 20%, 40%, 60% and 80% of the training dataset. Model performance, assessed on the same test set, demonstrated an increase in AUC with larger training sample sizes (Figure <ref type="figure" target="#fig_1">2E</ref>). For certain biomarkers, the test set AUC showed significant improvement (∆AUC &gt; 10%) with larger training sample sizes, for example, AKT1 (in metastatic prostate cancer, AUC increased from 0.43 to 0.77), TSC2 (in primary renal cell carcinoma, AUC increased from 0.52 to 0.98), and CTNNB1 (primary endometrial cancer, AUC increased from 0.77 to 0.87). This observation highlights the potential benefit of curating additional samples to further enhance their predictive performance. In contrast, biomarkers such as GNA11 mutation (primary melanoma), TP53 mutation (primary ovarian cancer), WT1 fusion (primary soft tissue sarcoma), MEN1 mutation (primary pancreatic cancer), and RB1 mutation (metastatic prostate cancer) exhibited relatively stable performance (∆AUC &lt; 3%) across varying training sample sizes. No difference was found in label prevalence between labels that showed minimal change in performance and those that exhibited a large increase in performance as the training sample size increased (Figure <ref type="figure" target="#fig_1">2F</ref>), suggesting that the characteristics underlying the two groups of labels are independent of label prevalence. A: The Om-niScreen workflow: H&amp;E WSIs from diverse tumor histologies are processed using Virchow2 to generate tile embeddings. These representations, along with genomic ground truth, serve as input to train an aggregator network for biomarker prediction. The use cases of biomarker predictions include genetic alteration prediction, genotype-phenotype correlation, treatment target prediction, and pathway and chromosomal instability phenotype detection. B: Sample counts across diverse cancer types in the dataset, split by train, tune and test. Remaining rare cancers account for 4% of all samples (category 'Other', not visualized). 3% of all samples do not have an associated cancer type (category 'Unknown', not visualized). Sample distributions are stratified by data cohort and tumor site. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.3">OmniScreen predictions are associated with histologic cancer subtypes</head><p>We next sought to determine whether OmniScreen could diagnose histologic cancer subtypes associated with the genomic alterations it was trained to detect.</p><p>For each top-performing genomic biomarker within a cancer type, we compared the test set inference probabilities of the biomarker between the histologic subtypes. Our analysis revealed 52 subtype-specific biomarker predictions among 46 different genes (Kolmogorov-Smirnov (KS) test adjusted p-value &lt; 0.01, and AUC &gt; 0.85; Figures <ref type="figure">3A-B</ref>, Table <ref type="table">S6</ref>). We subsequently assessed the performance of these biomarkers in predicting the subtype diagnosis within the withheld test set.</p><p>OmniScreen accurately diagnosed subtypes by leveraging both classic histological features and subtle patterns less apparent to human pathologists. For example, CDH1 alteration has a strong phenotype-genotype correlation with the invasive lobular carcinoma subtype of breast carcinoma (Figure <ref type="figure" target="#fig_5">S5A</ref>). OmniScreen predicted the likelihood of CDH1 oncogenic mutations in breast cancers, accurately diagnosing invasive lobular carcinoma with an AUC of 0.93. The regions highly attended to by OmniScreen when predicting CDH1 mutation in breast cancer exhibited classic histologic features of invasive lobular carcinoma, including intracytoplasmic lumina and single-file invasive carcinoma cells (Figure <ref type="figure">3C</ref>). These features were necessary but insufficient to predict CDH1 mutation in breast cancer, as lobular carcinoma-like features such as single-file and individual cell infiltration patterns were also observed in CDH1-wildtype breast cancers. Despite this mimicry, OmniScreen accurately identified these cases as true negatives while also recognizing cases with less classic invasive lobular carcinoma features as true positives for CDH1. This association was further validated in the TCGA cohort, where it achieved an AUC of 0.95, and was thoroughly analyzed in one of our previous studies <ref type="bibr" target="#b26">[27]</ref>.</p><p>In glioma, oligodendroglioma is genetically defined by an IDH mutation and 1p19q codeletion <ref type="bibr" target="#b27">[28]</ref>. OmniScreen's prediction of IDH1 oncogenic mutation identified oligodendroglioma with an AUC of 0.89. The attention heatmap (Figure <ref type="figure">3B</ref>) reveals that OmniScreen focused on the cytoplasmic clearing around the nucleus, a hallmark of formalin-fixed oligodendrogliomas creating their classic "fried egg" appearance, and at least one nucleus per tile (highlighted in red). This suggests that the model associates high likelihood of IDH1 mutation with classic oligodendroglioma traits, consistent with the known high incidence of IDH1 alterations in this tumor type, while also capturing key subtle nuclear characteristics that may be less apparent to human pathologists. Notably, OmniScreen accurately predicted IDH1 mutation even in cases with less classic oligodendroglioma features (Figure <ref type="figure">3D</ref>). As expected, true negative (TN) examples primarily featured other glioma variants without the distinct oligodendroglioma histology, which are less likely to harbor IDH1 mutations, thus enabling the model to reliably identify their IDH1-wildtype status.</p><p>Other notable genotype-phenotype associations identified by OmniScreen include VHL in clear cell renal cell carcinoma (ccRCC), MEN1 and ATRX in pancreatic neuroendocrine tumors, KRAS in pancreatic adenocarcinoma, and GNAQ/GNA11 in uveal melanoma (see Supplementary Note 8.1.6). OmniScreen effectively detected a wide range of genomic alterations and histopathological features across both common and rare soft tissue sarcoma subtypes, such as RB1-loss in leiomyosarcoma, MDM2 amplification in liposarcoma, TERT in myxoid liposarcoma, and WT1 fusions in desmoplastic small round cell tumors (DSRCT). Furthermore, it distinguished molecular subsets within histological subtypes, such as SOX2 amplification and KMT2D alterations in lung squamous cell carcinoma (LUSC), and identified shared pathological features, such as ARID1A deleterious mutations across ovarian clear cell carcinoma (OCCC) and endometrioid ovarian cancers.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.4">OmniScreen captures phenotypes linked to shared signaling pathways</head><p>In NSCLC, alterations in EGFR, BRAF, RAS, MET, ALK, ROS1, and RET signal through a shared molecular pathway associated with activated receptor tyrosine kinase activity. This leads to activation of downstream signaling pathways such as MAPK/ERK and parallel signaling via PI3K/AKT. We investigated whether mutations in genes that share a signaling pathway could result in a common phenotype detectable by OmniScreen. When using an operating point optimized for 90% sensitivity, 475 EGFR positive predictions were identified in NSCLC in our test set (Figure <ref type="figure" target="#fig_4">4A</ref>). Among these positive predictions, 176 were confirmed as EGFR-mutant cases by MSK-IMPACT sequencing. However, the remaining 299 EGFR cases were instead classified as EGFR wild-type by MSK-IMPACT. Among these EGFR false positives (FPs), 157 harbored alterations in other genes commonly mutated in NSCLC that signal through a shared molecular pathway with activating EGFR mutations (N=115 KRAS oncogenic mutations, N=23 activating MET and N=19 ALK/RET/ROS1 fusions; Figure <ref type="figure" target="#fig_4">4B</ref>). These results are consistent with an AI model detecting a phenotype associated with the net phenotypic effect of activating oncogene mutations via their shared downstream signaling activity rather than distinguishing individual gene-specific alterations in members of the shared signaling pathway. While reviewing the corresponding WSIs, we observed that the regions highly attended to by OmniScreen for true positive (TP) EGFR prediction in NSCLC predominantly contained adenocarcinomas, as expected, and exhibited lepidic, acinar, and papillary/micropapillary growth patterns, along with moderate to high nuclear atypia consistent with features associated with TP EGFR alterations (Figure <ref type="figure" target="#fig_4">4C</ref>). In the EGFR FP slides harboring KRAS mutations, MET mutations, or ALK/RET/ROS1 fusions, the predominant morphologic features included acinar and solid-type growth patterns, along with moderate to marked nuclear pleomorphism and atypia (Figure <ref type="figure" target="#fig_4">4D</ref>). Notably, these histologic characteristics overlap substantially with those seen in EGFR-mutated lung adenocarcinomas, potentially reflecting the shared molecular signaling cascades associated with these genetic alterations.</p><p>Building on our EGFR hypothesis in NSCLC, we hypothesized that muta-tions in any member of molecular pathways may result in overlapping, shared phenotypes due to the interconnected nature of their signaling cascade. Supporting this hypothesis, OmniScreen successfully predicted, per case, the presence of oncogenic genomic alterations in any of the genes within canonical pathways (Figure <ref type="figure" target="#fig_7">S4C</ref>, Tables <ref type="table">S8</ref>, <ref type="table">S9</ref>). For example, RTK/MEK/ERK pathway alterations were predicted with AUC &gt; 0.75 in primary samples of glioma, NSCLC, prostate and breast cancers. Similarly, mTOR pathway alterations were detected in primary endometrial, thyroid, and renal cell carcinoma (RCC) (AUC &gt; 0.75). In primary CRC, OmniScreen identified alterations in homologous recombination deficiency (HRD), TGF-β, and DNA damage response (DDR) with a mean AUC of 0.80 (range: 0.78-0.82).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.5">OmniScreen improves prediction of clinically relevant low-prevalence biomarkers</head><p>To compare the performance of OmniScreen with conventional approaches which train individual models for each biomarker within a specific cancer type, we selected 20 biomarkers spanning multiple tumor types, representing a broad range of prevalence and trained a single model for each (Methods 4.4, Figures <ref type="figure" target="#fig_5">5A-B</ref>).</p><p>Overall, the AUC values of biomarkers generated by OmniScreen correlated strongly with those obtained using the conventional method (Figure <ref type="figure" target="#fig_5">5C</ref>). However, notable variation was observed in the relative change in AUC (i.e., ∆AUC) across biomarkers. Stratifying biomarkers into two groups based on ∆AUC (&lt; 2% and &gt; 2%) revealed that biomarkers with smaller relative changes in performance were associated with higher prevalence, whereas those with larger relative changes corresponded to lower prevalence (Figure <ref type="figure" target="#fig_5">5D</ref>). These findings suggest that for high-prevalence biomarkers, the conventional approach yielded AUC values comparable to those achieved by OmniScreen, while OmniScreen demonstrated superior average performance for low-prevalence biomarkers, albeit with slightly greater variability.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3">Discussion</head><p>Genomic alterations can give rise to distinct cancer phenotypes, some of which manifest as specific morphological features visible under light microscopy. For example, bi-allelic inactivation of E-cadherin (CDH1) in breast cancer produces a characteristic discohesive single-file pattern, recognized by pathologists as invasive lobular carcinoma <ref type="bibr" target="#b26">[27,</ref><ref type="bibr" target="#b28">29]</ref>. However, certain genomic alterations may result in phenotypes that are either too subtle, or too overlapping, to be reliably detected by routine human assessment.</p><p>The integration of machine learning into digital pathology offers a transformative solution, enabling scalable analysis of WSIs to uncover subtle phenotypegenotype correlations. Leveraging large, expertly annotated datasets and advanced computational methods, AI-driven models can identify digital biomarkers associated with clinically relevant genomic alterations. This enhances diag-nostic precision, informs therapeutic decision-making, and accelerates clinical research by generating novel phenotype-genotype hypotheses and refining patient selection for clinical trials <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b29">30]</ref>.</p><p>In this study, we introduce OmniScreen, a robustly performing artificial intelligence (AI)-based model trained on histological and molecular data from MSKCC and TCGA.</p><p>OmniScreen was successfully evaluated on the 15 most common cancer types treated at MSKCC, using molecular ground truth from the MSK-IMPACT NGS assay. It demonstrated strong performance in detecting clinically relevant genomic biomarkers routinely screened for targeted therapy selection and response prediction, including hotspot mutations in NSCLC (EGFR, KRAS, MET, and RET), ERBB2 amplification in breast and gastric cancers for HER2-targeted therapy, FGFR3 alterations in urothelial carcinoma, and BRAF V600E mutations in thyroid cancers, melanoma and CRC.</p><p>The model demonstrated robust performance in predicting MSI-H/dMMR phenotypes across colorectal, endometrial, gastric, and bladder cancers, as well as detecting tumor mutation burden-high (TMB-H) in colorectal and endometrial cancers. It identified rare TMB-H cases in low-prevalence histologies, such as soft tissue sarcoma <ref type="bibr" target="#b30">[31]</ref>, highlighting its potential to identify patients who may benefit from immune checkpoint inhibitor (ICI) therapy, even in less frequently screened tumor types. These findings support the use of AI-assisted digital biomarker screening with H&amp;E-stained WSIs as a cost-effective, time-efficient, and tissue-sparing approach to prioritize patients for definitive molecular testing.</p><p>While certain genes did not reach high AUCs, when applying a threshold for high-sensitivity screening (sensitivity &gt; 0.9), predictions for genomic alterations, such as RET fusions and ERBB2 amplifications in NSCLC, demonstrated a high NPV of 100%. This suggests their potential as "rule-out" digital biomarkers, for triaging patients unlikely to harbor these mutations to reduce unnecessary molecular testing.</p><p>As proof of concept, we estimated cost savings for enrolling 500 patients, prescreened by OmniScreen, with all confirmed positive via definitive NGS or PCR (see Supplementary Note 8.1.7). The AI-assisted triage demonstrated potential average savings of $320K (5-30% reduction) for PCR and $1,086K (13-39% reduction) for NGS (Figure <ref type="figure" target="#fig_7">S4B</ref>). Cost savings were most pronounced for lowprevalence targets, highlighting the potential of AI-assisted triage to overcome financial barriers in clinical studies targeting rare mutations. Beyond clinical trials, the digital biomarker screening approach offers opportunities to reduce routine testing costs in specific laboratory and practice settings by optimizing the use of more expensive definitive tests.</p><p>Our results demonstrate the expected bias of genomic alterations associated with specific phenotypes and histologic subtypes, such as MDM2 amplification in liposarcoma, VHL loss in clear cell renal carcinoma, and IDH1 prediction in oligodendroglioma. These results confirm that the model reliably identifies established diagnostic phenotype-genotype correlations, effectively training itself on known phenotypes. The consistent detection of expected biases across histologies further supports the validity of the model's predictions, even for genomic alterations without previously described phenotypic associations.</p><p>Variations in the accuracy of biomarker predictions across tumor types may be attributed to differences in sample size, mutation prevalence, and the intrinsic strength of phenotypic manifestations associated with specific biomarkers.</p><p>Our development cohort included a higher proportion of primary samples compared to metastatic samples, which may account for the generally better performance observed in primary samples across the tested histologies. Expanding the dataset to include more samples from metastatic lesions may uncover additional biomarkers associated with metastasis, and potentially enhance the accuracy of genomic alteration predictions in metastatic tumors.</p><p>While some genomic alterations were represented by relatively small numbers of cases in our dataset, biomarkers with strong genotype-phenotype associations, such as GNA11 in melanoma, MEN1 in pancreatic cancer, and WT1 fusion in soft tissue sarcoma, exhibited distinct morphological features that were reliably detectable even with limited sample sizes. However, not all genomic alterations exhibit distinct or robust phenotypes, which can constrain their detectability. For such biomarkers, increasing the number of cases with these alterations during model training could amplify the signal detection and further improve prediction performance.</p><p>As low tumor content may influence the accuracy of biomarker prediction, we investigate its impact by using tumor area as a surrogate marker for tumor content. While the AI model may struggle with slides containing insufficient tumor area, an exceptionally large tumor area did not consistently improve performance. Some biomarkers, such as AR amplification (metastatic prostate cancer), CCND1 amplification (primary gastric cancer), and BRAF oncogenic mutation (primary melanoma), were more sensitive to limited tumor area than others. This suggests that biology, in terms of the robustness of a genomic alteration associated phenotype, is a significant, if not controlling, factor in ability to train AI to predict features such as underlying genomic alterations. A strong, robust phenotype associated with a genomic alteration may be identifiable via AI on WSIs even with small tumor areas. Conversely, a genomic alteration with a weak phenotypic effect on the tumor in H&amp;E WSIs may require a greater minimum amount of tumor present for accurate identification. If the phenotype is too weak or lacks sufficient differentiation, even large tumor areas may not improve performance. Some biomarkers may not have a robust enough phenotype to ever be learnable by ML on WSIs to a level that would allow clinical use.</p><p>Furthermore, we found in some cases that slides with extremely large tumor areas sometimes skewed training or were underrepresented in the training set but appeared in the test set. In rare tumor types, small or large biopsies may be over-or underrepresented due to limited cases for training. Ensuring AI models are trained on a diverse range of tumor phenotypes, including variations in tumor amounts, sample sizes, and primary versus metastatic settings, is critical for capturing phenotype variability.</p><p>Unexplored factors such as crush/cautery artifacts or prolonged tissue is-chemia may impact the phenotype on H&amp;E WSIs. This underscores the need to consider phenotypic and spatial diversity, not only tumor size, when evaluating biomarker performance. The robustness and clinical utility of AI applied to WSIs may also be restricted by biology in other ways. For example, where common gene activating alterations converge on a shared oncogenic molecular pathway, such as the commonly therapeutically targeted genes in NSCLC (EGFR, KRAS, MET, BRAF, ERBB2 and ALK/ROS1/RET), distinguishing gene-specific phenotypes based solely on morphologic features can be challenging, even for AI. The phenotype may be most robust for the shared molecular endpoint, rather than the specific gene of origin, making an AI algorithm best at identifying if any of the convergent genes are altered versus discriminating which gene was altered to create the phenotype. However, this highlights an opportunity to leverage AI-assisted methods to screen panels of related genes in a single test via activation of the shared molecular pathway by identifying the 'pathway-active' phenotype. When combined with definitive molecular testing, it could prioritize cases for confirmatory sequencing of panel genes to identify specific gene alterations, as well as identify mutations functionally linked to pathway activation, enhancing diagnostic precision and improving therapy response prediction, beyond genotyping alone.</p><p>In summary, we describe a fully automated method for rapid high-throughput AI-assisted screening of cancer WSIs, not only to detect clinically meaningful genomic abnormalities across histologies, but also to identify the histologies characterized by genomic alterations. This may select patients for definitive genomic analysis and/or enable phenotype-genotype correlations to improve clinical decisions. This pipeline is cost and time efficient, tissue sparing and capable of application to large patient populations across a wide range of cancer with reliable performance metrics. Such an approach is suitable for application in research, including clinical trial settings.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4">Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.1">Patient cohorts, histopathologic and genomic analyses</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.1.1">MSK cohort: MSK IMPACT Dataset</head><p>A sample is defined as an MSK-IMPACT assay paired with one or more H&amp;E stained WSIs taken from the same formalin-fixed paraffin-embedded (FFPE) tissue block. The MSK-IMPACT dataset consists of 67,608 samples (75,383 WSIs) from 72 cancer groups (71 cancer types and an "Unknown" category for which the cancer type is not known). 46,650 (65%) of samples are primary cancer sites while the remaining 20,958 (35%) are metastasis samples. All image data were retrieved from the hospital archives and verified to meet staining quality standards for histopathology review. All biopsy glass slides were scanned with Leica Aperio AT2 scanners (Leica Biosystems, Division of Leica Microsystems Inc, Buffalo Grove, IL, USA) at 20× (0.5 microns per pixel) or 40× (0.25 microns per pixel) magnification. See Table <ref type="table">S11</ref> for a detailed breakdown of patient, sample and slide counts by cancer type and tumor site in the dataset.</p><p>The cohort underwent paired tumor-normal targeted sequencing using the FDA-cleared MSK-IMPACT assay <ref type="bibr" target="#b31">[32]</ref>. MSK in-house bioinformatic pipelines were employed to analyze the sequencing results. The analysis determined the genomic alteration status, including mutations (single-nucleotide variants (SNVs) and insertions/deletions (indels)), copy number variations (amplification and deletions), and structural rearrangements (fusions) in 489 important cancer associated genes. The list of genes was compiled from four MSK-IMPACT versions including v3 (N=341 genes), v5 (N=410), v6 (N=468 genes) and v7 (N=505 genes). Additional fusion events confirmed by the MSK-Fusion panel <ref type="bibr" target="#b32">[33,</ref><ref type="bibr" target="#b33">34]</ref> via RNA sequencing were incorporated to improve the coverage of fusion detection for the genes that are available from MSK-IMPACT panel. The annotation of the oncogenicity and clinical relevance of specific genetic alterations was determined using OncoKB <ref type="bibr" target="#b23">[24,</ref><ref type="bibr" target="#b24">25]</ref>. Tumor mutation burden (TMB) score, microsatellite instability (MSI) score, loss-of-heterozygosity (LOH), and whole genome doubling (WGD), where available, were analyzed and retrieved at Memorial Sloan Kettering (MSK). Furthermore, the status of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2s (HER2s), programmed death-ligand 1 (PD-L1), and deficient mismatch repair (dMMR) were confirmed by immunohistochemistry (IHC).</p><p>Among MSK-IMPACT panel genes, five groups of genes that canonically participate in shared pathways associated with DNA repair mechanisms were identified. The gene members of each pathway were retrieved from MCG <ref type="bibr" target="#b21">[22,</ref><ref type="bibr" target="#b22">23]</ref>. Table <ref type="table">S8</ref> summarizes the list of gene candidates associated with each pathway, including DNA damage response (DDR), receptor tyrosine kinase (RTK) MEK/ERK pathway, homologous recombination deficiency (HRD) pathway, mTOR signaling pathway, and TGF-β signaling pathway.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.1.2">TCGA cohort: TCGA PanCancer Atlas</head><p>The external cohort consists of samples from TCGA PanCancer Atlas project <ref type="bibr" target="#b16">[17]</ref>. A total of 11,406 diagnostic WSIs, corresponding to 32 cancer types, were retrieved from TCGA. The corresponding genomic alteration data, including mutation, copy number aberration, and fusion, were downloaded from cBioPortal (<ref type="url" target="http://www.cbioportal.org">http://www.cbioportal.org</ref>). A total of 400 slides were excluded from model training and evaluation. This included 360 slides that have no associations with any biomarkers, 36 slides missing microns-per-pixel (mpp) information, and 4 slides that were out of focus and had no foreground tiles detected. Of the remaining samples, 7,119 <ref type="bibr" target="#b7">(8,</ref><ref type="bibr">725 WSIs)</ref> were used in training and 1,868 (2,281 WSIs) define the validation cohort. See Table S12 for a detailed breakdown of patient, sample and slide counts by cancer type in the dataset.</p><p>4.2 Development of an AI-based system for the detection of pan-cancer digital biomarkers using whole slide images We developed OmniScreen, a pan-cancer digital biomarker screening model to predict genomic abnormalities of interest in human cancers from H&amp;E WSIs. The model was trained on 51,747 diagnostic clinical WSIs from a cohort of 41,468 patients (N=34,349 treated at MSK; N=7,119 TCGA patients). The training cohort covers 71 different cancer types with 489 genes assessed by the MSK-IMPACT targeted sequencing oncology assay (Figure <ref type="figure" target="#fig_0">S1</ref>, Table <ref type="table">1</ref>). 1,637 training ground truth labels include oncogenic point mutations, copy number variations (amplifications or deletions) and fusion events, or the presence of these types of genetic variations in any of a group of genes canonically participating in a shared signaling pathway associated with cancer, e.g., DNA damage responses, tyrosine kinase receptor (RTK) pathway, and mTOR signaling pathway (Figure <ref type="figure" target="#fig_1">S2</ref>, Table <ref type="table">S8</ref>).</p><p>The task is framed as multi-label binary classification, where genomic features (biomarkers) are represented as binary labels. Each label indicates the presence or absence of genomic alterations in a single gene, or in any of a group genes that participate in a shared signaling pathway. The genomic feature binary labels derived from MSK-IMPACT results are oncogenic mutations, copy number amplification, copy number deletions, fusions, or the combination of oncogenic mutation/amplification if a gene is an oncogene and oncogenic mutation/deletion if a gene is a tumor suppressor gene (TSG) (Figure <ref type="figure" target="#fig_1">S2</ref>). Additional genomic features included in training are TMB-H for TMB ≥ 10 mutations/megabase (mut/Mb), microsatellite instability high (MSI-H) for MSI score ≥ 10, and microsatellite stable (MSS) for MSI score &lt; 3, dMMR for loss of IHC staining in mismatch repair (MMR) (MLH1, MSH2, MSH6, and PMS2) proteins and harbored genetic alterations in MMR genes, Lynch Syndrome for the presence of germline mutation in any of MLH1, MSH2, MSH6, PMS2, EPCAM, and CIN measures: tetraploidy, whole genome doubling (WGD), loss-of-heterozygosity (LOH) in ≥ 50% genome, fraction of genome altered (FGA) ≥ 30%, and genome instability index (GI index) ≥ 20%. The GI index is a metric derived from fraction of genome altered (FGA) and LOH, ranging from 0 to 1.</p><p>The MSK development cohort was split into train, tune and test datasets with a ratio of 4:1:1. This partitioning resulted in sample sizes of 46,201 (51,747 WSIs) for the train set, 9,677 (10,710 WSIs) for the tune set, and 9,862 (10,645 WSIs) for the test set. The distribution of cancer types across the datasets included 71 different types in the train set, 63 in the tune set, and 62 in the test set (Figures 1B, S1B, Table <ref type="table">S11</ref>). Each dataset also includes the category of an "Unknown" histology. A total of 1,637 biomarker labels with at least 8 positive and 8 negative samples in the train set and at least 4 positive and 4 negative samples in the tune set were included in the training. This corresponds to 489 genes out of 505 MSK-IMPACT panel genes. To enhance the model's generalizability, the TCGA cohort was divided into training and evalu-ation sets. Specifically, 80% of the TCGA cases were combined with the MSK train dataset to form the training cohort, while the remaining 20% of TCGA cases served as an independent validation set.</p><p>Each slide is split into image tiles of size 224 × 224 pixels. The tiles are filtered to only include those representing foreground (tissue) using a foreground detection model based on a Fully Convolutional Network (FCN). Each foreground tile is embedded with the foundation model Virchow2 <ref type="bibr" target="#b19">[20,</ref><ref type="bibr" target="#b20">21]</ref> into a tile embedding of length 1280. Each slide is thus represented as a N × 1280 tensor, where N is the number of foreground tiles.</p><p>The embeddings serve as input into a feed-forward network with an attention mechanism that aggregates the tile-level embeddings into a slide-level prediction <ref type="bibr" target="#b19">[20]</ref>. See Supplementary Note 8.1.1 for an overview of OmniScreen model and training parameters. The model was trained on slide level. The final prediction per sample was determined as the maximum prediction over slides in the sample.</p><p>Checkpoint selection was done on the tune set using the mean AUC and mean average precision (AP) across labels that contained at least 5 positive samples. The operating threshold for each label was determined on the tune set by optimizing for 90% sensitivity in each cancer type present in the tune set. A threshold thus corresponds to a label and cancer type pair. These thresholds were then applied to generate sample-level binary predictions from the inference probabilities in the MSK test set and the TCGA validation set, indicating the presence or absence of the genetic mutation.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.3">Tumor area estimation in WSIs using the Paige Pan-Cancer Detect</head><p>We applied Paige PanCancer Detect <ref type="bibr" target="#b19">[20]</ref> to generate cancer and precursor tissuemaps for each slide in the tune and test sets.</p><p>The Paige PanCancer Detect model consists of a feature embedder (Vir-chow2 <ref type="bibr" target="#b20">[21]</ref> was used) and a tile classifier network. The tile classifier is a small fully connected network trained on embeddings of 1.4M slides containing 54 tissue types, using a combination of strong and weak supervision. In order to overcome different levels of data imbalance across different tissue types, multiple networks were trained on diverse subsets of tissue types.</p><p>During inference, an ensemble of 8 linear models is used to classify cancer and an ensemble of 4 models is used to classify precursor lesions. Each slide is divided into 224 × 224 tiles, and tile embeddings are generated using Virchow2. These embeddings are processed by both ensembles to compute cancer and precursor scores for each tile. The scores are then arranged based on the spatial coordinates of the tiles to produce probability maps that represent their spatial distribution. A threshold of 0.1 is applied to the probability maps, followed by smoothing to convert them into tissuemaps-overlay images highlighting all detected cancer or precursor regions on the slide.</p><p>The tumor area for a WSI was estimated as the union of cancer and precursor regions. Tumor area thresholds were determined based on the 1st, 5th, 10th, and up to the 95th percentiles of tumor areas in the slides from the tune set. These thresholds were then applied to filter slides in the test set, enabling the evaluation of biomarker performance on a subset of samples.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.4">Training single biomarker label models</head><p>To evaluate the performance of OmniScreen relative to the conventional approach-where models are trained separately for individual biomarker labels within specific cancer types-we selected a panel of 20 biomarkers that are clinically relevant or well-established in the literature for specific tumor types.</p><p>For each biomarker, we trained a model on a subset of the training dataset restricted to the associated tumor type. 20 single label biomarker models were then trained. The models were evaluated using the relevant subsets of the tune and test datasets.</p><p>See Supplementary Note 8.1.3 for an overview of the model and training parameters. The models were trained on slide level. The final sample-level prediction was determined as the maximum prediction over slides in the sample.</p><p>When comparing the conventional approach with OmniScreen, we computed ∆AUC, i.e., the relative change in AUC, to quantify the difference in performance between two approaches.</p><formula xml:id="formula_0">∆ AU C = AU C OmniScreen -AU C SingleLabel AU C SingleLabel</formula><p>Due to the limited availability of metastatic samples for certain biomarkers, we ranked the biomarkers based on their ∆AUC in primary samples. Using the median ∆AUC value of 2%, we divided the biomarkers into two groups: ∆AUC &lt; 2% and ∆AUC &gt; 2%.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.5">Phenotype-genotype correlation analysis</head><p>For each histology subtype in a cancer, we used the Kolmogorov-Smirnov (KS) one-side test to examine whether the inference probabilities of a biomarker label in the target subtype is greater than the inference probabilities in the other subtypes of cancer. The p-values were adjusted using the Benjamini-Hochberg method. P-values &lt; 0.01 were considered as statistically significant. A histologic subtype ground truth is defined as a binary label indicating if the sample was annotated for a given histologic subtype. For a biomarker with significantly higher inference probabilities in a specific histologic subtype of cancer, the AUC of the biomarker in prediction of the corresponding subtype was evaluated by using inference probabilities as prediction and the binary label of histologic subtype as ground truth. The sensitivity and specificity was computed by using the binary prediction of the genomic alterations as prediction label and the binary label of histologic subtype as ground truth.</p><p>C KMT2D: Lung Squamous Cell Carcinoma A KRAS: Pancreatic Adenocarcinoma MEN1: Pancreatic Neuroendocrine Tumor VHL: Renal Clear Cell Carcinoma CDH1: Breast Invasive Lobular Carcinoma B CDH1 TP CDH1 TN IDH1 TP IDH1 TN D SOX2: Lung Squamous Cell Carcinoma ATRX: Pancreatic Neuroendocrine Tumor</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Example ii Example i</head><p>Example ii Example i Figure <ref type="figure">3</ref>: Biomarkers associated with histologic subtypes of cancers. A: -log10(KS test, adjusted p-value) vs. AUC. Evaluation was performed using OmniScreen biomarker prediction scores and histologic subtypes as ground truth. Grey dots represent biomarkers with AUC ≤ 0.85, blue dots denote those with AUC &gt; 0.85. Text labels highlight example biomarkers stroongly associated with histologic subtypes, with -log10(KS test, adjusted p-value) &gt; 30 and AUC &gt; 0.9. B: Example of an H&amp;E-stained WSI with an attention heatmap illustrating OmniScreen's prediction of IDH1 mutation likelihood for an oligodendroglioma, highlighting the targeted morphological features (regions highly attended by the model). The higher magnification tiles (top row) display the typical "fried egg" appearance of a classic oligodendroglioma. The attention heatmap (bottom row) highlights regions of high attention (red areas), focusing on the cytoplasmic clearing around the nucleus-characteristic of a formalin-fixed oligodendroglioma-and attention to at least one nucleus in each image. Examples of 1024 × 1024 regions in WSIs that were highly attended by OmniScreen during the prediction of (C) CDH1 oncogenic mutations in breast cancer, and (D) IDH1 oncogenic mutations in glioma, including both true positive (TP) and true negative (TN) cases. C: Representative images of CDH1-mutant cases (TP) showing the classic lobular invasive carcinoma histologic appearance with intracytoplasmic lumina and single file invasive carcinoma cells; and CDH1-wildtype breast cancers (TN), exhibiting some of the single file and individual cell infiltration pattern. D: Representative images of IDH1-mutant cases (TP) exhibiting classic features of oligodendroglioma, including (i) the classic cytoplasmic clearing of formalin fixed oligodendroglioma cells and (ii) less classic oligodendroglioma features; and IDH1-wildtype cases (TN), displaying morphological features characteristic of other glioma variants.</p><p>EGFR Counts FP 299 TP 176 FN 11 TN 417 x KRAS MET ALK/ROS1/RET A B D C EGFR Example i Example ii Examples of 1024 × 1024 regions in lung adenocarcinomas slides that were highly attended by OmniScreen during the prediction of EGFR oncogenic mutations, C: EGFR TPs, showing histologic patterns consistent with a likelihood of EGFR alteration, such as lepidic (ii), acinar (i), and papillary/micropapillary growth patterns were evident, as were moderate (i, ii) to high nuclear atypia; D: EGFR FPs, predicted with high EGFR mutation likelihood by OmniScreen, confirmed as EGFR wild type and harboring KRAS, MET, or ALK/ROS1/RET mutations. These cases predominantly exhibit acinar (KRAS: i, ii; MET: ii), papillary (MET: i; ALK/ROS/RET: ii), solid-type growth (ALK/ROS/RET: i) patterns, with moderate or greater (KRAS: ii; ALK/ROS/RET: i) nuclear pleomorphism and atypia. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5">Acknowledgement</head><p>We would like to extend our sincere gratitude to several individuals who contributed significantly to the success of this project. Philippe Mathieu, Alexander van Eck, Wayne Hendricks, Sid Senthilnathan, Michael Singer and Eric Robert played a crucial role in developing the AI and data infrastructure, which enabled the large-scale training and evaluation essential to this work.</p><p>We also wish to acknowledge Jan Bernhard for his earlier contributions to the development of digital biomarker projects related to MSI detection, which laid the foundational work for this project.</p><p>Our thanks also go to Eugene Vorontsov, Julian Viret, Adam Casson, George Shaikovski and Donghun Lee for their invaluable work in the development of the foundation model Virchow2 and PanCancer Detect.</p><p>We would like to thank Dani Gorton for her valuable advice, as well as her time and effort in reviewing the design and editing of Figure <ref type="figure" target="#fig_0">1</ref> included in this study.</p><p>Finally, we are deeply grateful to Brandon Rothrock for his supervision and mentorship during the early stages of the biomarker-related research, which significantly influenced the direction of this research.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="6">Data protection</head><p>This project was governed by an Institutional Review Board approved retrospective research protocol, under which consent/authorization was waived before research was carried out. Data collection was conducted exclusively at MSK. The AI model was developed by Paige.</p><p>22 Table 1: Development and validation datasets -sample and slide counts Train Tune Test Dataset Samples WSIs Samples WSIs Samples WSIs MSK 39,082 43,022 9,677 10,710 9,862 10,645 TCGA 7,119 8,725 --1,868 2,281 8 Supplementary Information 8.1 Supplementary Methods 8.1.1 OmniScreen Aggregator Training The aggregator model code can be accessed at <ref type="url" target="https://github.com/Paige-AI/paige-ml-sdk">https://github.com/Paige-AI/  paige-ml-sdk</ref>. The aggregator model was trained with model parameters described in Table S1. The model was trained for 50 epochs with training parameters described in Table S2. The input embedding (generated by Virchow2) consists of class token only (dimension 1280). The training took approximately 52 hours and was performed on 2 NVIDIA A100 (40GB) nodes (8 GPUs per node). Table S1: Aggregator model parameters Parameter description Parameter name Parameter value Dimension of the input embedding in features 1280 Dimension of first linear layer layer1 out features 320 Dimension of second linear layer layer2 out features 640 Number of attention queries n attention queries 16 Table S2: Aggregator model training parameters Parameter name Parameter value Batch size 10 Optimizer AdamW [35] Learning rate 0.0001 Weight decay 0.05 Training loss Binary cross-entropy 8.1.2 Filtering criteria for biomarker performance categories By assessing the AP and area under the receiver operating characteristic curve (AUC) for 1,637 biomarkers in the MSK test set, we observed a positive correlation between AP and the prevalence of labels in the training set, defined as the proportion of positive samples (Figure S3A). In contrast, AUC demonstrated no strong correlation with prevalence. To further evaluate model performance, we computed sensitivity and specificity for biomarkers with AUC &gt; 0.5 (Figure S3B). Considering screening requirements, we categorize biomarkers into different groups by applying criteria defined in Table S3: 1. Baseline criteria for identifying biomarkers with signals exceeding those expected by chance 2. High-performing biomarkers as potential candidates for screening 3. Top-performing biomarkers with high prevalence. 4. Hotspot detection Table S3: Filtering criteria Description Parameter &gt; threshold Baseline (selected from all genes and all tumor types) AUC 0.5 positive ratio 0.02 N positives 2 High-performing biomarkers AUC 0.75 positive ratio 0.02 N positives 2 N total 50 sensitivity 0.75 specificity 0.20 Top-performing biomarkers with high prevalence AUC 0.85 positive ratio 0.05 sensitivity 0.80 specificity 0.30 Hotspot detection AUC 0.75 N positives 4 N total 50 sensitivity 0.75 specificity 0.20</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.1.3">Single Label Aggregator Training</head><p>The single label aggregator models were all trained with the model parameters described in Table <ref type="table">S4</ref>. The models were trained for 20 epochs with the same training parameters as OmniScreen, described in Table <ref type="table">S2</ref>.</p><p>The input embedding (generated by Virchow2) consists of class token only (dimension 1280). The training time varied from 1h (KMT2D in esophagogastric cancer) to 8h (ESR1 in breast cancer) due to differing training set sizes. Training was performed on 1 NVIDIA A100 (40GB) node (8 GPUs). Table S4: Single label aggregator model parameters Parameter description Parameter name Parameter value Dimension of the input embedding in features 1280 Dimension of first linear layer layer1 out features 160 Dimension of second linear layer layer2 out features 320 Number of attention queries n attention queries 1 8.1.4 Biomarkers associated with targeted therapeutic hotspots</p><p>We evaluated OmniScreen's predictions of genomic alterations linked to therapeutic targets of FDA-approved drugs across various cancer types. A list of 54 treatment-associated genes with specific hotspot mutations reported in MCG <ref type="bibr" target="#b21">[22,</ref><ref type="bibr" target="#b22">23]</ref> and OncoKB <ref type="bibr" target="#b23">[24,</ref><ref type="bibr" target="#b24">25]</ref> was compiled, focusing on the actionable targets that are FDA-approved predictive biomarkers (OncoKB therapeutic evidence level 1) or standard of care biomarkers recommended by the National Comprehensive Cancer Network (NCCN) or other expert panels (OncoKB therapeutic evidence level 2). The ground truth for each sample in the test set was determined based on the presence or absence of hotspot mutations specific to its cancer type. We identified 52 predictive biomarkers among the 15 most common cancers where OmniScreen could predict the likelihood of the mutation, positioning it as a strong candidate for a screening assay (Figure <ref type="figure" target="#fig_7">S4A</ref>, Table <ref type="table">S7</ref>). For example, BRAF V600E mutation testing is standard of care in melanoma, glioma, thyroid, lung and CRCs, where such mutations are common and therapeutically actionable targets in these malignancies <ref type="bibr" target="#b35">[36]</ref>.</p><p>OmniScreen demonstrated strong performance in predicting BRAF mutations, with AUCs of 0.93 and 0.89 in primary and metastatic thyroid cancers, respectively. Additionally, it achieved notable accuracy in primary CRCs (AUC = 0.91), glioma (AUC = 0.88), and melanoma (AUC = 0.76), despite limited metastatic cases. In NSCLC, where BRAF mutations are relatively rare (1-2% of NSCLC <ref type="bibr" target="#b36">[37]</ref>), our model accurately predicted the presence of the BRAF V600E mutation in confirmed cases, achieving an AUC of 0.77 (N=11/903, 1.2%). Further improvements in predictive performance may be feasible with access to additional positive cases for model training.</p><p>OmniScreen achieved an AUC of 0.81 for predicting ERBB2 amplification (predictive of response to drugs such as trastuzumab) in both primary breast cancers and metastatic gastric cancers. In metastatic NSCLC, our evaluation showed that the prediction of ERBB2 oncogenic alterations and amplification associated with response to Fam-Trastuzumab Deruxtecan-nxki both achieved an AUC of 0.79. In particular, the ERBB2 amplification prediction demonstrated a NPV of 100%, suggesting its potential to accurately identify patients without ERBB2 amplification who are unlikely to benefit from HER2-targeted therapy.</p><p>In addition to ERBB2, OmniScreen identified multiple actionable oncogenic drivers in NSCLC (AUC &gt;0.75) with approved TKI-based therapies targeting specific mutations in genes such as EGFR, KRAS, MET, and RET. In primary NSCLC, OmniScreen demonstrated robust performance in predicting TKI-targetable EGFR mutations (p.L858R, p.T790M, exon 19 deletions, and exon 20 insertions; AUC=0.87), KRAS p.G12C (AUC=0.83), and MET exon 14 deletion/splicing mutations (AUC=0.79), highlighting its potential for precision oncology applications. OmniScreen also performed well in detecting rarer NSCLC mutations associated with targeted therapies, such as RET fusion detection, achieving an AUC of 0.77 in primary samples (N=12/903, 1.3%) and 0.89 in metastatic samples (N=7/390, 1.8%). Notably, RET fusion detection demonstrated an NPV of 100%, reliably excluding patients unlikely to harbor this alteration, and further underscoring the clinical utility of OmniScreen in screening both common and rare actionable mutations.</p><p>Other noteworthy examples include OmniScreen's prediction of FGFR3 hotspot mutations (R248C, S249C, G370C, Y373C), which are predictive of response to drugs like erdafitinib, reaching an AUC of 0.93 in primary bladder cancer, slightly better than its performance in metastatic lesions (AUC=0.82).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.1.5">Biomarkers associated with genome instability</head><p>Genomic instability is a hallmark of many cancers and is associated with an increased likelihood of response to many therapies that improve immune system response to tumor cells. To evaluate whether phenotypes indicative of genomic instability could be detected, we examined three key measures: high tumor mutation burden (TMB-H), microsatellite instability or deficient mismatch repair (MSI-H/dMMR), and chromosomal instability (CIN) (Figure <ref type="figure" target="#fig_7">S4C</ref>).</p><p>OmniScreen demonstrated strong performance in predicting TMB-H, achieving a mean AUC of 0.88 (range: 0.79-0.91) across nine cancer types. Notably, primary CRCs and endometrial cancers, both enriched in TMB-H with prevalence &gt; 20%, demonstrated an AUC of 0.9. Similarly, the model performed well in metastatic esophagogastric cancer, achieving an AUC of 0.87. In soft tissue sarcoma, where TMB-H represents a rare molecular subgroup and the majority of cases exhibit low TMB levels, OmniScreen identified a small subset of primary samples with TMB-H (N=8/346, 2.3%) in our test set, achieving an AUC of 0.89. Further analysis of the TCGA evaluation set substantiated the efficacy of the model in detecting TMB-H across five distinct cancer types, with a mean AUC of 0.89 (Table <ref type="table">S5</ref>).</p><p>Our model exhibited exceptional diagnostic performance in identifying MSI-H/dMMR across various primary tumor types, including CRC (AUC = 0.97), endometrial cancer (AUC = 0.87), esophagogastric cancer (AUC = 0.96), and bladder cancer (AUC = 0.97). In colon adenocarcinomas, the highly attended tiles, to which OmniScreen assigned significant importance during inference, prominently displayed histopathological features characteristic of MSI-H/dMMR, including poorly differentiated, medullary-like patterns of tumor growth with "pushing" borders, tumor infiltrating lymphocytes (TILs), and mucin production (Figure <ref type="figure" target="#fig_5">S5F</ref>). Analysis of the TCGA dataset further validated the robustness of OmniScreen in detecting MSI-H/dMMR phenotypes across CRC, endometrial and gastric cancers, demonstrating a mean AUC of 0.9.</p><p>Individuals with LS are at an increased hereditary risk for MSI-H/dMMRassociated cancers <ref type="bibr" target="#b25">[26]</ref>. LS is diagnosed through the identification of germline pathogenic mutations in MMR genes or EPCAM. Using a surrogate ground truth based on these mutations, OmniScreen achieved strong performance in primary CRC, with an AUC of 0.85 for LS prediction.</p><p>While MSI-H/dMMR highlights genomic instability driven by small-scale mutations, CIN represents a distinct form of genomic instability characterized by large-scale structural and numerical chromosomal alterations. In this study, CIN data were exclusively curated for breast and ovarian cancers, and assessed using five metrics indicative of chromosomal aberrations: tetraploidy, WGD, FGA ≥ 30%, LOH ≥ 50%, and genome instability index (GI index) ≥ 20% (see <ref type="bibr">Methods 4)</ref>. Our model demonstrated robust performance in predicting CIN, achieving a mean AUC of 0.84 in primary breast and ovarian samples. In metastatic lesions, slightly higher performance was observed in breast (AUC = 0.83) compared to ovarian cancer (AUC = 0.8).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.1.6">Biomarkers associated with histological subtypes</head><p>In renal cell carcinoma, loss of function in VHL is a hallmark of ccRCC <ref type="bibr" target="#b37">[38,</ref><ref type="bibr" target="#b38">39]</ref>. The prediction of VHL oncogenic mutation accurately identified ccRCC with an AUC of 0.94. The regions highly attended by OmniScreen demonstrated its ability to detect the characteristic clear cell histology of renal cell carcinoma, even in cases with high WHO/ISUP 4 nuclear grades (Figure <ref type="figure" target="#fig_5">S5C</ref>).</p><p>Similarly, within pancreatic cancers, MEN1 and ATRX were frequently mutated in pancreatic neuroendocrine tumor <ref type="bibr" target="#b39">[40]</ref>. Prediction of oncogenic mutation/deletion in these two genes could diagnose pancreatic neuroendocrine tumor (MEN1, AUC=0.98; ATRX, AUC=0.93), while KRAS oncogenic mutation prediction correctly identified pancreatic adenocarcinoma diagnosis with an AUC of 0.95. Other examples of distinct phenotypic associations include the prediction of genomic alterations in GNAQ (AUC=0.92) and GNA11 (AUC=0.9), identifying uveal melanoma, and RET mutations detecting medullary thyroid cancer (MTC) with an AUC of 0.99.</p><p>OmniScreen effectively detected a wide range of genomic alterations and histopathological features across diverse soft tissue sarcoma subtypes, highlighting its versatility in diagnosing both common and rare sarcoma entities. For example, the prediction of RB1 deletion achieved high accuracy (AUC=0.91) in identifying leiomyosarcoma, a subtype of sarcoma with high incidence of RB1 loss. In RB1-loss WSIs, the model focused on hallmark features of leiomyosarcoma, such as spindle-shaped tumor cells with eosinophilic cytoplasm arranged in storiform or fascicular growth patterns and areas with pronounced nuclear atypia (Figure <ref type="figure" target="#fig_5">S5D</ref>). OmniScreen accurately predicted MDM2 amplification to diagnose well-differentiated (WDLPS) and dedifferentiated liposarcoma (DDLPS) with AUCs of 0.91 and 0.86, respectively, reflecting the high prevalence of MDM2 amplification in these subtypes <ref type="bibr" target="#b40">[41,</ref><ref type="bibr" target="#b41">42]</ref>. OmniScreen also effectively detected TERT oncogenic mutations for diagnosing myxoid liposarcoma (AUC=0.93), and demonstrated exceptional accuracy in predicting WT1 fusions to identify desmoplastic small round cell tumor (DSRCTs; AUC=0.99), which are canonically characterized by the EWSR1-WT1 fusion <ref type="bibr" target="#b42">[43]</ref>.</p><p>OmniScreen not only identifies established histological subtypes but also differentiates subsets within the same subtype based on distinct molecular profiles. In LUSC, KMT2D deficiency promotes tumor progression <ref type="bibr" target="#b43">[44]</ref> and enhances sensitivity to therapies targeting the RTK-RAS signaling pathway. Our evaluation demonstrated that diagnosing LUSC through the prediction of KMT2D onco-genic mutation achieved an AUC of 0.90. Highly attended regions in KMT2D TP WSIs indicated that the model focused on areas with moderate to high nuclear pleomorphism and atypia along with features characteristic of squamous cell differentiation, such as intercellular bridges and focal keratinization (Figure <ref type="figure" target="#fig_5">S5E</ref>). KMT2D prediction by OmniScreen was also accurate in poorly differentiated examples, where squamous differentiation might require ancillary IHC to diagnose. In contrast, SOX2 amplification represents a distinct category of chromosomal aberrations in LUSC, contributing to tumor initiation and progression in a substantial subset of cases <ref type="bibr" target="#b44">[45]</ref>. The prediction of SOX2 amplification achieved an AUC of 0.91 for diagnosing specific subsets of cases in LUSC.</p><p>Lastly, a single biomarker can identify shared pathological features across tumor subtypes. For example, the prediction of ARID1A deleterious mutations, frequently found in clear cell and endometrioid ovarian cancers <ref type="bibr" target="#b45">[46]</ref>, achieved AUCs of 0.95 and 0.89 for identifying OCCC (N=29) and endometrioid ovarian cancers (N=23) respectively.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.1.7">Cost saving analysis</head><p>We first assumed a typical Phase 3 study seeking to enroll 500 patients with a mutation in a target gene in a particular type of cancer. We selected BRAF (CRC and melanoma), EGFR (NSCLC), FGFR3 (bladder cancer), KRAS (NSCLC and CRC), and MET (NSCLC), as these are commonly assessed by NGS or PCR clinically, allowing good estimates of the cost of these molecular assays along with a nominal cost of AI model screening. Prevalence of these mutations in these forms of cancer at published rates was assumed, with KRAS in NSCLC given a low estimate for a population with little to no smoking and a higher estimate for a population with high smoking prevalence. From this, we calculated the estimated cost savings due to reduced numbers of definitive NGS or PCR tests needed after our AI model identified cases unlikely to harbor the targeted mutation, and hence would not benefit from the targeted therapy or respond to targeted drugs.</p><p>We found potential for substantial savings across all genes and cancer types investigated (Figure <ref type="figure" target="#fig_7">S4B</ref>). Study enrollment savings for screening PCR or NGS were highest for genes in which the targeted mutation type was lower in prevalence, due to reduced numbers of mutation negative patients sent on for definitive molecular screening. On average, an 18% and 26% cost saving in our hypothetical setting could be achieved in PCR (range 5%-30%) and NGS (range 13%-39%) testing, respectively. This translates to an average cost reduction of approximately $320K (range $31K-$1,215K) and $1,086K (range $188K-$3,930K) for enrollment screening PCR and NGS testing.</p><p>The cost savings calculation for using an AI model to triage for downstream molecular testing were done according to the following method:</p><p>Assuming enrollment of a target number of patients all with tumors harboring a specific mutation, cost estimation for patient screening was calculated by 1) estimating cost to enroll the target number of patients using a conventional molecular test (NGS or PCR) only, and 2) NGS or PCR following AI-based pre-screening to eliminate patients who were not likely to have the targeted mutation. The cost savings was then calculated as follows: Number of patients to be screened by molecular testing without AI model:</p><formula xml:id="formula_1">•</formula><formula xml:id="formula_2">N conventional = N target prevalence</formula><p>Total cost of patients to be screened by molecular testing only without engaging an AI model:</p><formula xml:id="formula_3">C conventional = C testing × N conventional 2.</formula><p>Cost estimation for patient screening using a molecular testing with an AI model for pre-screening:</p><p>Number of patients to be screened with an AI model:</p><formula xml:id="formula_4">N screened = N target prevalence × sensitivity</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Number of true positives (TP):</head><formula xml:id="formula_5">T P = N screened × prevalence × sensitivity</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Number of false positives (FP):</head><formula xml:id="formula_6">F P = N screened × (1 -prevalence) × (1 -specif icity)</formula><p>Number of patients sent for molecular testing:</p><formula xml:id="formula_7">N sent = T P + F P</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cost of AI model for screening all patients:</head><formula xml:id="formula_8">C total(AI) = C AI × N screened</formula><p>Cost of molecular testing for patients sent for testing:</p><formula xml:id="formula_9">C total(testing) = C testing × N sent</formula><p>Total cost of patients' molecular testing with AI screening:</p><formula xml:id="formula_10">C with AI = C total(AI) + C total(testing)</formula><p>Total cost saving by using an AI model for pre-screening:</p><formula xml:id="formula_11">C saving = C conventional -C with AI</formula><p>Hence, the percentage of cost reduction by using an AI model for prescreening:</p><formula xml:id="formula_12">C% = C saving C conventional</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.2">Supplementary Tables</head><p>Table S5: Genetic alteration biomarkers validated in both MSK and TCGA cohorts Gene Biomarker Cancer Type MSK TCGA AUC Sensitivity Specificity AUC Sensitivity Specificity E2F3 E2F3 amplification Bladder Cancer 0.88 1.00 0.51 0.86 1.00 0.23 FGFR FGFR oncogenic mutation Bladder Cancer 0.92 0.95 0.47 0.80 0.86 0.46 FGFR3 FGFR3 oncogenic alterations: amplification/mutation Bladder Cancer 0.91 0.98 0.30 0.81 0.91 0.37 ER Breast Cancer 0.95 0.93 0.76 0.92 0.93 0.79 CDH1 CDH1 oncogenic mutation Breast Cancer 0.94 0.87 0.91 0.88 0.72 0.88 PR Breast Cancer 0.89 0.95 0.56 0.83 0.97 0.53 CDH1 CDH1 oncogenic alterations: deletion/mutation Breast Cancer 0.94 0.89 0.91 0.90 0.85 0.86 TP53 TP53 oncogenic alterations: deletion/mutation Breast Cancer 0.89 0.93 0.63 0.89 0.89 0.71 TP53 TP53 oncogenic mutation Breast Cancer 0.89 0.93 0.61 0.88 0.90 0.71 Fragment of genome altered ≥ 30% Breast Cancer 0.90 0.89 0.68 0.87 0.83 0.68 RNF43 RNF43 oncogenic mutation Colorectal Cancer 0.93 0.97 0.65 0.96 1.00 0.74 TGFBR2 TGFBR2 oncogenic alterations: deletion/mutation Colorectal Cancer 0.95 1.00 0.72 0.83 1.00 0.72 KMT2D KMT2D oncogenic mutation Colorectal Cancer 0.91 0.86 0.87 0.98 1.00 0.90 KMT2B KMT2B oncogenic mutation Colorectal Cancer 0.94 1.00 0.62 0.91 1.00 0.71 KMT2B KMT2B oncogenic alterations: deletion/mutation Colorectal Cancer 0.94 0.98 0.63 0.92 1.00 0.67 ZFHX3 ZFHX3 oncogenic alterations: deletion/mutation Colorectal Cancer 0.93 1.00 0.69 0.97 1.00 0.59 RTEL1 RTEL1 amplification Colorectal Cancer 0.86 0.82 0.72 0.82 0.62 0.80 RNF43 RNF43 oncogenic alterations: deletion/mutation Colorectal Cancer 0.93 0.99 0.66 0.93 1.00 0.71 ZFHX3 ZFHX3 oncogenic mutation Colorectal Cancer 0.93 1.00 0.70 0.99 1.00 0.75 BCL2L1 BCL2L1 amplification Colorectal Cancer 0.86 0.86 0.70 0.77 0.80 0.63 MSI-H vs MSS Colorectal Cancer 0.98 0.93 0.93 0.95 0.88 0.90 AXIN2 AXIN2 oncogenic mutation Colorectal Cancer 0.88 0.97 0.49 0.88 1.00 0.72 MSI-H/dMMR Colorectal Cancer 0.97 0.93 0.92 0.97 0.88 0.86 B2M B2M oncogenic alterations: deletion/mutation Colorectal Cancer 0.91 0.94 0.78 0.79 0.75 0.71 TMB-H Colorectal Cancer 0.90 0.89 0.61 0.93 0.93 0.71 B2M B2M oncogenic mutation Colorectal Cancer 0.90 0.94 0.78 0.81 1.00 0.77 CTNNB1 CTNNB1 oncogenic alterations: amplification/mutation Endometrial Cancer 0.87 0.92 0.57 0.79 0.90 0.52 POLE POLE oncogenic mutation Endometrial Cancer 0.87 0.81 0.77 0.87 1.00 0.55 PTEN PTEN oncogenic alterations: deletion/mutation Endometrial Cancer 0.88 0.95 0.63 0.93 0.97 0.54 PTEN PTEN oncogenic mutation Endometrial Cancer 0.89 0.96 0.64 0.91 0.92 0.57 TMB-H Endometrial Cancer 0.90 0.85 0.76 0.87 0.79 0.84 JAK1 JAK1 oncogenic alterations: deletion/mutation Endometrial Cancer 0.91 0.83 0.80 0.82 0.56 0.87 MSI-H/dMMR Endometrial Cancer 0.87 0.86 0.75 0.81 0.86 0.59 MSI-H vs MSS Endometrial Cancer 0.91 0.85 0.82 0.83 0.86 0.64 TP53 TP53 oncogenic alterations: deletion/mutation Endometrial Cancer 0.90 0.85 0.86 0.90 0.85 0.83 TP53 TP53 oncogenic mutation Endometrial Cancer 0.90 0.87 0.87 0.90 0.84 0.82 CTNNB1 CTNNB1 oncogenic mutation Endometrial Cancer 0.87 0.92 0.58 0.79 0.90 0.52 KMT2D KMT2D oncogenic mutation Esophagogastric Cancer 0.87 0.81 0.73 0.94 1.00 0.70 CDH1 CDH1 oncogenic mutation Esophagogastric Cancer 0.89 0.89 0.73 0.96 1.00 0.84 CDH1 CDH1 oncogenic alterations: deletion/mutation Esophagogastric Cancer 0.90 0.89 0.77 0.96 1.00 0.86 KMT2D KMT2D oncogenic alterations: deletion/mutation Esophagogastric Cancer 0.89 0.94 0.76 0.93 1.00 0.74 EGFR EGFR oncogenic alterations: amplification/mutation Glioma 0.85 0.87 0.59 0.90 0.91 0.70 CIC CIC oncogenic mutation Glioma 0.96 0.82 0.92 0.93 0.78 0.87 CDKN2A CDKN2A (p14ARF) deletion Glioma 0.86 0.93 0.59 0.86 0.89 0.66 CDKN2A CDKN2A (p16INK4a) deletion Glioma 0.86 0.93 0.56 0.86 0.87 0.67 IDH1 IDH1 oncogenic mutation Glioma 0.94 0.88 0.87 0.94 0.91 0.81 CDKN2B CDKN2B deletion Glioma 0.86 0.92 0.61 0.85 0.87 0.67 CDKN2B CDKN2B oncogenic alterations: deletion/mutation Glioma 0.86 0.92 0.62 0.89 0.91 0.72 IDH1 IDH1 oncogenic alterations: amplification/mutation Glioma 0.95 0.89 0.86 0.93 0.92 0.76 ATRX ATRX oncogenic mutation Glioma 0.86 0.92 0.46 0.92 1.00 0.37 CIC CIC oncogenic alterations: deletion/mutation Glioma 0.96 0.82 0.94 0.91 0.72 0.89 EGFR EGFR amplification Glioma 0.87 0.87 0.62 0.90 0.93 0.67 ATRX ATRX oncogenic alterations: deletion/mutation Glioma 0.86 0.90 0.53 0.92 1.00 0.47 IDH1 IDH1 oncogenic alterations: amplification/mutation Hepatobiliary Cancer 0.87 0.85 0.79 0.92 0.80 0.95 SF3B1 SF3B1 oncogenic mutation Melanoma 0.93 1.00 0.60 0.98 1.00 0.19 EGFR EGFR oncogenic mutation Non-Small Cell Lung Cancer 0.88 0.94 0.58 0.81 0.67 0.87 STK11 STK11 oncogenic alterations: deletion/mutation Non-Small Cell Lung Cancer 0.87 0.84 0.72 0.94 1.00 0.64 STK11 STK11 oncogenic mutation Non-Small Cell Lung Cancer 0.87 0.81 0.73 0.94 1.00 0.75 AKT2 AKT2 oncogenic alterations: amplification/mutation Ovarian Cancer 0.86 0.92 0.50 0.90 1.00 0.30 AKT2 AKT2 amplification Ovarian Cancer 0.86 1.00 0.49 0.86 1.00 0.23 TP53 TP53 oncogenic alterations: deletion/mutation Pancreatic Cancer 0.86 0.88 0.63 0.76 0.88 0.43 VHL VHL oncogenic alterations: deletion/mutation Renal Cell Carcinoma 0.87 0.93 0.73 0.88 0.69 0.87 VHL VHL oncogenic mutation Renal Cell Carcinoma 0.87 0.97 0.72 0.86 0.82 0.80 MDM2 MDM2 oncogenic alterations: amplification/mutation Soft Tissue Sarcoma 0.88 0.85 0.70 0.76 1.00 0.49 MDM2 MDM2 amplification Soft Tissue Sarcoma 0.88 0.83 0.76 0.76 0.91 0.53 RB1 RB1 oncogenic alterations: deletion/mutation Soft Tissue Sarcoma 0.87 0.84 0.72 0.78 1.00 0.28 BRAF BRAF oncogenic mutation Thyroid Cancer 0.91 0.88 0.58 0.93 0.96 0.40 BRAF BRAF oncogenic alterations: amplification/mutation Thyroid Cancer 0.91 0.88 0.71 0.92 0.96 0.46 Table S6: Genetic alteration biomarkers associated with histologic subtypes Cancer Type Histology Biomarker KS-test adj.P-value AUC AP Sensitivity Specificity PPV NPV Positive Negative Total Breast Cancer Breast Invasive Lobular Carcinoma CDH1 oncogenic alterations: deletion/mutation 1.88e-74 0.94 0.68 0.86 0.90 0.51 0.98 131 1046 Colorectal Cancer Mucinous Adenocarcinoma of the Colon and Rectum GNAS oncogenic mutation 6.98e-13 0.94 0.25 1.00 0.72 0.07 1.00 20 970 Endometrial Cancer Uterine Endometrioid Carcinoma SOX17 oncogenic mutation 2.15e-43 0.88 0.87 0.69 0.88 0.87 0.71 263 222 Endometrial Cancer Uterine Endometrioid Carcinoma PTEN oncogenic alterations: deletion/mutation 5.20e-46 0.88 0.88 0.86 0.74 0.80 0.82 263 222 Endometrial Cancer Uterine Endometrioid Carcinoma CTCF oncogenic mutation 7.92e-47 0.87 0.87 0.72 0.84 0.84 0.72 263 222 Endometrial Cancer Uterine Serous Carcinoma/Uterine Papillary Serous Carcinoma TP53 oncogenic alterations: deletion/mutation 1.04e-33 0.90 0.55 1.00 0.64 0.36 1.00 83 402 Endometrial Cancer Uterine Serous Carcinoma/Uterine Papillary Serous Carcinoma CCNE1 oncogenic alterations: amplification/mutation 8.86e-27 0.88 0.57 0.81 0.80 0.45 0.95 83 402 Endometrial Cancer Uterine Serous Carcinoma/Uterine Papillary Serous Carcinoma ERBB2 amplification 6.37e-25 0.86 0.49 0.86 0.74 0.41 0.96 83 402 Esophagogastric Cancer Esophageal Squamous Cell Carcinoma FGF19 amplification 2.91e-08 0.88 0.44 1.00 0.45 0.11 1.00 24 350 Esophagogastric Cancer Esophageal Squamous Cell Carcinoma FGF3 oncogenic alterations: amplification/mutation 6.04e-10 0.88 0.41 1.00 0.40 0.10 1.00 24 350 Esophagogastric Cancer Esophageal Squamous Cell Carcinoma CCND1 amplification 1.27e-07 0.88 0.43 1.00 0.45 0.11 1.00 24 350 Esophagogastric Cancer Esophageal Squamous Cell Carcinoma FGF4 oncogenic alterations: amplification/mutation 5.77e-08 0.86 0.37 0.96 0.47 0.11 0.99 24 350 Esophagogastric Cancer Signet Ring Cell Carcinoma of the Stomach CDH1 oncogenic alterations: deletion/mutation 1.71e-03 0.86 0.13 0.78 0.75 0.07 0.99 9 365 Glioma Anaplastic Oligodendroglioma NOTCH1 oncogenic mutation 1.18e-09 0.98 0.50 1.00 0.78 0.11 1.00 10 376 Glioma Anaplastic Oligodendroglioma CIC oncogenic alterations: deletion/mutation 2.54e-10 0.97 0.36 1.00 0.92 0.25 1.00 10 376 Glioma Anaplastic Oligodendroglioma IDH1 oncogenic alterations: amplification/mutation 4.91e-05 0.87 0.10 1.00 0.68 0.08 1.00 10 376 Glioma Oligodendroglioma CIC oncogenic mutation 8.19e-21 0.95 0.56 0.74 0.94 0.55 0.97 35 351 Glioma Oligodendroglioma IDH1 oncogenic alterations: amplification/mutation 1.06e-14 0.89 0.35 0.94 0.72 0.25 0.99 35 351 Hepatobiliary Cancer Fibrolamellar Carcinoma DNAJB1 fusion 4.33e-05 0.86 0.62 0.86 0.99 0.67 1.00 7 226 Hepatobiliary Cancer Hepatocellular Carcinoma CTNNB1 oncogenic mutation 1.47e-19 0.90 0.73 0.84 0.83 0.56 0.95 49 184 Melanoma Uveal Melanoma GNAQ oncogenic mutation 1.71e-12 0.92 0.58 0.91 0.81 0.26 0.99 22 307 Melanoma Uveal Melanoma GNA11 oncogenic mutation 4.24e-12 0.90 0.68 0.82 0.79 0.22 0.98 22 307 Melanoma Uveal Melanoma SF3B1 oncogenic alterations: amplification/mutation 2.63e-08 0.89 0.40 0.91 0.70 0.18 0.99 22 307 Non-Small Cell Lung Cancer Lung Squamous Cell Carcinoma SOX2 amplification 2.7e-51 0.91 0.67 0.56 0.97 0.66 0.95 139 1154 Non-Small Cell Lung Cancer Lung Squamous Cell Carcinoma KMT2D oncogenic mutation 1.29e-55 0.90 0.62 0.94 0.53 0.20 0.99 139 1154 Non-Small Cell Lung Cancer Lung Squamous Cell Carcinoma FGF3 oncogenic alterations: amplification/mutation 1.31e-44 0.86 0.47 0.90 0.63 0.23 0.98 139 1154 Non-Small Cell Lung Cancer Lung Squamous Cell Carcinoma FGF4 amplification 1.55e-43 0.86 0.49 0.89 0.64 0.23 0.98 139 1154 Non-Small Cell Lung Cancer Lung Squamous Cell Carcinoma PRKCI amplification 2.21e-40 0.86 0.54 0.77 0.78 0.30 0.97 139 1154 Non-Small Cell Lung Cancer Lung Squamous Cell Carcinoma FGF19 oncogenic alterations: amplification/mutation 3.91e-39 0.85 0.43 0.91 0.58 0.21 0.98 139 1154 Non-Small Cell Lung Cancer Lung Squamous Cell Carcinoma CCND1 oncogenic alterations: amplification/mutation 6.15e-36 0.85 0.40 0.96 0.50 0.19 0.99 139 1154 Ovarian Cancer Clear Cell Ovarian Cancer ARID1A oncogenic mutation 9.72e-20 0.95 0.58 0.97 0.61 0.15 1.00 29 420 Ovarian Cancer Clear Cell Ovarian Cancer PPP2R1A oncogenic mutation 8.25e-13 0.92 0.56 0.93 0.69 0.17 0.99 29 420 Ovarian Cancer Clear Cell Ovarian Cancer PIK3CA oncogenic mutation 7.28e-15 0.92 0.44 1.00 0.34 0.09 1.00 29 420 Ovarian Cancer Clear Cell Ovarian Cancer PIK3R1 oncogenic mutation 4.3e-11 0.88 0.29 0.90 0.66 0.15 0.99 29 420 Ovarian Cancer Endometrioid Ovarian Cancer ARID1A oncogenic mutation 4.86e-13 0.89 0.32 0.96 0.60 0.11 1.00 23 426 Ovarian Cancer Endometrioid Ovarian Cancer KMT2B oncogenic alterations: deletion/mutation 2.21e-07 0.86 0.45 0.48 0.96 0.42 0.97 23 426 Pancreatic Cancer Pancreatic Adenocarcinoma KRAS oncogenic alterations: amplification/mutation 8.46e-56 0.95 0.98 0.86 0.95 0.98 0.64 370 92 Pancreatic Cancer Pancreatic Adenocarcinoma TP53 oncogenic mutation 6.85e-22 0.86 0.95 0.81 0.73 0.92 0.48 370 92 Pancreatic Cancer Pancreatic Neuroendocrine Tumor MEN1 oncogenic alterations: deletion/mutation 2.98e-43 0.98 0.88 0.82 0.96 0.78 0.97 65 397 Pancreatic Cancer Pancreatic Neuroendocrine Tumor ATRX oncogenic alterations: deletion/mutation 4.18e-32 0.93 0.77 0.29 1.00 0.95 0.90 65 397 Prostate Cancer Prostate Adenocarcinoma SPOP oncogenic mutation 9.10e-12 0.94 1.00 0.70 1.00 1.00 0.07 665 16 Renal Cell Carcinoma Chromophobe Renal Cell Carcinoma TP53 oncogenic mutation 3.54e-09 0.94 0.45 1.00 0.64 0.16 1.00 15 219 Renal Cell Carcinoma Renal Clear Cell Carcinoma VHL oncogenic mutation 8.11e-39 0.94 0.93 0.96 0.86 0.89 0.95 129 105 Renal Cell Carcinoma Renal Clear Cell Carcinoma PBRM1 oncogenic alterations: deletion/mutation 1.07e-28 0.92 0.93 0.71 0.91 0.91 0.72 129 105 Renal Cell Carcinoma Renal Clear Cell Carcinoma SETD2 oncogenic alterations: deletion/mutation 3.49e-20 0.85 0.85 0.93 0.63 0.75 0.88 129 105 Soft Tissue Sarcoma Dedifferentiated Liposarcoma CDK4 amplification 1.27e-20 0.87 0.46 0.82 0.81 0.37 0.97 56 406 Soft Tissue Sarcoma Dedifferentiated Liposarcoma MDM2 oncogenic alterations: amplification/mutation 3.53e-20 0.86 0.42 0.88 0.67 0.27 0.97 56 406 Soft Tissue Sarcoma Dedifferentiated Liposarcoma TNFAIP3 amplification 6.81e-15 0.85 0.49 0.93 0.61 0.25 0.98 56 406 Soft Tissue Sarcoma Desmoplastic Small-Round-Cell Tumor WT1 fusion 5.16e-19 0.99 0.84 0.94 0.97 0.52 1.00 17 445 Soft Tissue Sarcoma Leiomyosarcoma MAP2K4 amplification 1.15e-28 0.94 0.80 0.92 0.81 0.37 0.99 49 413 Soft Tissue Sarcoma Leiomyosarcoma NCOR1 amplification 3.88e-24 0.93 0.71 0.92 0.80 0.35 0.99 49 413 Soft Tissue Sarcoma Leiomyosarcoma RB1 deletion 6.08e-24 0.91 0.54 0.96 0.74 0.30 0.99 49 413 Soft Tissue Sarcoma Leiomyosarcoma CYSLTR2 deletion 5.49e-18 0.87 0.42 0.90 0.70 0.27 0.98 49 413 Soft Tissue Sarcoma Myxoid/Round-Cell Liposarcoma TERT oncogenic mutation 3.48e-07 0.93 0.63 1.00 0.39 0.04 1.00 12 450 Soft Tissue Sarcoma Well-Differentiated Liposarcoma MDM2 amplification 5.97e-09 0.91 0.38 0.95 0.70 0.12 1.00 19 443 Thyroid Cancer Anaplastic Thyroid Cancer TP53 oncogenic mutation 1.03e-10 0.89 0.63 0.88 0.72 0.33 0.97 25 159 Thyroid Cancer Hurthle Cell Thyroid Cancer DAXX oncogenic mutation 1.26e-08 0.97 0.66 1.00 0.67 0.15 1.00 10 174 Thyroid Cancer Medullary Thyroid Cancer RET oncogenic mutation 2.38e-17 0.99 0.94 0.44 1.00 1.00 0.94 18 166 Table S7: Genetic alteration biomarkers associated with specific therapeutic hotspot mutations in target genes. Target Gene Cancer Type Tumor Site Biomarker AUC AP Sensitivity Specificity PPV NPV Positive Negative Total AKT1 Bladder Cancer Primary AKT1 oncogenic mutation 0.93 0.30 1.00 0.26 0.03 1.00 7 342 AKT1 Colorectal Cancer Primary AKT1 oncogenic mutation 0.77 0.04 0.88 0.65 0.03 1.00 8 691 AKT1 Endometrial Cancer Primary AKT1 oncogenic mutation 0.81 0.17 0.85 0.55 0.07 0.99 13 352 AKT1 Prostate Cancer Metastasis AKT1 oncogenic mutation 0.77 0.07 1.00 0.24 0.03 1.00 6 291 ATM Colorectal Cancer Primary ATM oncogenic mutation 0.77 0.24 0.90 0.34 0.09 0.98 48 651 ATM Melanoma Metastasis ATM deletion 0.76 0.07 0.83 0.55 0.05 0.99 6 202 ATR Colorectal Cancer Primary ATR oncogenic mutation 0.88 0.10 1.00 0.70 0.07 1.00 16 683 ATR Endometrial Cancer Primary ATR oncogenic mutation 0.89 0.21 1.00 0.71 0.08 1.00 9 356 BARD1 Colorectal Cancer Primary BARD1 oncogenic mutation 0.88 0.08 1.00 0.70 0.06 1.00 12 687 BRAF Colorectal Cancer Primary BRAF oncogenic mutation 0.91 0.58 1.00 0.46 0.15 1.00 62 637 BRAF Colorectal Cancer Primary BRAF fusion 0.85 0.47 0.95 0.44 0.14 0.99 62 637 BRAF Glioma Primary BRAF oncogenic mutation 0.88 0.12 1.00 0.45 0.04 1.00 9 375 BRAF Glioma Primary BRAF amplification 0.75 0.05 1.00 0.36 0.04 1.00 9 375 BRAF Melanoma Primary BRAF oncogenic mutation 0.76 0.46 0.96 0.31 0.27 0.97 25 96 BRAF Non-Small Cell Lung Cancer Primary BRAF oncogenic mutation 0.77 0.09 1.00 0.25 0.02 1.00 11 892 BRAF Thyroid Cancer Metastasis BRAF oncogenic mutation 0.89 0.88 0.88 0.71 0.69 0.89 48 66 BRAF Thyroid Cancer Primary BRAF oncogenic mutation 0.93 0.94 0.90 0.59 0.64 0.88 31 39 BRCA1 Breast Cancer Primary BRCA1 oncogenic mutation 0.90 0.07 1.00 0.59 0.03 1.00 7 528 BRCA1 Breast Cancer Primary BRCA1 fusion 0.88 0.18 0.86 0.62 0.03 1.00 7 528 BRCA1 Colorectal Cancer Primary BRCA1 oncogenic mutation 0.87 0.07 0.90 0.67 0.04 1.00 10 689 BRCA1 Endometrial Cancer Primary BRCA1 oncogenic mutation 0.85 0.08 1.00 0.66 0.05 1.00 7 358 BRCA2 Colorectal Cancer Primary BRCA2 oncogenic mutation 0.81 0.16 0.85 0.47 0.06 0.99 27 672 BRCA2 Endometrial Cancer Primary BRCA2 oncogenic mutation 0.84 0.27 0.78 0.79 0.16 0.99 18 347 BRCA2 Esophagogastric Cancer Primary BRCA2 oncogenic mutation 0.81 0.29 1.00 0.49 0.05 1.00 7 283 BRCA2 Non-Small Cell Lung Cancer Primary BRCA2 oncogenic mutation 0.77 0.02 1.00 0.46 0.01 1.00 5 898 BRIP1 Non-Small Cell Lung Cancer Primary BRIP1 fusion 0.83 0.02 1.00 0.29 0.01 1.00 5 898 CCND1 Esophagogastric Cancer Metastasis CCND1 amplification 0.84 0.50 0.82 0.62 0.24 0.96 11 73 CCND1 Esophagogastric Cancer Primary CCND1 amplification 0.81 0.24 0.95 0.40 0.10 0.99 19 271 CCND1 Non-Small Cell Lung Cancer Metastasis CCND1 amplification 0.78 0.11 0.92 0.31 0.04 0.99 13 377 CCND1 Non-Small Cell Lung Cancer Primary CCND1 amplification 0.85 0.19 0.96 0.58 0.06 1.00 24 879 CDK12 Colorectal Cancer Primary CDK12 oncogenic mutation 0.88 0.18 1.00 0.27 0.04 1.00 21 678 CDK4 Glioma Primary CDK4 amplification 0.81 0.25 0.96 0.40 0.11 0.99 27 357 CDK4 Non-Small Cell Lung Cancer Primary CDK4 amplification 0.76 0.15 0.83 0.48 0.05 0.99 30 873 CDK4 Soft Tissue Sarcoma Primary CDK4 amplification 0.87 0.73 0.77 0.82 0.52 0.94 71 285 CHEK2 Endometrial Cancer Primary CHEK2 oncogenic mutation 0.93 0.25 1.00 0.53 0.03 1.00 5 360 EGFR Non-Small Cell Lung Cancer Primary EGFR oncogenic mutation 0.87 0.61 0.94 0.58 0.35 0.97 179 724 ERBB2 Breast Cancer Primary ERBB2 amplification 0.81 0.51 0.86 0.50 0.19 0.96 65 470 ERBB2 Breast Cancer Primary ERBB2 fusion 0.75 0.33 0.88 0.34 0.15 0.95 65 470 ERBB2 Esophagogastric Cancer Metastasis ERBB2 amplification 0.81 0.54 0.81 0.59 0.32 0.93 16 68 ERBB2 Esophagogastric Cancer Metastasis ERBB2 fusion 0.78 0.43 1.00 0.22 0.23 1.00 16 68 ERBB2 Non-Small Cell Lung Cancer Metastasis ERBB2 oncogenic mutation 0.79 0.28 0.86 0.47 0.06 0.99 14 376 ERBB2 Non-Small Cell Lung Cancer Metastasis ERBB2 amplification 0.79 0.23 1.00 0.20 0.04 1.00 14 376 ESR1 Breast Cancer Primary ESR1 oncogenic mutation 0.87 0.13 0.80 0.69 0.02 1.00 5 530 ESR1 Breast Cancer Primary ESR1 fusion 0.79 0.03 0.80 0.76 0.03 1.00 5 530 ESR1 Endometrial Cancer Primary ESR1 oncogenic mutation 0.82 0.14 1.00 0.47 0.03 1.00 6 359 FGFR2 Esophagogastric Cancer Primary FGFR2 amplification 0.78 0.08 1.00 0.54 0.06 1.00 9 281 FGFR2 Hepatobiliary Cancer Primary FGFR2 fusion 0.79 0.20 0.77 0.74 0.20 0.97 13 156 FGFR3 Bladder Cancer Metastasis FGFR3 oncogenic mutation 0.82 0.70 0.81 0.51 0.27 0.93 16 74 FGFR3 Bladder Cancer Primary FGFR3 oncogenic mutation 0.93 0.86 0.97 0.32 0.32 0.97 86 263 FGFR3 Glioma Primary FGFR3 fusion 0.95 0.42 1.00 0.49 0.05 1.00 11 373 FGFR3 Glioma Primary FGFR3 amplification 0.84 0.16 0.91 0.53 0.05 0.99 11 373 IDH1 Glioma Primary IDH1 oncogenic mutation 0.94 0.81 0.88 0.87 0.72 0.95 104 280 IDH1 Hepatobiliary Cancer Primary IDH1 oncogenic mutation 0.87 0.31 0.77 0.80 0.24 0.98 13 156 IDH2 Hepatobiliary Cancer Primary IDH2 oncogenic mutation 0.92 0.59 1.00 0.37 0.07 1.00 8 161 KIT Glioma Primary KIT amplification 0.81 0.18 1.00 0.36 0.09 1.00 24 360 KRAS Bladder Cancer Primary KRAS oncogenic mutation 0.75 0.14 0.93 0.39 0.06 0.99 15 334 KRAS Colorectal Cancer Metastasis KRAS oncogenic mutation 0.78 0.80 0.88 0.46 0.60 0.80 141 150 KRAS Colorectal Cancer Primary KRAS oncogenic mutation 0.78 0.73 0.91 0.44 0.53 0.87 289 410 KRAS Endometrial Cancer Metastasis KRAS oncogenic mutation 0.81 0.60 0.79 0.62 0.28 0.94 19 101 KRAS Esophagogastric Cancer Primary KRAS oncogenic mutation 0.83 0.47 0.87 0.47 0.08 0.98 15 275 KRAS Hepatobiliary Cancer Metastasis KRAS oncogenic mutation 0.93 0.66 1.00 0.46 0.30 1.00 12 52 KRAS Hepatobiliary Cancer Primary KRAS oncogenic mutation 0.93 0.54 1.00 0.57 0.13 1.00 10 159 KRAS Non-Small Cell Lung Cancer Primary KRAS oncogenic mutation 0.83 0.68 0.94 0.42 0.40 0.95 263 640 KRAS Ovarian Cancer Metastasis KRAS oncogenic mutation 0.92 0.62 0.93 0.81 0.25 0.99 15 217 KRAS Ovarian Cancer Primary KRAS oncogenic mutation 0.91 0.63 0.96 0.78 0.39 0.99 27 190 KRAS Pancreatic Cancer Metastasis KRAS oncogenic mutation 0.90 0.94 0.82 0.78 0.89 0.68 148 69 KRAS Pancreatic Cancer Primary KRAS oncogenic mutation 0.85 0.94 0.90 0.66 0.90 0.67 189 56 MET Esophagogastric Cancer Metastasis MET amplification 0.84 0.50 1.00 0.39 0.09 1.00 5 79 MET Glioma Primary MET fusion 0.83 0.15 1.00 0.49 0.03 1.00 6 378 MET Non-Small Cell Lung Cancer Primary MET oncogenic mutation 0.79 0.20 0.84 0.56 0.09 0.99 44 859 Table S7: Genetic alteration biomarkers associated with specific therapeutic hotspot mutations in target genes. (continued) MLH1 Colorectal Cancer Primary MLH1 oncogenic mutation 0.95 0.42 1.00 0.78 0.10 1.00 17 682 MLH1 Endometrial Cancer Primary MLH1 oncogenic mutation 0.86 0.24 0.82 0.74 0.09 0.99 11 354 MSH2 Bladder Cancer Primary MSH2 oncogenic mutation 0.96 0.40 1.00 0.55 0.04 1.00 7 342 MSH2 Colorectal Cancer Primary MSH2 oncogenic mutation 0.93 0.22 1.00 0.67 0.09 1.00 21 678 MSH2 Endometrial Cancer Primary MSH2 oncogenic mutation 0.83 0.37 0.80 0.80 0.14 0.99 15 350 MSH6 Colorectal Cancer Primary MSH6 oncogenic mutation 0.91 0.22 0.97 0.81 0.19 1.00 31 668 NBN Colorectal Cancer Primary NBN oncogenic mutation 0.92 0.18 0.92 0.72 0.06 1.00 13 686 NRAS Soft Tissue Sarcoma Primary NRAS oncogenic mutation 0.75 0.03 1.00 0.49 0.03 1.00 5 351 NRAS Thyroid Cancer Primary NRAS oncogenic mutation 0.75 0.42 0.80 0.68 0.30 0.95 10 60 PALB2 Colorectal Cancer Primary PALB2 oncogenic mutation 0.89 0.15 0.91 0.65 0.04 1.00 11 688 PDGFRA Glioma Primary PDGFRA oncogenic mutation 0.77 0.05 1.00 0.30 0.02 1.00 5 379 PIK3CA Hepatobiliary Cancer Metastasis PIK3CA oncogenic mutation 0.76 0.47 0.83 0.36 0.12 0.95 6 58 PIK3CA Ovarian Cancer Metastasis PIK3CA oncogenic mutation 0.81 0.31 1.00 0.37 0.14 1.00 21 211 PIK3CA Ovarian Cancer Primary PIK3CA oncogenic mutation 0.90 0.41 1.00 0.32 0.13 1.00 20 197 PIK3CA Thyroid Cancer Metastasis PIK3CA oncogenic mutation 0.80 0.14 1.00 0.28 0.06 1.00 5 109 PMS2 Colorectal Cancer Primary PMS2 oncogenic mutation 0.86 0.06 0.88 0.66 0.03 1.00 8 691 POLE Colorectal Cancer Primary POLE oncogenic mutation 0.92 0.14 0.77 0.86 0.10 0.99 13 686 POLE Endometrial Cancer Primary POLE oncogenic mutation 0.87 0.43 0.81 0.76 0.21 0.98 26 339 PTEN Colorectal Cancer Metastasis PTEN oncogenic mutation 0.84 0.12 0.80 0.61 0.03 0.99 5 286 PTEN Colorectal Cancer Primary PTEN oncogenic mutation 0.86 0.35 0.95 0.58 0.13 0.99 42 657 PTEN Endometrial Cancer Primary PTEN oncogenic mutation 0.89 0.87 0.96 0.64 0.73 0.93 186 179 PTEN Glioma Primary PTEN oncogenic mutation 0.76 0.43 0.87 0.52 0.33 0.93 82 302 PTEN Non-Small Cell Lung Cancer Metastasis PTEN fusion 0.77 0.08 1.00 0.22 0.03 1.00 10 380 PTEN Ovarian Cancer Primary PTEN oncogenic mutation 0.92 0.67 0.90 0.81 0.18 0.99 10 207 PTEN Renal Cell Carcinoma Metastasis PTEN oncogenic mutation 0.81 0.33 1.00 0.43 0.18 1.00 7 54 PTEN Renal Cell Carcinoma Primary PTEN fusion 0.81 0.12 1.00 0.33 0.04 1.00 5 168 RET Non-Small Cell Lung Cancer Metastasis RET fusion 0.89 0.11 1.00 0.52 0.04 1.00 7 383 RET Non-Small Cell Lung Cancer Primary RET fusion 0.77 0.05 0.83 0.54 0.02 1.00 12 891 SMARCB1 Colorectal Cancer Primary SMARCB1 oncogenic mutation 0.86 0.20 1.00 0.28 0.01 1.00 6 693 SMARCB1 Soft Tissue Sarcoma Primary SMARCB1 deletion 0.86 0.20 0.86 0.52 0.03 0.99 7 349 TP53 Breast Cancer Metastasis TP53 oncogenic mutation 0.76 0.36 0.91 0.41 0.24 0.96 110 532 TP53 Breast Cancer Primary TP53 oncogenic mutation 0.79 0.38 0.97 0.48 0.29 0.99 95 440 TP53 Hepatobiliary Cancer Metastasis TP53 oncogenic mutation 0.81 0.24 1.00 0.51 0.15 1.00 5 59 TP53 Melanoma Metastasis TP53 oncogenic mutation 0.81 0.17 0.90 0.35 0.07 0.99 10 198 TP53 Melanoma Primary TP53 oncogenic mutation 0.83 0.19 1.00 0.52 0.11 1.00 7 114 TP53 Non-Small Cell Lung Cancer Primary TP53 oncogenic mutation 0.75 0.25 0.92 0.43 0.18 0.98 104 799 TP53 Thyroid Cancer Metastasis TP53 oncogenic mutation 0.82 0.17 0.80 0.62 0.09 0.99 5 109 TSC1 Endometrial Cancer Primary TSC1 oncogenic mutation 0.92 0.27 0.83 0.73 0.05 1.00 6 359 TSC2 Colorectal Cancer Primary TSC2 oncogenic mutation 0.77 0.05 1.00 0.35 0.02 1.00 11 688 TSC2 Pancreatic Cancer Metastasis TSC2 oncogenic mutation 0.98 0.54 1.00 0.52 0.05 1.00 5 212 TSC2 Renal Cell Carcinoma Primary TSC2 oncogenic mutation 0.98 0.70 1.00 0.90 0.24 1.00 5 168 Table S9: Performance Metrics for Biomarker Prediction on the MSK Test Set. The performance of biomarkers in primary and metastatic lesions of the 15 most common cancer types are summarized in the following sub-tables S9.1 -S9.15. Metrics include Area Under the Curve (AUC), Average Precision (AP), Sensitivity, Specificity, Positive Predictive Value (PPV), and Negative Predictive Value (NPV). Sample counts are provided for each biomarker, indicating the number of positive, negative, and total samples.</p><p>Table S9.1. Biomarkers detected in Bladder Cancer Tumor Site Biomarker AUC AP Sensitivity Specificity PPV NPV Positive Negative Total Primary MSI-H vs MSS 0.97 0.60 1.00 0.61 0.06 1.00 8 305 Primary MSH2 oncogenic alterations: deletion/mutation 0.97 0.40 1.00 0.64 0.05 1.00 7 342 Primary MSI-H/dMMR 0.97 0.46 1.00 0.60 0.06 1.00 8 305 Primary MSH2 oncogenic mutation 0.96 0.40 1.00 0.55 0.04 1.00 7 342 Primary FGFR3 hotspots/FGFR fusions 0.94 0.86 1.00 0.35 0.32 1.00 76 251 Primary AKT1 oncogenic mutation 0.93 0.30 1.00 0.26 0.03 1.00 7 342 Primary FGFR3 hotspots 0.93 0.86 0.97 0.23 0.28 0.97 76 252 Primary FGFR oncogenic mutation 0.92 0.83 0.95 0.47 0.36 0.97 82 261 Primary FGFR3 oncogenic mutation 0.92 0.81 0.96 0.31 0.30 0.97 81 268 Primary FGFR3 oncogenic alterations: amplification/mutation 0.91 0.83 0.98 0.30 0.31 0.98 86 263 Primary AKT1 oncogenic alterations: amplification/mutation 0.90 0.26 1.00 0.58 0.05 1.00 7 342 Primary MYC amplification 0.89 0.34 1.00 0.35 0.05 1.00 11 338 Primary RB1 deletion 0.88 0.18 0.78 0.71 0.07 0.99 9 340 Primary MYC oncogenic alterations: amplification/mutation 0.88 0.33 1.00 0.35 0.05 1.00 11 338 Primary E2F3 amplification 0.88 0.40 1.00 0.51 0.19 1.00 35 314 Primary TP53 oncogenic alterations: deletion/mutation 0.88 0.86 0.93 0.57 0.67 0.90 169 180 Primary MTAP oncogenic alterations: deletion/mutation 0.87 0.57 1.00 0.36 0.22 1.00 24 133 Primary MTAP deletion 0.87 0.58 1.00 0.34 0.21 1.00 23 134 Primary TP53 oncogenic mutation 0.86 0.84 0.93 0.58 0.66 0.91 165 184 Primary ERBB2 amplification 0.86 0.26 0.92 0.41 0.06 0.99 13 336 Primary RB1 oncogenic alterations: deletion/mutation 0.85 0.52 0.92 0.65 0.36 0.97 61 288 Primary CDK12 amplification 0.85 0.19 0.75 0.73 0.09 0.99 12 337 Primary CDH1 oncogenic alterations: deletion/mutation 0.84 0.45 0.86 0.61 0.09 0.99 14 335 Primary RB1 oncogenic mutation 0.83 0.45 0.89 0.61 0.29 0.97 54 295 Primary GATA3 amplification 0.83 0.09 0.89 0.48 0.04 0.99 9 340 Primary CDKN2A (p14ARF) deletion 0.83 0.51 0.98 0.47 0.29 0.99 62 287 Primary CDH1 oncogenic mutation 0.82 0.46 0.86 0.44 0.06 0.99 14 335 Primary CDKN2B deletion 0.82 0.48 0.98 0.43 0.25 0.99 57 292 Primary CDKN2B oncogenic alterations: deletion/mutation 0.82 0.48 0.98 0.43 0.25 0.99 57 292 Primary CDKN2A (p16INK4a) deletion 0.82 0.51 0.95 0.48 0.29 0.98 64 285 Primary FGFR1 amplification 0.82 0.10 1.00 0.27 0.04 1.00 9 340 Primary TGFBR1 oncogenic alterations: deletion/mutation 0.82 0.11 1.00 0.50 0.04 1.00 7 342 Primary PPARG amplification 0.82 0.35 0.93 0.34 0.07 0.99 15 291 Primary SDHC amplification 0.81 0.17 0.94 0.38 0.07 0.99 16 333 Primary RAF1 amplification 0.81 0.18 1.00 0.34 0.05 1.00 12 337 Primary CCNE1 amplification 0.81 0.13 0.89 0.54 0.05 0.99 9 340 Primary TERT oncogenic alterations: amplification/mutation 0.81 0.86 0.95 0.26 0.68 0.76 216 133 Primary CCNE1 oncogenic alterations: amplification/mutation 0.80 0.20 0.78 0.56 0.05 0.99 9 340 Primary RICTOR amplification 0.80 0.09 0.88 0.52 0.04 0.99 8 341 Primary IL7R amplification 0.79 0.07 0.86 0.51 0.03 0.99 7 342 Primary AKT2 amplification 0.79 0.07 0.88 0.54 0.04 0.99 8 341 Primary TERT oncogenic mutation 0.79 0.82 0.96 0.26 0.66 0.82 208 141 Primary RICTOR oncogenic alterations: amplification/mutation 0.78 0.08 0.88 0.57 0.05 0.99 8 341 Primary MDM2 oncogenic alterations: amplification/mutation 0.78 0.15 1.00 0.33 0.08 1.00 18 331 Primary DROSHA amplification 0.78 0.07 0.88 0.51 0.05 0.99 8 298 Primary MCL1 oncogenic alterations: amplification/mutation 0.77 0.22 0.94 0.40 0.07 0.99 16 333 Primary MDM2 amplification 0.77 0.19 1.00 0.30 0.07 1.00 18 331 Primary H3C13 amplification 0.76 0.13 0.75 0.57 0.04 0.99 8 336 Primary NF2 amplification 0.76 0.09 0.78 0.56 0.05 0.99 9 340 Primary SETDB1 amplification 0.76 0.24 0.88 0.60 0.10 0.99 8 149 Table S9.1. Biomarkers detected in Bladder Cancer (continued) Tumor Site Biomarker AUC AP Sensitivity Specificity PPV NPV Positive Negative Total Metastasis CYSLTR2 deletion 1.00 1.00 1.00 0.49 0.08 1.00 3 67 Metastasis RB1 deletion 1.00 1.00 1.00 0.80 0.15 1.00 3 87 Metastasis TGFBR1 oncogenic alterations: deletion/mutation 0.99 0.83 1.00 0.72 0.07 1.00 2 88 Metastasis NFE2L2 oncogenic mutation 0.98 0.70 1.00 0.44 0.06 1.00 3 87 Metastasis FOXO1 deletion 0.97 0.33 1.00 0.78 0.10 1.00 2 88 Metastasis SDHA amplification 0.96 0.60 1.00 0.49 0.08 1.00 4 86 Metastasis TGFBR1 deletion 0.94 0.27 1.00 0.90 0.18 1.00 2 88 Metastasis CREBBP oncogenic alterations: deletion/mutation 0.94 0.51 1.00 0.34 0.08 1.00 5 85 Metastasis TERT amplification 0.93 0.57 1.00 0.26 0.07 1.00 5 85 Metastasis GATA3 oncogenic alterations: amplification/mutation 0.92 0.35 1.00 0.32 0.05 1.00 3 87 Metastasis GATA3 amplification 0.90 0.46 1.00 0.61 0.08 1.00 3 87 Metastasis H3C13 amplification 0.90 0.41 1.00 0.57 0.15 1.00 6 77 Metastasis H3C14 amplification 0.90 0.30 1.00 0.62 0.17 1.00 6 77 Metastasis DROSHA amplification 0.89 0.56 1.00 0.40 0.05 1.00 2 68 Metastasis RICTOR oncogenic alterations: amplification/mutation 0.89 0.30 1.00 0.49 0.04 1.00 2 88 Metastasis TENT5C amplification 0.88 0.12 1.00 0.59 0.05 1.00 2 88 Metastasis RICTOR amplification 0.88 0.29 1.00 0.36 0.03 1.00 2 88 Metastasis FGFR oncogenic mutation 0.87 0.80 0.88 0.71 0.40 0.96 16 73 Metastasis AKT1 oncogenic mutation 0.87 0.16 1.00 0.36 0.05 1.00 3 87 Metastasis FOXO1 oncogenic alterations: deletion/mutation 0.87 0.17 1.00 0.33 0.03 1.00 2 88 Metastasis FGFR3 oncogenic alterations: amplification/mutation 0.86 0.81 0.86 0.55 0.26 0.95 14 76 Metastasis TGF beta pathway 0.86 0.15 1.00 0.22 0.04 1.00 3 87 Metastasis MCL1 amplification 0.86 0.26 1.00 0.51 0.15 1.00 7 83 Metastasis ZFHX3 oncogenic alterations: deletion/mutation 0.86 0.29 1.00 0.27 0.03 1.00 2 88 Metastasis FBXW7 oncogenic mutation 0.86 0.37 1.00 0.70 0.13 1.00 4 86 Metastasis FGFR3 hotspots/FGFR fusions 0.85 0.76 0.77 0.63 0.28 0.94 13 71 Metastasis CREBBP oncogenic mutation 0.85 0.49 1.00 0.35 0.08 1.00 5 85 Metastasis CDKN2B deletion 0.84 0.50 1.00 0.48 0.25 1.00 13 77 Metastasis DDR2 oncogenic alterations: amplification/mutation 0.84 0.20 1.00 0.38 0.09 1.00 5 85 Metastasis YES1 oncogenic alterations: amplification/mutation 0.84 0.14 1.00 0.56 0.05 1.00 2 88 Metastasis FGFR3 oncogenic mutation 0.84 0.74 0.86 0.51 0.24 0.95 14 76 Metastasis MCL1 oncogenic alterations: amplification/mutation 0.84 0.22 1.00 0.37 0.12 1.00 7 83 Metastasis FGFR3 hotspots 0.84 0.75 0.77 0.55 0.23 0.93 13 73 Metastasis CDKN2B oncogenic alterations: deletion/mutation 0.84 0.47 1.00 0.51 0.25 1.00 13 77 Metastasis FBXW7 oncogenic alterations: deletion/mutation 0.84 0.37 1.00 0.26 0.06 1.00 4 86 Metastasis CDKN2A (p16INK4a) deletion 0.83 0.45 1.00 0.51 0.27 1.00 14 76 Metastasis IL7R amplification 0.82 0.22 1.00 0.40 0.05 1.00 3 87 Metastasis DDR2 amplification 0.82 0.20 1.00 0.56 0.12 1.00 5 85 Metastasis BRAF oncogenic mutation 0.82 0.29 1.00 0.36 0.10 1.00 6 84 Metastasis SDHC amplification 0.82 0.18 1.00 0.44 0.09 1.00 5 85 Metastasis CDKN2A (p14ARF) deletion 0.81 0.43 1.00 0.51 0.29 1.00 15 75 Metastasis SPEN fusion 0.80 0.08 1.00 0.59 0.05 1.00 2 88 Metastasis TSC1 oncogenic mutation 0.80 0.40 1.00 0.30 0.06 1.00 4 86 Metastasis AKT1 oncogenic alterations: amplification/mutation 0.79 0.13 1.00 0.55 0.07 1.00 3 87 Metastasis RBM10 oncogenic mutation 0.78 0.53 1.00 0.42 0.04 1.00 2 88 Metastasis MYCL oncogenic alterations: amplification/mutation 0.78 0.21 1.00 0.45 0.15 1.00 8 82 Metastasis MYCL amplification 0.78 0.21 1.00 0.34 0.13 1.00 8 82 Metastasis ERBB2 amplification 0.77 0.33 0.86 0.34 0.10 0.97 7 83 Metastasis EGFR amplification 0.76 0.09 1.00 0.54 0.07 1.00 3 87 Metastasis PIK3CA oncogenic mutation 0.76 0.31 0.92 0.24 0.16 0.95 12 78 Table S9.2. Biomarkers detected in Breast Cancer Tumor Site Biomarker AUC AP Sensitivity Specificity PPV NPV Positive Negative Total Primary ER 0.95 0.99 0.93 0.76 0.94 0.75 326 87 Primary ER-/PR-/HER2-0.94 0.68 0.94 0.81 0.51 0.99 68 325 Primary PREX2 amplification 0.94 0.23 1.00 0.78 0.10 1.00 11 437 Primary CDH1 oncogenic mutation 0.94 0.65 0.87 0.91 0.52 0.98 54 481 Primary ER-/PR-/HER2+ 0.94 0.34 0.82 0.89 0.18 0.99 11 382 Primary CDH1 oncogenic alterations: deletion/mutation 0.94 0.64 0.89 0.91 0.53 0.99 56 479 Primary RB1 oncogenic alterations: deletion/mutation 0.92 0.21 1.00 0.44 0.05 1.00 16 519 Primary ER+/PR+/HER2+ 0.91 0.39 1.00 0.52 0.10 1.00 19 374 Primary PRDM14 amplification 0.90 0.26 0.88 0.78 0.13 0.99 16 432 Primary Fragment of genome altered ≥ 30% 0.90 0.95 0.89 0.68 0.84 0.78 272 146 Primary NBN amplification 0.90 0.32 0.88 0.78 0.17 0.99 26 509 Primary HER2 0.90 0.55 0.97 0.48 0.16 0.99 36 364 Primary TP53 oncogenic alterations: deletion/mutation 0.89 0.84 0.93 0.63 0.62 0.94 210 325 Primary CCNE1 amplification 0.89 0.14 1.00 0.45 0.04 1.00 11 524 Primary SOX17 amplification 0.89 0.18 1.00 0.63 0.06 1.00 12 523 Primary PR 0.89 0.94 0.95 0.56 0.82 0.85 279 133 Primary ER+/PR+/HER2-0.89 0.93 0.97 0.53 0.77 0.92 243 150 Primary CCNE1 oncogenic alterations: amplification/mutation 0.89 0.19 1.00 0.48 0.04 1.00 11 524 Primary TP53 oncogenic mutation 0.89 0.83 0.93 0.61 0.60 0.93 206 329 Primary RB1 oncogenic mutation 0.89 0.12 1.00 0.41 0.04 1.00 14 521 Primary AGO2 amplification 0.88 0.46 0.76 0.81 0.26 0.97 37 411 Primary ELOC amplification 0.88 0.22 0.80 0.74 0.11 0.99 20 515 Primary CBFB oncogenic alterations: deletion/mutation 0.88 0.20 1.00 0.31 0.05 1.00 19 516 Primary SPOP amplification 0.87 0.18 0.94 0.53 0.06 1.00 18 517 Primary PRKAR1A amplification 0.87 0.28 1.00 0.46 0.07 1.00 21 514 Primary PPM1D oncogenic alterations: amplification/mutation 0.87 0.30 0.97 0.51 0.13 1.00 36 479 Primary CBFB oncogenic mutation 0.86 0.19 0.94 0.38 0.05 0.99 18 517 Primary PPM1D amplification 0.85 0.27 0.97 0.57 0.14 1.00 35 480 Primary ERBB2 amplification 0.85 0.53 0.91 0.50 0.18 0.98 56 479 Primary AXIN2 amplification 0.85 0.26 0.95 0.57 0.09 1.00 22 513 Primary BRIP1 amplification 0.84 0.16 0.94 0.53 0.06 1.00 16 519 Primary Genome instability ≥ 20% 0.84 0.84 0.80 0.64 0.67 0.78 200 218 Primary Tetraploidy 0.84 0.76 0.87 0.57 0.54 0.88 141 242 Primary RECQL4 amplification 0.84 0.33 0.84 0.70 0.21 0.98 45 490 Primary RNF43 amplification 0.83 0.17 1.00 0.57 0.07 1.00 18 517 Primary RRAS amplification 0.83 0.07 1.00 0.24 0.03 1.00 10 438 Primary CD79B amplification 0.83 0.19 0.96 0.57 0.10 1.00 24 511 Primary RTEL1 amplification 0.83 0.16 0.83 0.56 0.05 0.99 12 436 Primary RARA amplification 0.83 0.13 0.86 0.49 0.04 0.99 14 521 Primary CDK12 amplification 0.83 0.39 0.93 0.48 0.13 0.99 41 494 Primary HRD mutation signature 0.83 0.40 0.89 0.53 0.17 0.98 27 255 Primary HER2 Amplification 0.83 0.31 0.94 0.50 0.14 0.99 33 383 Primary RAD21 amplification 0.83 0.31 0.94 0.59 0.19 0.99 48 487 Primary RAD51C amplification 0.83 0.23 0.95 0.58 0.08 1.00 20 515 Primary FOXA1 amplification 0.82 0.19 0.93 0.50 0.05 1.00 14 521 Primary MDM2 amplification 0.82 0.17 0.94 0.43 0.05 1.00 18 517 Primary GATA3 oncogenic alterations: deletion/mutation 0.82 0.31 1.00 0.32 0.16 1.00 63 472 Primary MDM2 oncogenic alterations: amplification/mutation 0.82 0.18 0.89 0.45 0.05 0.99 18 517 Primary GATA3 oncogenic mutation 0.81 0.30 1.00 0.32 0.16 1.00 63 472 Primary Whole genome doubling 0.81 0.59 0.81 0.63 0.42 0.91 75 229 Primary Loss of heterozygosity ≥ 50% 0.81 0.19 0.88 0.52 0.10 0.99 24 394 Primary ERBB2 oncogenic alterations: amplification/mutation 0.80 0.48 0.89 0.48 0.19 0.97 65 470 Primary MSI2 amplification 0.80 0.14 0.86 0.62 0.07 0.99 14 434 Primary FOXA1 oncogenic alterations: deletion/mutation 0.80 0.15 1.00 0.25 0.03 1.00 13 522 Primary TERT oncogenic alterations: amplification/mutation 0.80 0.18 1.00 0.39 0.03 1.00 11 524 Primary CDKN2A (p14ARF) deletion 0.79 0.07 0.80 0.59 0.05 0.99 15 520 Primary CDKN2A (p16INK4a) deletion 0.78 0.08 0.80 0.61 0.06 0.99 15 520 Primary RPS6KB2 amplification 0.78 0.17 0.85 0.41 0.05 0.99 20 515 Primary CDKN2B oncogenic alterations: deletion/mutation 0.78 0.07 0.93 0.56 0.05 1.00 14 521 Primary ELF3 amplification 0.78 0.10 0.82 0.65 0.05 0.99 11 437 Primary CDKN2B deletion 0.78 0.07 0.86 0.63 0.06 0.99 14 521 Primary GNAS amplification 0.77 0.10 0.90 0.54 0.07 0.99 20 515 Primary AURKA oncogenic alterations: amplification/mutation 0.77 0.09 0.76 0.64 0.08 0.99 21 514 Primary GATA3 oncogenic alterations: amplification/mutation 0.77 0.33 1.00 0.23 0.17 1.00 71 464 Primary RTK pathway 0.76 0.66 0.90 0.44 0.52 0.87 218 317 Primary HRD pathway 0.76 0.41 0.94 0.33 0.20 0.97 80 455 Primary FGFR1 oncogenic alterations: amplification/mutation 0.76 0.30 0.95 0.29 0.14 0.98 58 477 Primary AURKA amplification 0.76 0.09 0.81 0.62 0.08 0.99 21 514 Primary FGFR1 amplification 0.76 0.33 0.93 0.33 0.14 0.98 58 477 Primary MAP2K4 oncogenic alterations: deletion/mutation 0.75 0.08 1.00 0.25 0.04 1.00 18 517 Table S9.2. Biomarkers detected in Breast Cancer (continued) Tumor Site Biomarker AUC AP Sensitivity Specificity PPV NPV Positive Negative Total Metastasis ER-/PR-/HER2-0.87 0.60 0.95 0.59 0.36 0.98 78 327 Metastasis ER 0.86 0.95 0.86 0.69 0.90 0.61 340 110 Metastasis Tetraploidy 0.86 0.80 0.96 0.48 0.56 0.94 166 240 Metastasis Whole genome doubling 0.84 0.60 0.89 0.63 0.39 0.95 61 234 Metastasis DUSP4 deletion 0.84 0.36 0.80 0.75 0.09 0.99 15 502 Metastasis HER2 Amplification 0.83 0.47 0.94 0.29 0.15 0.97 53 394 Metastasis RAD52 amplification 0.83 0.11 1.00 0.46 0.04 1.00 13 629 Metastasis ER-/PR-/HER2+ 0.83 0.29 0.80 0.76 0.18 0.98 25 380 Metastasis TP53 oncogenic mutation 0.82 0.78 0.89 0.52 0.56 0.87 260 382 Metastasis Genome instability ≥ 20% 0.82 0.81 0.92 0.54 0.68 0.86 226 210 Metastasis TP53 oncogenic alterations: deletion/mutation 0.82 0.78 0.87 0.52 0.57 0.84 268 374 Metastasis Fragment of genome altered ≥ 30% 0.81 0.92 0.94 0.32 0.79 0.65 321 116 Metastasis CBFB oncogenic alterations: deletion/mutation 0.80 0.10 0.88 0.38 0.04 0.99 17 625 Metastasis HER2 0.80 0.43 0.94 0.33 0.20 0.97 62 355 Metastasis ERBB2 amplification 0.78 0.41 0.84 0.45 0.17 0.96 75 567 Metastasis MYC amplification 0.77 0.36 0.91 0.45 0.18 0.97 75 567 Metastasis ER+/PR+/HER2+ 0.77 0.14 0.91 0.46 0.09 0.99 22 383 Metastasis ERBB2 oncogenic mutation 0.77 0.14 0.96 0.41 0.06 1.00 26 616 Metastasis MYC oncogenic alterations: amplification/mutation 0.77 0.33 0.92 0.39 0.17 0.97 75 567 Metastasis ER+/PR+/HER2-0.76 0.66 0.85 0.54 0.55 0.84 162 243 Metastasis PR 0.76 0.70 0.80 0.59 0.63 0.77 203 234 Metastasis AXIN2 amplification 0.76 0.08 0.90 0.45 0.05 0.99 21 621 Metastasis PREX2 amplification 0.76 0.17 0.80 0.59 0.05 0.99 15 502 Metastasis CDK12 amplification 0.76 0.32 0.82 0.43 0.13 0.96 61 581 Metastasis CD79B amplification 0.75 0.21 0.91 0.45 0.08 0.99 32 610 40 Table S9.3. Biomarkers detected in Colorectal Cancer Tumor Site Biomarker AUC AP Sensitivity Specificity PPV NPV Positive Negative Total Primary MSI-H vs MSS 0.98 0.91 0.93 0.93 0.72 0.99 105 563 Primary MSI-H/dMMR 0.97 0.91 0.93 0.92 0.69 0.99 106 562 Primary HNF1A oncogenic alterations: deletion/mutation 0.95 0.39 0.84 0.89 0.21 0.99 25 674 Primary TGFBR2 oncogenic mutation 0.95 0.50 0.95 0.81 0.22 1.00 38 661 Primary MLH1 oncogenic mutation 0.95 0.42 1.00 0.78 0.10 1.00 17 682 Primary SPEN oncogenic alterations: deletion/mutation 0.95 0.20 0.93 0.86 0.12 1.00 14 685 Primary HNF1A oncogenic mutation 0.95 0.40 0.80 0.89 0.21 0.99 25 674 Primary TGFBR2 oncogenic alterations: deletion/mutation 0.95 0.42 1.00 0.72 0.18 1.00 40 659 Primary SPEN oncogenic mutation 0.94 0.28 0.93 0.85 0.12 1.00 14 685 Primary KMT2B oncogenic mutation 0.94 0.57 1.00 0.62 0.20 1.00 55 572 Primary MSH3 oncogenic alterations: deletion/mutation 0.94 0.60 0.88 0.90 0.42 0.99 50 577 Primary MLH1 oncogenic alterations: deletion/mutation 0.94 0.35 1.00 0.77 0.10 1.00 17 682 Primary MSH2 oncogenic alterations: deletion/mutation 0.94 0.31 1.00 0.72 0.10 1.00 21 678 Primary KMT2B oncogenic alterations: deletion/mutation 0.94 0.55 0.98 0.63 0.20 1.00 55 572 Primary MSH3 oncogenic mutation 0.94 0.55 0.90 0.89 0.41 0.99 50 577 Primary RNF43 oncogenic alterations: deletion/mutation 0.93 0.67 0.99 0.66 0.27 1.00 79 620 Primary ANKRD11 oncogenic mutation 0.93 0.23 0.93 0.80 0.09 1.00 14 685 Primary RNF43 oncogenic mutation 0.93 0.66 0.97 0.65 0.26 1.00 79 620 Primary PTPRS oncogenic mutation 0.93 0.23 1.00 0.38 0.05 1.00 23 676 Primary ZFHX3 oncogenic alterations: deletion/mutation 0.93 0.33 1.00 0.69 0.15 1.00 36 663 Primary ARHGAP35 oncogenic alterations: deletion/mutation 0.93 0.36 0.75 0.92 0.24 0.99 8 241 Primary ZFHX3 oncogenic mutation 0.93 0.37 1.00 0.70 0.15 1.00 36 663 Primary MSH2 oncogenic mutation 0.93 0.22 1.00 0.67 0.09 1.00 21 678 Primary ANKRD11 oncogenic alterations: deletion/mutation 0.93 0.17 0.93 0.80 0.09 1.00 14 685 Primary CASP8 oncogenic mutation 0.93 0.30 0.91 0.84 0.23 0.99 34 665 Primary CASP8 oncogenic alterations: deletion/mutation 0.93 0.31 0.94 0.83 0.23 1.00 34 665 Primary PTPRS oncogenic alterations: deletion/mutation 0.92 0.22 1.00 0.30 0.05 1.00 24 675 Primary TET1 oncogenic alterations: deletion/mutation 0.91 0.12 1.00 0.24 0.03 1.00 14 685 Primary MSH6 oncogenic mutation 0.91 0.22 0.97 0.81 0.19 1.00 31 668 Primary MSH6 oncogenic alterations: deletion/mutation 0.91 0.21 0.94 0.80 0.18 1.00 31 668 Primary B2M oncogenic alterations: deletion/mutation 0.91 0.40 0.94 0.78 0.24 0.99 50 649 Primary KMT2D oncogenic mutation 0.91 0.51 0.86 0.87 0.38 0.99 59 640 Primary KMT2D oncogenic alterations: deletion/mutation 0.90 0.49 0.80 0.90 0.42 0.98 59 640 Primary B2M oncogenic mutation 0.90 0.44 0.94 0.78 0.24 0.99 49 650 Primary TMB-H 0.90 0.84 0.89 0.61 0.42 0.95 166 530 Primary GNAS oncogenic mutation 0.90 0.25 1.00 0.68 0.07 1.00 17 682 Primary PPM1D oncogenic mutation 0.90 0.22 0.95 0.74 0.09 1.00 19 668 Primary HLA-B deletion/mutation 0.90 0.31 0.92 0.62 0.09 0.99 26 601 Primary GNAS oncogenic alterations: amplification/mutation 0.90 0.26 1.00 0.62 0.06 1.00 17 682 Primary PTCH1 oncogenic alterations: deletion/mutation 0.89 0.17 0.92 0.84 0.17 1.00 24 675 Primary PTCH1 oncogenic mutation 0.89 0.18 0.88 0.85 0.17 0.99 24 675 Primary CTCF oncogenic alterations: deletion/mutation 0.89 0.20 0.95 0.56 0.06 1.00 21 678 Primary TOP1 amplification 0.89 0.27 0.79 0.86 0.13 0.99 19 680 Primary PPM1D oncogenic alterations: amplification/mutation 0.89 0.18 0.95 0.67 0.08 1.00 19 668 Primary CTCF oncogenic mutation 0.89 0.16 0.95 0.53 0.06 1.00 21 678 Primary MGA oncogenic mutation 0.89 0.19 0.95 0.65 0.08 1.00 21 678 Primary FAT1 oncogenic mutation 0.89 0.20 1.00 0.42 0.06 1.00 24 675 Primary NOTCH1 oncogenic alterations: deletion/mutation 0.89 0.15 0.93 0.42 0.03 1.00 15 684 Primary NCOA3 amplification 0.89 0.27 0.86 0.81 0.12 0.99 21 666 Primary KMT2A oncogenic alterations: deletion/mutation 0.89 0.18 0.85 0.75 0.09 0.99 20 679 Primary ASXL1 amplification 0.89 0.32 0.80 0.83 0.15 0.99 25 674 Primary CDK12 oncogenic alterations: deletion/mutation 0.89 0.22 1.00 0.31 0.04 1.00 21 678 Primary NOTCH1 oncogenic alterations: amplification/mutation 0.89 0.14 0.93 0.57 0.05 1.00 15 684 Primary NOTCH1 oncogenic mutation 0.89 0.15 1.00 0.33 0.03 1.00 15 684 Primary DNMT3B amplification 0.89 0.33 0.83 0.83 0.14 0.99 23 676 Primary KMT2A oncogenic mutation 0.89 0.23 0.85 0.75 0.09 0.99 20 679 Primary AXIN2 oncogenic mutation 0.88 0.33 0.97 0.49 0.09 1.00 35 664 Primary ATR oncogenic alterations: deletion/mutation 0.88 0.10 1.00 0.76 0.09 1.00 16 683 Primary INPPL1 oncogenic mutation 0.88 0.14 0.93 0.77 0.09 1.00 15 612 Primary RAD50 oncogenic mutation 0.88 0.13 0.80 0.84 0.10 0.99 15 684 Primary RECQL4 amplification 0.88 0.27 0.93 0.46 0.04 1.00 15 684 Primary SRC oncogenic alterations: amplification/mutation 0.88 0.27 0.85 0.75 0.12 0.99 27 672 Primary JAK1 oncogenic alterations: amplification/mutation 0.88 0.15 0.90 0.83 0.13 1.00 20 679 Primary MGA oncogenic alterations: deletion/mutation 0.88 0.19 1.00 0.26 0.04 1.00 22 677 Primary NOTCH3 oncogenic alterations: deletion/mutation 0.88 0.14 0.95 0.44 0.05 1.00 22 677 Primary CDK12 oncogenic mutation 0.88 0.18 1.00 0.27 0.04 1.00 21 678 Primary NOTCH3 oncogenic mutation 0.88 0.14 0.95 0.54 0.06 1.00 22 677 Primary JAK1 oncogenic alterations: deletion/mutation 0.88 0.16 0.90 0.81 0.12 1.00 20 679 Primary ATR oncogenic mutation 0.88 0.10 1.00 0.70 0.07 1.00 16 683 Primary AXIN2 oncogenic alterations: deletion/mutation 0.88 0.32 1.00 0.29 0.07 1.00 35 664 Primary NOTCH3 oncogenic alterations: amplification/mutation 0.88 0.14 0.95 0.64 0.08 1.00 22 677 Primary REST oncogenic mutation 0.87 0.12 1.00 0.74 0.09 1.00 6 243 Primary RAD50 oncogenic alterations: deletion/mutation 0.87 0.11 0.93 0.71 0.07 1.00 15 684 Primary RB1 oncogenic mutation 0.87 0.17 0.93 0.63 0.05 1.00 14 685 Primary RB1 oncogenic alterations: deletion/mutation 0.87 0.10 1.00 0.59 0.05 1.00 14 685 Primary SRC amplification 0.87 0.25 0.85 0.75 0.12 0.99 27 672 Primary EP300 oncogenic alterations: deletion/mutation 0.87 0.27 0.96 0.32 0.05 1.00 24 675 Table S9.3. Biomarkers detected in Colorectal Cancer (continued) Tumor Site Biomarker AUC AP Sensitivity Specificity PPV NPV Positive Negative Total Primary JAK1 oncogenic mutation 0.87 0.13 0.90 0.81 0.12 1.00 20 679 Primary INPPL1 oncogenic alterations: deletion/mutation 0.87 0.12 0.93 0.74 0.08 1.00 15 612 Primary AURKA amplification 0.86 0.24 0.82 0.81 0.10 0.99 17 682 Primary PTEN oncogenic mutation 0.86 0.35 0.95 0.58 0.13 0.99 42 657 Primary RTEL1 amplification 0.86 0.30 0.82 0.72 0.15 0.99 34 593 Primary GNAS amplification 0.86 0.23 0.84 0.72 0.10 0.99 25 674 Primary AGO2 amplification 0.86 0.30 0.94 0.52 0.05 1.00 16 611 Primary CIC oncogenic alterations: deletion/mutation 0.86 0.19 0.93 0.76 0.14 1.00 27 672 Primary BCL2L1 amplification 0.86 0.32 0.86 0.70 0.13 0.99 35 664 Primary AURKA oncogenic alterations: amplification/mutation 0.86 0.21 0.82 0.74 0.07 0.99 17 682 Primary EP300 oncogenic mutation 0.85 0.19 0.96 0.30 0.05 1.00 24 675 Primary CIC oncogenic mutation 0.85 0.17 0.93 0.76 0.13 1.00 27 672 Primary Lynch Syndrome 0.85 0.33 0.92 0.54 0.10 0.99 26 479 Primary KMT2C oncogenic alterations: deletion/mutation 0.85 0.22 0.97 0.25 0.07 0.99 36 663 Primary REST oncogenic alterations: deletion/mutation 0.84 0.08 1.00 0.72 0.08 1.00 6 243 Primary KMT2C oncogenic mutation 0.84 0.21 0.97 0.35 0.07 1.00 36 663 Primary SMAD2 oncogenic mutation 0.84 0.13 0.94 0.63 0.06 1.00 17 682 Primary SMARCA4 oncogenic alterations: deletion/mutation 0.84 0.12 0.90 0.41 0.05 0.99 21 678 Primary FAT1 oncogenic alterations: deletion/mutation 0.84 0.20 0.90 0.39 0.06 0.99 29 670 Primary MAP3K1 oncogenic mutation 0.83 0.11 0.93 0.42 0.03 1.00 14 685 Primary ARID1A oncogenic alterations: deletion/mutation 0.83 0.45 0.94 0.31 0.16 0.97 85 614 Primary NCOR1 oncogenic mutation 0.83 0.16 0.95 0.31 0.04 1.00 20 679 Primary BCOR oncogenic mutation 0.83 0.19 0.94 0.35 0.03 1.00 17 682 Primary SMARCA4 oncogenic mutation 0.82 0.13 0.90 0.25 0.04 0.99 21 678 Primary PIK3R1 oncogenic mutation 0.82 0.29 0.92 0.43 0.08 0.99 37 662 Primary PTEN oncogenic alterations: deletion/mutation 0.82 0.34 0.88 0.52 0.11 0.99 43 656 Primary TP53BP1 oncogenic alterations: deletion/mutation 0.82 0.19 0.92 0.48 0.07 0.99 26 601 Primary ARID1A oncogenic mutation 0.82 0.42 0.93 0.27 0.15 0.96 85 614 Primary TET2 oncogenic mutation 0.82 0.11 0.88 0.59 0.05 1.00 16 683 Primary DNA damage response 0.82 0.57 0.88 0.38 0.24 0.93 128 571 Primary BCOR oncogenic alterations: deletion/mutation 0.81 0.19 0.82 0.55 0.04 0.99 17 682 Primary BRAF oncogenic alterations: amplification/mutation 0.81 0.47 0.84 0.53 0.18 0.97 77 622 Primary TP53 oncogenic alterations: deletion/mutation 0.81 0.89 0.87 0.64 0.86 0.66 499 200 Primary BRAF oncogenic mutation 0.81 0.51 0.88 0.46 0.17 0.97 77 622 Primary ARID1B oncogenic alterations: deletion/mutation 0.81 0.10 1.00 0.28 0.04 1.00 22 677 Primary TP53 oncogenic mutation 0.81 0.89 0.87 0.61 0.85 0.66 497 202 Primary BRCA2 oncogenic mutation 0.81 0.16 0.85 0.47 0.06 0.99 27 672 Primary PIK3R1 oncogenic alterations: deletion/mutation 0.81 0.24 0.92 0.44 0.08 0.99 37 662 Primary BRCA2 oncogenic alterations: deletion/mutation 0.81 0.16 0.85 0.43 0.06 0.99 27 672 Primary SMAD2 oncogenic alterations: deletion/mutation 0.81 0.17 0.95 0.43 0.05 1.00 22 677 Primary MYC amplification 0.81 0.22 0.94 0.39 0.07 0.99 31 668 Primary FGFR1 oncogenic alterations: amplification/mutation 0.81 0.09 0.93 0.45 0.04 1.00 15 684 Primary TCF7L2 oncogenic alterations: deletion/mutation 0.81 0.41 0.96 0.24 0.15 0.98 85 614 Primary TP53BP1 oncogenic mutation 0.80 0.16 0.85 0.65 0.09 0.99 26 601 Primary CDH1 oncogenic alterations: deletion/mutation 0.80 0.13 0.94 0.21 0.03 0.99 17 682 Primary CDK12 amplification 0.80 0.08 0.93 0.61 0.05 1.00 15 684 Primary APC oncogenic mutation 0.80 0.86 0.92 0.53 0.81 0.75 483 216 Primary FGFR1 amplification 0.80 0.07 0.93 0.49 0.04 1.00 15 684 Primary CDH1 oncogenic mutation 0.80 0.10 0.94 0.32 0.03 1.00 17 682 Primary CCND2 amplification 0.80 0.17 0.93 0.30 0.03 1.00 15 684 Primary ASXL2 oncogenic mutation 0.79 0.08 0.94 0.25 0.03 0.99 16 683 Primary TCF7L2 oncogenic mutation 0.79 0.41 0.99 0.23 0.15 0.99 85 614 Primary NSD3 amplification 0.79 0.07 0.93 0.51 0.04 1.00 15 612 Primary APC oncogenic alterations: deletion/mutation 0.79 0.86 0.92 0.52 0.81 0.73 483 216 Primary BRCA1 germline/somatic point mutation/deletion or fusion 0.79 0.21 0.94 0.33 0.10 0.99 36 476 Primary ERBB2 amplification 0.79 0.11 0.95 0.52 0.06 1.00 21 678 Primary HRD pathway 0.79 0.54 0.91 0.30 0.22 0.94 124 575 Primary ARID1B oncogenic mutation 0.79 0.11 0.95 0.28 0.04 0.99 22 677 Primary SETD2 oncogenic mutation 0.79 0.17 0.93 0.44 0.06 0.99 28 671 Primary CCND2 oncogenic alterations: amplification/mutation 0.79 0.15 0.93 0.30 0.03 1.00 15 684 Primary PBRM1 oncogenic mutation 0.79 0.12 0.92 0.38 0.05 0.99 25 674 Primary MAP3K1 oncogenic alterations: deletion/mutation 0.79 0.10 0.87 0.37 0.03 0.99 15 684 Primary TERT oncogenic mutation 0.79 0.13 0.89 0.44 0.06 0.99 28 671 Primary ASXL2 oncogenic alterations: deletion/mutation 0.79 0.06 0.94 0.44 0.04 1.00 16 683 Primary MYC oncogenic alterations: amplification/mutation 0.78 0.22 0.90 0.43 0.07 0.99 31 668 Primary PBRM1 oncogenic alterations: deletion/mutation 0.78 0.12 0.92 0.38 0.05 0.99 25 674 Primary FLT1 oncogenic alterations: amplification/mutation 0.78 0.16 0.92 0.44 0.06 0.99 26 673 Primary KRAS oncogenic alterations: amplification/mutation 0.78 0.74 0.90 0.42 0.54 0.85 301 398 Primary MAP2K4 oncogenic alterations: deletion/mutation 0.78 0.11 0.94 0.27 0.03 0.99 16 683 Primary TGF beta pathway 0.78 0.48 0.92 0.38 0.31 0.94 163 536 Primary KRAS oncogenic mutation 0.78 0.74 0.90 0.44 0.54 0.86 294 405 Primary CDK8 amplification 0.77 0.08 0.80 0.57 0.05 0.99 20 679 Primary SETD2 oncogenic alterations: deletion/mutation 0.77 0.17 0.82 0.56 0.07 0.99 28 671 Primary TET2 oncogenic alterations: deletion/mutation 0.77 0.10 0.88 0.59 0.05 1.00 17 682 Primary FLT1 amplification 0.77 0.12 0.92 0.44 0.06 0.99 26 673 Primary ATM oncogenic mutation 0.77 0.24 0.90 0.34 0.09 0.98 48 651 Primary ATM oncogenic alterations: deletion/mutation 0.76 0.23 0.90 0.31 0.09 0.98 48 651 Primary CDK8 oncogenic alterations: amplification/mutation 0.75 0.09 0.81 0.48 0.05 0.99 21 678 Primary FLT3 amplification 0.75 0.17 0.91 0.48 0.08 0.99 33 666 Table S9.3. Biomarkers detected in Colorectal Cancer (continued) Tumor Site Biomarker AUC AP Sensitivity Specificity PPV NPV Positive Negative Total Metastasis KMT2B oncogenic mutation 0.95 0.48 1.00 0.74 0.10 1.00 6 211 Metastasis MSI-H/dMMR 0.93 0.58 0.83 0.98 0.45 1.00 6 250 Metastasis KMT2B oncogenic alterations: deletion/mutation 0.92 0.54 0.83 0.70 0.07 0.99 6 211 Metastasis MALT1 deletion 0.92 0.33 1.00 0.32 0.06 1.00 11 267 Metastasis DIS3 amplification 0.92 0.21 1.00 0.63 0.05 1.00 6 285 Metastasis TOP1 amplification 0.92 0.28 0.89 0.77 0.11 1.00 9 282 Metastasis LATS2 amplification 0.91 0.43 1.00 0.46 0.07 1.00 11 280 Metastasis PMAIP1 oncogenic alterations: deletion/mutation 0.91 0.24 1.00 0.54 0.08 1.00 11 280 Metastasis PIK3C3 deletion 0.90 0.26 0.78 0.83 0.13 0.99 9 282 Metastasis CTCF oncogenic alterations: deletion/mutation 0.90 0.25 0.83 0.69 0.05 0.99 6 285 Metastasis RB1 amplification 0.89 0.32 1.00 0.64 0.06 1.00 6 285 Metastasis PMAIP1 deletion 0.89 0.23 1.00 0.59 0.09 1.00 11 280 Metastasis BCL2 deletion 0.87 0.33 0.92 0.57 0.09 0.99 13 278 Metastasis FGFR1 deletion 0.87 0.21 1.00 0.46 0.04 1.00 7 284 Metastasis SRC oncogenic alterations: amplification/mutation 0.87 0.21 0.92 0.65 0.11 0.99 13 278 Metastasis SRC amplification 0.86 0.19 0.92 0.67 0.12 0.99 13 278 Metastasis FLT1 oncogenic alterations: amplification/mutation 0.86 0.31 1.00 0.39 0.06 1.00 11 280 Metastasis DUSP4 deletion 0.85 0.44 0.91 0.58 0.21 0.98 23 194 Metastasis NKX3-1 oncogenic alterations: deletion/mutation 0.85 0.39 0.82 0.68 0.21 0.97 28 263 Metastasis FLT3 amplification 0.85 0.29 1.00 0.41 0.07 1.00 13 278 Metastasis BRCA2 amplification 0.85 0.23 1.00 0.44 0.04 1.00 6 285 Metastasis NCOA3 amplification 0.84 0.30 0.83 0.71 0.11 0.99 12 266 Metastasis FLT1 amplification 0.84 0.27 1.00 0.36 0.06 1.00 11 280 Metastasis SMAD4 deletion 0.84 0.38 0.96 0.32 0.11 0.99 23 268 Metastasis GAB2 amplification 0.83 0.54 1.00 0.49 0.05 1.00 2 77 Metastasis DNMT3B amplification 0.83 0.21 0.75 0.75 0.11 0.99 12 279 Metastasis AURKA oncogenic alterations: amplification/mutation 0.82 0.30 0.77 0.66 0.10 0.98 13 278 Metastasis AURKA amplification 0.82 0.20 0.77 0.73 0.12 0.99 13 278 Metastasis GAB2 oncogenic alterations: amplification/mutation 0.81 0.53 1.00 0.43 0.04 1.00 2 77 Metastasis CDK8 amplification 0.81 0.32 0.82 0.47 0.06 0.99 11 280 Metastasis BCL2L1 amplification 0.81 0.23 0.89 0.65 0.15 0.99 19 272 Metastasis GNAS amplification 0.80 0.20 0.77 0.60 0.08 0.98 13 278 Metastasis FLT3 oncogenic alterations: amplification/mutation 0.80 0.30 1.00 0.36 0.07 1.00 14 277 Metastasis SMAD2 deletion 0.80 0.25 0.83 0.53 0.07 0.99 12 279 Metastasis TP53 oncogenic mutation 0.80 0.92 0.88 0.51 0.86 0.57 223 68 Metastasis RECQL4 amplification 0.80 0.25 1.00 0.25 0.07 1.00 16 275 Metastasis CDK8 oncogenic alterations: amplification/mutation 0.79 0.18 0.91 0.42 0.06 0.99 11 280 Metastasis SERPINB4 deletion 0.79 0.08 1.00 0.29 0.04 1.00 2 77 Metastasis KRAS oncogenic alterations: amplification/mutation 0.79 0.80 0.88 0.41 0.59 0.78 143 148 Metastasis PTEN oncogenic alterations: deletion/mutation 0.79 0.10 0.83 0.44 0.03 0.99 6 285 Metastasis TP53 oncogenic alterations: deletion/mutation 0.79 0.91 0.88 0.48 0.85 0.55 224 67 Metastasis RTEL1 amplification 0.79 0.20 0.75 0.68 0.16 0.97 16 201 Metastasis FGFR1 oncogenic alterations: amplification/mutation 0.79 0.07 1.00 0.32 0.04 1.00 7 284 Metastasis KRAS oncogenic mutation 0.78 0.80 0.88 0.46 0.60 0.80 141 150 Metastasis CCND2 oncogenic alterations: amplification/mutation 0.77 0.07 1.00 0.43 0.04 1.00 7 284 Metastasis SERPINB3 deletion 0.76 0.07 1.00 0.29 0.04 1.00 2 77 Metastasis CCND2 amplification 0.76 0.07 1.00 0.39 0.04 1.00 7 284 Table S9.4. Biomarkers detected in Endometrial Cancer Tumor Site Biomarker AUC AP Sensitivity Specificity PPV NPV Positive Negative Total Primary JAK1 oncogenic alterations: amplification/mutation 0.91 0.55 0.76 0.78 0.23 0.97 29 336 Primary JAK1 oncogenic alterations: deletion/mutation 0.91 0.55 0.83 0.80 0.26 0.98 29 336 Primary JAK1 oncogenic mutation 0.91 0.52 0.76 0.82 0.26 0.98 29 336 Primary MSI-H vs MSS 0.91 0.59 0.85 0.82 0.40 0.97 39 283 Primary TP53 oncogenic alterations: deletion/mutation 0.90 0.88 0.85 0.86 0.82 0.89 154 211 Primary TMB-H 0.90 0.80 0.85 0.76 0.58 0.93 101 264 Primary TP53 oncogenic mutation 0.90 0.87 0.87 0.87 0.83 0.90 154 211 Primary ATR oncogenic mutation 0.89 0.21 1.00 0.71 0.08 1.00 9 356 Primary PTEN oncogenic mutation 0.89 0.87 0.96 0.64 0.73 0.93 186 179 Primary SPEN oncogenic mutation 0.88 0.17 0.91 0.72 0.09 1.00 11 354 Primary ERBB2 amplification 0.88 0.27 0.94 0.69 0.13 1.00 17 348 Primary APC oncogenic alterations: deletion/mutation 0.88 0.15 1.00 0.43 0.05 1.00 10 355 Primary ANKRD11 oncogenic mutation 0.88 0.15 0.88 0.70 0.06 1.00 8 357 Primary PTEN oncogenic alterations: deletion/mutation 0.88 0.85 0.95 0.63 0.73 0.92 187 178 Primary APC oncogenic mutation 0.88 0.15 0.90 0.61 0.06 1.00 10 355 Primary CTNNB1 oncogenic alterations: amplification/mutation 0.87 0.60 0.92 0.57 0.25 0.98 49 316 Primary ATR oncogenic alterations: deletion/mutation 0.87 0.19 1.00 0.73 0.09 1.00 9 356 Primary GRIN2A oncogenic alterations: deletion/mutation 0.87 0.15 0.75 0.74 0.06 0.99 8 357 Primary RASA1 oncogenic mutation 0.87 0.43 0.95 0.22 0.07 0.99 21 344 Primary CTNNB1 oncogenic mutation 0.87 0.56 0.92 0.58 0.25 0.98 49 316 Primary POLE oncogenic mutation 0.87 0.45 0.81 0.77 0.22 0.98 27 338 Primary CDK12 amplification 0.87 0.12 0.89 0.79 0.10 1.00 9 356 Primary CCNE1 oncogenic alterations: amplification/mutation 0.87 0.34 0.79 0.74 0.17 0.98 24 341 Primary MSI-H/dMMR 0.87 0.56 0.86 0.75 0.39 0.97 49 273 Primary CCNE1 amplification 0.86 0.32 0.75 0.76 0.18 0.98 24 341 Primary CEBPA amplification 0.86 0.16 0.92 0.73 0.11 1.00 12 345 Primary MLH1 oncogenic mutation 0.86 0.24 0.82 0.74 0.09 0.99 11 354 Primary PTPRT oncogenic alterations: deletion/mutation 0.86 0.27 0.78 0.83 0.11 0.99 9 356 Primary PTPRT oncogenic mutation 0.86 0.26 0.78 0.86 0.12 0.99 9 356 Primary NFE2L2 oncogenic mutation 0.85 0.15 1.00 0.36 0.05 1.00 11 354 Primary BRCA2 oncogenic mutation 0.84 0.27 0.78 0.79 0.16 0.99 18 347 Primary ATRX oncogenic mutation 0.84 0.21 0.80 0.68 0.07 0.99 10 355 Primary AKT2 oncogenic alterations: amplification/mutation 0.84 0.13 0.92 0.69 0.10 1.00 13 352 Primary MSH3 oncogenic alterations: deletion/mutation 0.84 0.28 0.82 0.69 0.13 0.99 17 312 Primary KMT2C oncogenic mutation 0.84 0.12 0.92 0.61 0.07 1.00 12 353 Primary TERT oncogenic mutation 0.84 0.35 0.92 0.37 0.05 0.99 13 352 Primary AKT2 amplification 0.84 0.13 0.85 0.73 0.10 0.99 13 352 Primary RNF43 oncogenic alterations: deletion/mutation 0.84 0.32 0.94 0.53 0.18 0.99 36 329 Primary BRCA1 germline/somatic point mutation/deletion or fusion 0.84 0.22 0.83 0.53 0.10 0.98 18 280 Primary NF1 oncogenic mutation 0.84 0.43 0.76 0.68 0.20 0.97 34 331 Primary NCOR1 oncogenic mutation 0.83 0.26 0.80 0.73 0.08 0.99 10 355 Primary ARID1A oncogenic alterations: deletion/mutation 0.83 0.77 0.88 0.51 0.55 0.87 147 218 Primary MSH2 oncogenic mutation 0.83 0.37 0.80 0.80 0.14 0.99 15 350 Primary RNF43 oncogenic mutation 0.83 0.27 0.94 0.53 0.18 0.99 36 329 Primary NSD1 oncogenic alterations: amplification/mutation 0.83 0.32 0.82 0.64 0.10 0.99 17 348 Primary MLH1 oncogenic alterations: deletion/mutation 0.83 0.18 0.82 0.69 0.08 0.99 11 354 Primary mTOR pathway 0.82 0.95 0.94 0.33 0.85 0.57 293 72 Primary MSH2 oncogenic alterations: deletion/mutation 0.82 0.38 0.87 0.72 0.12 0.99 15 350 Primary NSD1 oncogenic mutation 0.82 0.31 0.76 0.69 0.11 0.98 17 348 Primary SPEN oncogenic alterations: deletion/mutation 0.82 0.16 0.75 0.79 0.11 0.99 12 353 Primary MSH6 oncogenic alterations: deletion/mutation 0.82 0.15 0.80 0.73 0.11 0.99 15 350 Primary SOX17 oncogenic mutation 0.82 0.24 0.96 0.50 0.14 0.99 28 337 Primary INPPL1 oncogenic mutation 0.82 0.30 0.85 0.70 0.20 0.98 27 302 Primary PIK3CB oncogenic mutation 0.82 0.07 1.00 0.50 0.04 1.00 8 357 Primary KMT2B oncogenic mutation 0.82 0.30 0.94 0.61 0.20 0.99 31 298 Primary ARID1A oncogenic mutation 0.81 0.74 0.88 0.52 0.56 0.87 147 218 Primary ATRX oncogenic alterations: deletion/mutation 0.81 0.17 0.80 0.65 0.06 0.99 10 355 Primary AKT1 oncogenic mutation 0.81 0.17 0.85 0.55 0.07 0.99 13 352 Primary DICER1 oncogenic alterations: deletion/mutation 0.81 0.21 0.78 0.71 0.06 0.99 9 356 Primary INPPL1 oncogenic alterations: deletion/mutation 0.81 0.29 0.79 0.73 0.21 0.97 28 301 Primary PTCH1 oncogenic mutation 0.81 0.07 0.88 0.67 0.06 1.00 8 357 Primary KMT2B oncogenic alterations: deletion/mutation 0.81 0.28 0.90 0.67 0.22 0.99 31 298 Primary NSD1 oncogenic alterations: deletion/mutation 0.81 0.30 0.82 0.61 0.09 0.99 17 348 Primary AKT1 oncogenic alterations: amplification/mutation 0.81 0.19 0.85 0.47 0.06 0.99 13 352 Primary NFE2L2 oncogenic alterations: amplification/mutation 0.81 0.14 1.00 0.38 0.05 1.00 11 354 Primary PTPRD oncogenic alterations: deletion/mutation 0.80 0.09 0.88 0.58 0.04 1.00 8 357 Primary CTCF oncogenic mutation 0.80 0.36 0.93 0.51 0.21 0.98 45 320 Primary SLX4 oncogenic alterations: deletion/mutation 0.80 0.17 1.00 0.37 0.03 1.00 7 322 Primary BRCA2 germline/somatic point mutation/deletion or fusion 0.80 0.43 0.86 0.51 0.23 0.96 44 257 Primary KMT2C oncogenic alterations: deletion/mutation 0.80 0.10 0.83 0.65 0.08 0.99 12 353 Primary ERRFI1 oncogenic mutation 0.80 0.19 0.89 0.40 0.04 0.99 9 348 Primary SOX17 oncogenic alterations: deletion/mutation 0.80 0.21 0.96 0.49 0.14 0.99 28 337 Primary TERT oncogenic alterations: amplification/mutation 0.79 0.29 0.93 0.47 0.07 0.99 15 350 Primary BRCA1/2 germline/somatic mutation/deletion or fusion 0.79 0.49 0.88 0.42 0.24 0.95 51 250 Primary CTCF oncogenic alterations: deletion/mutation 0.79 0.35 0.93 0.48 0.20 0.98 45 320 Primary ARID5B oncogenic alterations: deletion/mutation 0.79 0.20 0.75 0.69 0.15 0.98 24 341 Primary ANKRD11 oncogenic alterations: deletion/mutation 0.79 0.09 0.89 0.48 0.04 0.99 9 356 Primary EP300 oncogenic alterations: deletion/mutation 0.79 0.11 0.93 0.53 0.07 0.99 14 351 Primary ZFHX3 oncogenic mutation 0.79 0.32 0.80 0.64 0.17 0.97 30 335 Primary ERRFI1 oncogenic alterations: deletion/mutation 0.79 0.15 0.78 0.39 0.03 0.99 9 348 Primary TET2 oncogenic mutation 0.79 0.11 0.78 0.67 0.06 0.99 9 356 Primary ARID1B oncogenic mutation 0.78 0.15 0.85 0.63 0.08 0.99 13 352 Primary EP300 oncogenic mutation 0.78 0.11 0.85 0.58 0.07 0.99 13 352 Primary MGA oncogenic mutation 0.77 0.18 0.76 0.60 0.08 0.98 17 348 Primary ATM oncogenic mutation 0.77 0.23 0.75 0.67 0.14 0.97 24 341 Primary PTCH1 oncogenic alterations: deletion/mutation 0.77 0.06 0.75 0.69 0.05 0.99 8 357 Primary KMT2D oncogenic mutation 0.76 0.23 0.87 0.52 0.15 0.98 31 334 Primary RB1 oncogenic mutation 0.76 0.13 1.00 0.31 0.08 1.00 21 344 Primary KMT2D oncogenic alterations: deletion/mutation 0.76 0.23 0.84 0.51 0.14 0.97 32 333 Primary CREBBP oncogenic mutation 0.76 0.15 0.75 0.69 0.08 0.99 12 353 Primary CCND1 oncogenic mutation 0.75 0.12 0.89 0.55 0.10 0.99 19 346 Primary ERBB2 oncogenic alterations: amplification/mutation 0.75 0.24 0.88 0.34 0.09 0.97 26 339 Table S9.4. Biomarkers detected in Endometrial Cancer (continued) Tumor Site Biomarker AUC AP Sensitivity Specificity PPV NPV Positive Negative Total Metastasis MSI-H vs MSS 0.96 0.73 1.00 0.90 0.57 1.00 12 94 Metastasis CTNNB1 oncogenic alterations: amplification/mutation 0.95 0.86 0.97 0.82 0.64 0.99 29 91 Metastasis CTNNB1 oncogenic mutation 0.95 0.85 0.97 0.81 0.62 0.99 29 91 Metastasis MSH6 oncogenic mutation 0.95 0.48 1.00 0.88 0.18 1.00 3 117 Metastasis MSI-H/dMMR 0.93 0.67 0.85 0.89 0.52 0.98 13 94 Metastasis RNF43 oncogenic mutation 0.93 0.58 1.00 0.80 0.27 1.00 8 112 Metastasis TP53 oncogenic alterations: deletion/mutation 0.93 0.94 0.88 0.77 0.81 0.84 64 56 Metastasis MSH3 oncogenic alterations: deletion/mutation 0.92 0.41 0.75 0.84 0.17 0.99 4 93 Metastasis KMT2B oncogenic mutation 0.92 0.53 0.78 0.85 0.35 0.97 9 88 Metastasis MSH6 oncogenic alterations: deletion/mutation 0.92 0.17 1.00 0.88 0.18 1.00 3 117 Metastasis MSH3 oncogenic mutation 0.92 0.36 0.75 0.87 0.20 0.99 4 93 Metastasis KMT2B oncogenic alterations: deletion/mutation 0.92 0.45 0.78 0.90 0.44 0.98 9 88 Metastasis TP53 oncogenic mutation 0.92 0.93 0.86 0.79 0.82 0.83 64 56 Metastasis FAT1 oncogenic mutation 0.91 0.30 0.75 0.84 0.14 0.99 4 116 Metastasis NTRK1 oncogenic alterations: amplification/mutation 0.91 0.21 1.00 0.41 0.04 1.00 3 117 Metastasis RNF43 oncogenic alterations: deletion/mutation 0.90 0.54 0.88 0.79 0.23 0.99 8 112 Metastasis CBL oncogenic alterations: deletion/mutation 0.90 0.14 1.00 0.56 0.06 1.00 3 117 Metastasis ELF3 amplification 0.90 0.36 1.00 0.24 0.07 1.00 5 92 Metastasis TGF beta pathway 0.89 0.26 1.00 0.59 0.11 1.00 6 114 Metastasis INPPL1 oncogenic mutation 0.89 0.28 0.86 0.86 0.32 0.99 7 90 Metastasis INPPL1 oncogenic alterations: deletion/mutation 0.89 0.27 0.86 0.87 0.33 0.99 7 90 Metastasis ESR1 oncogenic mutation 0.88 0.22 1.00 0.66 0.09 1.00 4 116 Metastasis PDCD1LG2 deletion 0.88 0.21 1.00 0.71 0.07 1.00 2 95 Metastasis FGFR oncogenic mutation 0.87 0.34 0.83 0.67 0.12 0.99 6 113 Metastasis MTOR oncogenic mutation 0.87 0.22 0.75 0.73 0.09 0.99 4 116 Metastasis SMAD4 oncogenic alterations: deletion/mutation 0.86 0.39 1.00 0.27 0.04 1.00 4 116 Metastasis ARID1A oncogenic mutation 0.86 0.72 0.78 0.83 0.62 0.91 32 88 Metastasis ARID1A oncogenic alterations: deletion/mutation 0.86 0.74 0.85 0.77 0.58 0.93 33 87 Metastasis KMT2D oncogenic alterations: deletion/mutation 0.85 0.45 0.82 0.68 0.20 0.97 11 109 Metastasis SMARCA4 oncogenic mutation 0.85 0.10 1.00 0.23 0.03 1.00 3 117 Metastasis KMT2D oncogenic mutation 0.84 0.38 0.91 0.67 0.22 0.99 11 109 Metastasis SMARCA4 oncogenic alterations: deletion/mutation 0.83 0.09 1.00 0.31 0.04 1.00 3 117 Metastasis NOTCH3 oncogenic alterations: amplification/mutation 0.83 0.09 1.00 0.56 0.06 1.00 3 117 Metastasis FGFR2 oncogenic mutation 0.83 0.14 1.00 0.57 0.11 1.00 6 114 Metastasis NCOA3 amplification 0.83 0.34 0.75 0.65 0.07 0.99 4 113 Metastasis PTPRD oncogenic alterations: deletion/mutation 0.82 0.17 1.00 0.51 0.08 1.00 5 115 Metastasis FGFR2 oncogenic alterations: amplification/mutation 0.81 0.18 0.83 0.44 0.07 0.98 6 114 Metastasis NSD3 amplification 0.81 0.34 1.00 0.53 0.08 1.00 4 93 Metastasis KRAS oncogenic mutation 0.81 0.60 0.79 0.62 0.28 0.94 19 101 Metastasis MYCN oncogenic alterations: amplification/mutation 0.80 0.27 0.83 0.69 0.12 0.99 6 114 Metastasis ESR1 oncogenic alterations: amplification/mutation 0.79 0.37 0.75 0.52 0.05 0.98 4 116 Metastasis AKT2 oncogenic alterations: amplification/mutation 0.79 0.14 1.00 0.58 0.13 1.00 7 113 Metastasis DUSP4 deletion 0.79 0.07 1.00 0.41 0.03 1.00 2 95 Metastasis CDK12 amplification 0.79 0.24 0.75 0.83 0.13 0.99 4 116 Metastasis RECQL4 amplification 0.79 0.17 0.80 0.37 0.05 0.98 5 115 Metastasis PIK3R1 oncogenic alterations: deletion/mutation 0.79 0.48 0.75 0.63 0.29 0.93 20 100 Metastasis KRAS oncogenic alterations: amplification/mutation 0.79 0.61 0.81 0.51 0.26 0.93 21 99 Metastasis ERBB2 oncogenic mutation 0.77 0.15 0.80 0.66 0.09 0.99 5 115 Metastasis CEBPA amplification 0.77 0.14 0.86 0.59 0.12 0.98 7 110 Metastasis MYC amplification 0.77 0.28 0.89 0.63 0.16 0.99 9 111 Metastasis MYC oncogenic alterations: amplification/mutation 0.77 0.22 0.89 0.51 0.13 0.98 9 111 Metastasis RAD21 amplification 0.77 0.07 1.00 0.32 0.04 1.00 3 117 Metastasis FGFR1 oncogenic alterations: amplification/mutation 0.76 0.21 0.83 0.43 0.07 0.98 6 114 Metastasis H3C13 amplification 0.75 0.20 1.00 0.24 0.04 1.00 4 113 Table S9.5. Biomarkers detected in Esophagogastric Cancer Tumor Site Biomarker AUC AP Sensitivity Specificity PPV NPV Positive Negative Total Primary SOX2 amplification 0.97 0.76 0.83 0.96 0.29 1.00 6 284 Primary MSH3 oncogenic mutation 0.97 0.33 1.00 0.88 0.15 1.00 5 239 Primary MSH3 oncogenic alterations: deletion/mutation 0.97 0.44 1.00 0.89 0.16 1.00 5 239 Primary MSI-H vs MSS 0.96 0.84 0.92 0.90 0.31 1.00 12 255 Primary MSI-H/dMMR 0.96 0.84 1.00 0.54 0.10 1.00 13 254 Primary VEGFA oncogenic alterations: amplification/mutation 0.92 0.26 1.00 0.38 0.07 1.00 13 277 Primary VEGFA amplification 0.91 0.26 1.00 0.38 0.07 1.00 13 277 Primary CDH1 oncogenic alterations: deletion/mutation 0.90 0.34 0.89 0.77 0.22 0.99 19 271 Primary CDH1 oncogenic mutation 0.89 0.33 0.89 0.73 0.18 0.99 18 272 Primary KMT2D oncogenic alterations: deletion/mutation 0.89 0.46 0.94 0.76 0.18 1.00 16 274 Primary RNF43 oncogenic alterations: deletion/mutation 0.88 0.47 1.00 0.41 0.07 1.00 13 277 Primary RNF43 oncogenic mutation 0.88 0.49 1.00 0.51 0.08 1.00 12 278 Primary KMT2B oncogenic alterations: deletion/mutation 0.87 0.38 0.89 0.31 0.05 0.99 9 235 Primary KMT2D oncogenic mutation 0.87 0.41 0.81 0.73 0.15 0.99 16 274 Primary RHOA oncogenic mutation 0.86 0.16 1.00 0.40 0.04 1.00 7 283 Primary KMT2B oncogenic mutation 0.85 0.40 0.89 0.46 0.06 0.99 9 235 Primary HER2 0.85 0.64 0.96 0.44 0.28 0.98 23 100 Primary RHOA oncogenic alterations: amplification/mutation 0.84 0.14 1.00 0.43 0.04 1.00 7 283 Primary AURKA oncogenic alterations: amplification/mutation 0.84 0.13 1.00 0.37 0.03 1.00 6 284 Primary HER2 Amplification 0.83 0.63 0.91 0.53 0.30 0.96 22 101 Primary SMARCE1 amplification 0.83 0.76 0.75 0.72 0.09 0.99 4 105 Primary KRAS oncogenic mutation 0.83 0.47 0.87 0.47 0.08 0.98 15 275 Primary GNAS oncogenic alterations: amplification/mutation 0.83 0.22 0.75 0.74 0.08 0.99 8 282 Primary SOX9 oncogenic mutation 0.83 0.27 0.83 0.50 0.03 0.99 6 284 Primary FGF3 oncogenic alterations: amplification/mutation 0.81 0.24 0.94 0.38 0.09 0.99 18 272 Primary BRCA2 oncogenic alterations: deletion/mutation 0.81 0.26 1.00 0.45 0.04 1.00 7 283 Primary APC oncogenic mutation 0.81 0.21 0.77 0.71 0.11 0.98 13 277 Primary TP53 oncogenic mutation 0.81 0.89 0.92 0.48 0.78 0.75 194 96 Primary SOX9 oncogenic alterations: deletion/mutation 0.81 0.24 0.83 0.52 0.04 0.99 6 284 Primary CCND1 amplification 0.81 0.24 0.95 0.40 0.10 0.99 19 271 Primary EGFR amplification 0.80 0.31 0.94 0.34 0.09 0.99 18 272 Primary MYC amplification 0.80 0.24 0.95 0.24 0.09 0.98 22 268 Primary FGF4 oncogenic alterations: amplification/mutation 0.80 0.21 0.95 0.42 0.10 0.99 19 271 Primary FGF19 amplification 0.80 0.21 0.95 0.42 0.10 0.99 19 271 Primary FGF19 oncogenic alterations: amplification/mutation 0.80 0.22 0.95 0.33 0.09 0.99 19 271 Primary BRCA2 oncogenic mutation 0.80 0.32 1.00 0.49 0.04 1.00 6 284 Primary FGF4 amplification 0.80 0.24 0.89 0.44 0.10 0.98 19 271 Primary TP53 oncogenic alterations: deletion/mutation 0.80 0.88 0.93 0.46 0.78 0.76 194 96 Primary ARID2 oncogenic mutation 0.80 0.14 0.75 0.64 0.06 0.99 8 282 Primary CCND1 oncogenic alterations: amplification/mutation 0.80 0.21 0.89 0.39 0.09 0.98 19 271 Primary PD-L1 Negative 0.80 0.66 0.88 0.38 0.39 0.88 33 73 Primary MDM2 oncogenic alterations: amplification/mutation 0.79 0.18 0.88 0.61 0.11 0.99 16 274 Primary CDKN2A (p16INK4a) deletion 0.79 0.23 0.80 0.62 0.17 0.97 25 265 Primary AURKA amplification 0.79 0.07 0.83 0.41 0.03 0.99 6 284 Primary FGF3 amplification 0.79 0.22 0.94 0.40 0.09 0.99 18 272 Primary SOX9 oncogenic alterations: amplification/mutation 0.79 0.21 0.83 0.59 0.04 0.99 6 284 Primary CDKN2A (p14ARF) deletion 0.79 0.20 0.84 0.59 0.16 0.97 25 265 Primary TGFBR2 oncogenic mutation 0.79 0.40 0.83 0.56 0.08 0.99 12 278 Primary CCNE1 oncogenic alterations: amplification/mutation 0.78 0.21 1.00 0.25 0.09 1.00 21 269 Primary AGO2 amplification 0.78 0.11 0.80 0.74 0.06 0.99 5 239 Primary FGFR2 amplification 0.78 0.08 1.00 0.54 0.06 1.00 9 281 Primary MDM2 amplification 0.78 0.23 0.81 0.65 0.12 0.98 16 274 Primary CCND3 amplification 0.78 0.18 0.93 0.20 0.06 0.98 14 276 Primary PRKCI amplification 0.78 0.40 0.90 0.34 0.05 0.99 10 234 Primary ARID2 oncogenic alterations: deletion/mutation 0.78 0.12 0.88 0.48 0.05 0.99 8 282 Primary RARA amplification 0.77 0.34 0.88 0.41 0.08 0.98 16 274 Primary ARID1A oncogenic mutation 0.77 0.46 0.95 0.27 0.16 0.97 38 252 Primary ARID1A oncogenic alterations: deletion/mutation 0.77 0.49 0.92 0.26 0.16 0.96 39 251 Primary PD-L1 &gt; 1% positive-stained tumor cells 0.77 0.87 0.95 0.21 0.67 0.69 73 43 Primary CCNE1 amplification 0.77 0.17 0.95 0.22 0.09 0.98 21 269 Primary CDKN2B deletion 0.76 0.22 0.78 0.65 0.16 0.97 23 267 Primary TGFBR2 oncogenic alterations: deletion/mutation 0.76 0.36 0.83 0.35 0.05 0.98 12 278 Primary CDKN2B oncogenic alterations: deletion/mutation 0.76 0.21 0.83 0.58 0.15 0.97 23 267 Primary GNAS amplification 0.76 0.09 0.80 0.51 0.05 0.99 10 280 Primary RB1 oncogenic alterations: deletion/mutation 0.76 0.27 0.75 0.75 0.08 0.99 8 282 Primary ERBB2 amplification 0.75 0.39 0.86 0.41 0.17 0.95 36 254 Table S9.5. Biomarkers detected in Esophagogastric Cancer (continued) Tumor Site Biomarker AUC AP Sensitivity Specificity PPV NPV Positive Negative Total Metastasis STK11 oncogenic alterations: deletion/mutation 0.99 0.83 1.00 0.60 0.06 1.00 2 82 Metastasis KMT2A amplification 0.99 0.76 1.00 0.47 0.07 1.00 3 81 Metastasis MSI-H vs MSS 0.98 0.50 1.00 0.93 0.29 1.00 2 69 Metastasis PAK5 amplification 0.98 0.42 1.00 0.76 0.09 1.00 2 82 Metastasis PMAIP1 oncogenic alterations: deletion/mutation 0.97 0.48 1.00 0.74 0.12 1.00 3 81 Metastasis MSI-H/dMMR 0.97 0.45 1.00 0.64 0.07 1.00 2 69 Metastasis TERT oncogenic mutation 0.96 0.43 1.00 0.38 0.06 1.00 3 81 Metastasis CDH1 oncogenic alterations: deletion/mutation 0.95 0.56 1.00 0.80 0.24 1.00 5 79 Metastasis RASA1 oncogenic alterations: deletion/mutation 0.95 0.35 1.00 0.74 0.09 1.00 2 82 Metastasis GATA3 oncogenic alterations: deletion/mutation 0.95 0.24 1.00 0.77 0.10 1.00 2 82 Metastasis PMAIP1 deletion 0.94 0.27 1.00 0.73 0.08 1.00 2 82 Metastasis TGFBR1 oncogenic mutation 0.94 0.34 1.00 0.38 0.04 1.00 2 82 Metastasis AXIN1 oncogenic alterations: deletion/mutation 0.93 0.33 1.00 0.71 0.08 1.00 2 82 Metastasis KMT2B oncogenic alterations: deletion/mutation 0.93 0.35 1.00 0.59 0.07 1.00 2 63 Metastasis RASA1 oncogenic mutation 0.93 0.33 1.00 0.84 0.13 1.00 2 82 Metastasis PTPRD oncogenic alterations: deletion/mutation 0.93 0.57 1.00 0.52 0.05 1.00 2 82 Metastasis CDH1 oncogenic mutation 0.93 0.37 1.00 0.81 0.25 1.00 5 79 Metastasis CDK12 amplification 0.91 0.43 1.00 0.50 0.13 1.00 6 78 Metastasis AURKA oncogenic alterations: amplification/mutation 0.89 0.29 1.00 0.34 0.07 1.00 4 80 Metastasis MCL1 oncogenic alterations: amplification/mutation 0.89 0.29 1.00 0.44 0.08 1.00 4 80 Metastasis BCL2L1 amplification 0.89 0.26 1.00 0.76 0.21 1.00 5 79 Metastasis FGF4 amplification 0.88 0.53 0.88 0.70 0.23 0.98 8 76 Metastasis MCL1 amplification 0.88 0.29 1.00 0.38 0.07 1.00 4 80 Metastasis AGO2 amplification 0.88 0.56 1.00 0.46 0.06 1.00 2 63 Metastasis FGF19 oncogenic alterations: amplification/mutation 0.88 0.54 0.89 0.45 0.16 0.97 9 75 Metastasis FGF4 oncogenic alterations: amplification/mutation 0.88 0.54 0.88 0.63 0.20 0.98 8 76 Metastasis RARA amplification 0.87 0.22 1.00 0.54 0.07 1.00 3 81 Metastasis TMB-H 0.87 0.32 1.00 0.49 0.13 1.00 6 78 Metastasis FGF3 oncogenic alterations: amplification/mutation 0.87 0.51 0.88 0.49 0.15 0.97 8 76 Metastasis ASXL1 amplification 0.87 0.38 1.00 0.69 0.14 1.00 4 80 Metastasis CCND1 amplification 0.87 0.53 0.90 0.62 0.24 0.98 10 74 Metastasis H3C13 amplification 0.87 0.28 1.00 0.39 0.06 1.00 3 74 Metastasis FGF3 amplification 0.87 0.53 0.88 0.59 0.18 0.98 8 76 Metastasis FGF19 amplification 0.86 0.49 0.89 0.55 0.19 0.98 9 75 Metastasis CCND1 oncogenic alterations: amplification/mutation 0.86 0.50 0.91 0.58 0.24 0.98 11 73 Metastasis FGFR1 amplification 0.86 0.14 1.00 0.67 0.10 1.00 3 81 Metastasis ERBB2 amplification 0.86 0.57 0.86 0.59 0.29 0.95 14 70 Metastasis TERT oncogenic alterations: amplification/mutation 0.85 0.23 0.80 0.67 0.13 0.98 5 79 Metastasis H3C14 amplification 0.84 0.27 1.00 0.20 0.05 1.00 3 74 Metastasis NSD3 amplification 0.84 0.22 1.00 0.52 0.09 1.00 3 62 Metastasis MET amplification 0.84 0.50 1.00 0.39 0.09 1.00 5 79 Metastasis GNAS amplification 0.84 0.40 1.00 0.47 0.13 1.00 6 78 Metastasis AURKA amplification 0.83 0.16 1.00 0.34 0.07 1.00 4 80 Metastasis EGFR amplification 0.82 0.27 0.83 0.54 0.12 0.98 6 78 Metastasis CCND3 amplification 0.82 0.26 1.00 0.34 0.09 1.00 5 79 Metastasis MYC oncogenic alterations: amplification/mutation 0.81 0.49 1.00 0.24 0.14 1.00 9 75 Metastasis KRAS amplification 0.81 0.30 1.00 0.41 0.17 1.00 9 75 Metastasis ERBB2 oncogenic alterations: amplification/mutation 0.81 0.52 0.88 0.37 0.25 0.93 16 68 Metastasis CCND3 oncogenic alterations: amplification/mutation 0.81 0.31 1.00 0.27 0.08 1.00 5 79 Metastasis CCND2 amplification 0.80 0.08 1.00 0.68 0.07 1.00 2 82 Metastasis MET oncogenic alterations: amplification/mutation 0.80 0.35 1.00 0.33 0.09 1.00 5 79 Metastasis FGFR1 oncogenic alterations: amplification/mutation 0.80 0.11 1.00 0.74 0.12 1.00 3 81 Metastasis ARID1A oncogenic mutation 0.80 0.58 0.82 0.45 0.18 0.94 11 73 Metastasis MYC amplification 0.80 0.46 1.00 0.25 0.14 1.00 9 75 Metastasis VEGFA amplification 0.79 0.33 0.80 0.49 0.09 0.97 5 79 Metastasis APC oncogenic alterations: deletion/mutation 0.79 0.27 0.83 0.60 0.14 0.98 6 78 Metastasis EGFR oncogenic alterations: amplification/mutation 0.79 0.25 1.00 0.38 0.11 1.00 6 78 Metastasis FOXP1 amplification 0.78 0.53 1.00 0.48 0.04 1.00 2 82 Metastasis CCNE1 amplification 0.77 0.50 0.86 0.34 0.11 0.96 7 77 Metastasis PIK3CG amplification 0.77 0.07 1.00 0.30 0.03 1.00 2 82 Metastasis MAP2K1 oncogenic alterations: amplification/mutation 0.77 0.13 1.00 0.24 0.03 1.00 2 82 Metastasis VEGFA oncogenic alterations: amplification/mutation 0.76 0.42 0.80 0.51 0.09 0.98 5 79 Metastasis ARID1A oncogenic alterations: deletion/mutation 0.76 0.52 0.83 0.42 0.19 0.94 12 72 Metastasis RTEL1 amplification 0.76 0.23 1.00 0.28 0.08 1.00 4 61 Metastasis CCNE1 oncogenic alterations: amplification/mutation 0.76 0.40 0.86 0.34 0.11 0.96 7 77 Metastasis SMAD4 oncogenic alterations: deletion/mutation 0.76 0.32 0.83 0.44 0.10 0.97 6 78 Table S9.6. Biomarkers detected in Glioma Tumor Site Biomarker AUC AP Sensitivity Specificity PPV NPV Positive Negative Total Primary CIC oncogenic mutation 0.96 0.59 0.82 0.92 0.38 0.99 22 362 Primary CIC oncogenic alterations: deletion/mutation 0.96 0.53 0.82 0.94 0.45 0.99 22 362 Primary IDH1 oncogenic alterations: amplification/mutation 0.95 0.82 0.89 0.86 0.71 0.96 104 280 Primary RET deletion 0.95 0.41 0.95 0.85 0.25 1.00 19 365 Primary FGFR3 fusion 0.95 0.42 1.00 0.49 0.05 1.00 11 373 Primary IDH1 oncogenic mutation 0.94 0.81 0.88 0.87 0.72 0.95 104 280 Primary NOTCH1 oncogenic mutation 0.93 0.32 1.00 0.78 0.12 1.00 11 373 Primary NOTCH1 oncogenic alterations: deletion/mutation 0.92 0.24 1.00 0.61 0.08 1.00 12 372 Primary GATA3 deletion 0.92 0.57 0.83 0.86 0.23 0.99 18 366 Primary NOTCH1 oncogenic alterations: amplification/mutation 0.92 0.26 1.00 0.75 0.10 1.00 11 373 Primary GATA3 oncogenic alterations: deletion/mutation 0.92 0.41 0.94 0.75 0.16 1.00 18 366 Primary TERT oncogenic mutation 0.88 0.84 0.88 0.70 0.72 0.87 179 205 Primary TERT oncogenic alterations: amplification/mutation 0.88 0.83 0.89 0.72 0.74 0.88 180 204 Primary EGFR amplification 0.87 0.70 0.87 0.62 0.41 0.94 89 295 Primary TMB-H 0.86 0.19 0.92 0.52 0.06 0.99 12 369 Primary ATRX oncogenic alterations: deletion/mutation 0.86 0.54 0.90 0.53 0.19 0.98 42 342 Primary CDKN2B deletion 0.86 0.78 0.92 0.61 0.60 0.92 150 234 Primary CDKN2A (p14ARF) deletion 0.86 0.79 0.93 0.59 0.60 0.93 152 232 Primary CDKN2B oncogenic alterations: deletion/mutation 0.86 0.79 0.92 0.62 0.61 0.92 150 234 Primary CDKN2A (p16INK4a) deletion 0.86 0.79 0.93 0.56 0.58 0.93 151 233 Primary ATRX oncogenic mutation 0.86 0.55 0.92 0.46 0.16 0.98 39 345 Primary EGFR oncogenic alterations: amplification/mutation 0.85 0.73 0.87 0.59 0.44 0.93 102 282 Primary SMARCA2 oncogenic alterations: deletion/mutation 0.85 0.11 1.00 0.36 0.04 1.00 3 120 Primary EGFR fusion 0.85 0.45 0.89 0.62 0.29 0.97 56 328 Primary BRCA1 germline/somatic point mutation/deletion or fusion 0.83 0.18 1.00 0.40 0.06 1.00 5 124 Primary TP53 oncogenic mutation 0.82 0.72 0.90 0.57 0.58 0.90 151 233 Primary RTK pathway 0.82 0.82 0.93 0.54 0.68 0.88 198 186 Primary BRAF oncogenic alterations: amplification/mutation 0.82 0.17 0.93 0.24 0.04 0.99 14 370 Primary TP53 oncogenic alterations: deletion/mutation 0.82 0.74 0.86 0.59 0.59 0.87 154 230 Primary KIT amplification 0.81 0.18 1.00 0.36 0.09 1.00 24 360 Primary RB1 oncogenic mutation 0.81 0.28 0.83 0.66 0.17 0.98 30 354 Primary STAG2 oncogenic mutation 0.81 0.07 1.00 0.46 0.04 1.00 9 375 Primary KDR amplification 0.81 0.14 0.78 0.67 0.11 0.98 18 366 Primary PTEN deletion 0.81 0.19 0.93 0.62 0.09 1.00 15 369 Primary CDK4 amplification 0.81 0.25 0.96 0.40 0.11 0.99 27 357 Primary BRAF oncogenic mutation 0.81 0.15 0.93 0.45 0.06 0.99 14 370 Primary MDM2 amplification 0.80 0.22 0.89 0.55 0.09 0.99 19 365 Primary MDM2 oncogenic alterations: amplification/mutation 0.79 0.17 0.84 0.57 0.09 0.99 19 365 Primary CDK4 oncogenic alterations: amplification/mutation 0.79 0.23 0.93 0.49 0.12 0.99 27 357 Primary EGFR oncogenic mutation 0.79 0.29 0.83 0.64 0.22 0.97 42 342 Primary RB1 oncogenic alterations: deletion/mutation 0.79 0.26 0.86 0.53 0.15 0.97 35 349 Primary STAG2 oncogenic alterations: deletion/mutation 0.78 0.08 0.89 0.56 0.05 1.00 9 375 Primary PTEN oncogenic alterations: deletion/mutation 0.78 0.50 0.85 0.55 0.38 0.92 94 290 Primary H3-3A amplification/mutation 0.78 0.18 0.86 0.54 0.07 0.99 14 356 Primary MTAP oncogenic alterations: deletion/mutation 0.77 0.58 0.89 0.46 0.41 0.91 36 87 Primary PDGFRA amplification 0.77 0.21 0.97 0.33 0.12 0.99 34 350 Primary MTAP deletion 0.77 0.53 0.89 0.57 0.46 0.93 36 87 Primary PDGFRA oncogenic alterations: amplification/mutation 0.77 0.22 0.95 0.30 0.13 0.98 37 347 Primary PTEN oncogenic mutation 0.76 0.43 0.86 0.51 0.32 0.93 81 303 Primary KIT oncogenic alterations: amplification/mutation 0.76 0.14 1.00 0.26 0.08 1.00 24 360 Primary ARID1A oncogenic alterations: deletion/mutation 0.76 0.06 1.00 0.24 0.03 1.00 8 376 Table S9.7. Biomarkers detected in Hepatobiliary Cancer Tumor Site Biomarker AUC AP Sensitivity Specificity PPV NPV Positive Negative Total Primary CCNE1 amplification 0.98 0.46 1.00 0.64 0.06 1.00 4 165 Primary CCNE1 oncogenic alterations: amplification/mutation 0.98 0.41 1.00 0.70 0.07 1.00 4 165 Primary STK11 oncogenic alterations: deletion/mutation 0.95 0.28 1.00 0.86 0.15 1.00 4 165 Primary SMAD4 oncogenic mutation 0.93 0.46 1.00 0.58 0.13 1.00 10 159 Primary SMAD4 oncogenic alterations: deletion/mutation 0.93 0.44 1.00 0.59 0.15 1.00 11 158 Primary KRAS oncogenic mutation 0.92 0.52 1.00 0.57 0.14 1.00 11 158 Primary IDH2 oncogenic mutation 0.92 0.59 1.00 0.37 0.07 1.00 8 161 Primary KRAS oncogenic alterations: amplification/mutation 0.92 0.49 1.00 0.48 0.12 1.00 11 158 Primary RB1 oncogenic alterations: deletion/mutation 0.90 0.28 1.00 0.46 0.06 1.00 6 163 Primary TERT oncogenic mutation 0.90 0.63 0.91 0.63 0.28 0.98 23 146 Primary TGF beta pathway 0.89 0.42 1.00 0.64 0.19 1.00 13 156 Primary SOX17 amplification 0.89 0.49 1.00 0.49 0.05 1.00 4 165 Primary CDKN2A (p16INK4a) oncogenic mutation 0.87 0.13 1.00 0.30 0.03 1.00 4 165 Primary IDH1 oncogenic mutation 0.87 0.31 0.77 0.80 0.24 0.98 13 156 Primary IDH1 oncogenic alterations: amplification/mutation 0.87 0.32 0.85 0.79 0.26 0.98 13 156 Primary TERT oncogenic alterations: amplification/mutation 0.87 0.61 0.88 0.62 0.29 0.97 25 144 Primary MYC oncogenic alterations: amplification/mutation 0.86 0.24 1.00 0.64 0.09 1.00 6 163 Primary FGF4 oncogenic alterations: amplification/mutation 0.86 0.20 1.00 0.53 0.07 1.00 6 163 Primary NFE2L2 oncogenic mutation 0.85 0.22 1.00 0.59 0.08 1.00 6 163 Primary FGF3 amplification 0.85 0.23 1.00 0.52 0.07 1.00 6 163 Primary FGF4 amplification 0.84 0.25 1.00 0.53 0.07 1.00 6 163 Primary CDK12 amplification 0.84 0.19 0.75 0.84 0.10 0.99 4 165 Primary CDKN2A (p14ARF) deletion 0.84 0.26 0.87 0.68 0.21 0.98 15 154 Primary MDM2 oncogenic alterations: amplification/mutation 0.84 0.36 0.90 0.55 0.11 0.99 10 159 Primary CDKN2A (p16INK4a) deletion 0.84 0.24 0.86 0.65 0.18 0.98 14 155 Primary MDM2 amplification 0.83 0.29 0.90 0.52 0.11 0.99 10 159 Primary CTNNB1 oncogenic alterations: amplification/mutation 0.83 0.25 0.85 0.75 0.22 0.98 13 156 Primary CTNNB1 oncogenic mutation 0.82 0.24 0.85 0.72 0.20 0.98 13 156 Primary FGF3 oncogenic alterations: amplification/mutation 0.82 0.22 0.83 0.47 0.05 0.99 6 163 Primary NFE2L2 oncogenic alterations: amplification/mutation 0.81 0.27 0.83 0.65 0.08 0.99 6 163 Primary TP53 oncogenic mutation 0.81 0.68 0.77 0.67 0.51 0.87 52 117 Primary CDKN2B deletion 0.81 0.21 0.83 0.56 0.13 0.98 12 157 Primary TP53 oncogenic alterations: deletion/mutation 0.81 0.66 0.77 0.65 0.49 0.86 52 117 Primary CDKN2B oncogenic alterations: deletion/mutation 0.81 0.20 0.83 0.67 0.16 0.98 12 157 Primary ERBB2 oncogenic mutation 0.81 0.10 0.75 0.75 0.07 0.99 4 165 Primary AXIN1 oncogenic alterations: deletion/mutation 0.80 0.09 1.00 0.51 0.05 1.00 4 165 Primary APC oncogenic alterations: deletion/mutation 0.80 0.16 1.00 0.32 0.03 1.00 4 165 Primary PBRM1 oncogenic alterations: deletion/mutation 0.80 0.29 0.89 0.35 0.07 0.98 9 160 Primary FGFR2 fusion 0.78 0.19 0.75 0.73 0.18 0.97 12 157 Primary PBRM1 oncogenic mutation 0.77 0.19 1.00 0.23 0.07 1.00 9 160 Primary ATM oncogenic alterations: deletion/mutation 0.76 0.07 1.00 0.46 0.05 1.00 5 164 Primary ERBB2 oncogenic alterations: amplification/mutation 0.75 0.17 0.86 0.49 0.07 0.99 7 162 Primary PTEN oncogenic mutation 0.75 0.18 1.00 0.33 0.03 1.00 4 165 Metastasis DNAJB1 fusion 0.99 0.93 1.00 0.98 0.83 1.00 5 54 Metastasis HRD pathway 0.99 0.83 1.00 0.32 0.05 1.00 2 62 Metastasis STK11 oncogenic mutation 0.97 0.42 1.00 0.77 0.12 1.00 2 62 Metastasis STK11 oncogenic alterations: deletion/mutation 0.96 0.42 1.00 0.76 0.12 1.00 2 62 Metastasis ERBB2 amplification 0.96 0.48 0.75 0.95 0.50 0.98 4 60 Metastasis ERBB3 amplification 0.95 0.33 1.00 0.31 0.04 1.00 2 62 Metastasis NBN amplification 0.95 0.62 1.00 0.89 0.22 1.00 2 62 Metastasis GLI1 amplification 0.94 0.31 1.00 0.79 0.13 1.00 2 62 Metastasis GLI1 oncogenic alterations: amplification/mutation 0.94 0.29 1.00 0.63 0.08 1.00 2 62 Metastasis ERBB2 oncogenic alterations: amplification/mutation 0.94 0.47 1.00 0.48 0.11 1.00 4 60 Metastasis CDK4 oncogenic alterations: amplification/mutation 0.94 0.60 1.00 0.39 0.05 1.00 2 62 Metastasis ELOC amplification 0.94 0.27 1.00 0.90 0.25 1.00 2 62 Metastasis KRAS oncogenic alterations: amplification/mutation 0.93 0.67 1.00 0.35 0.26 1.00 12 52 Metastasis PRDM14 amplification 0.93 0.31 1.00 0.80 0.17 1.00 2 49 Metastasis KRAS oncogenic mutation 0.93 0.66 1.00 0.46 0.30 1.00 12 52 Metastasis SOX17 amplification 0.92 0.27 1.00 0.61 0.08 1.00 2 62 Metastasis SMAD4 oncogenic alterations: deletion/mutation 0.91 0.66 1.00 0.51 0.20 1.00 7 57 Metastasis SMAD4 oncogenic mutation 0.91 0.51 1.00 0.52 0.18 1.00 6 58 Metastasis BRAF oncogenic alterations: amplification/mutation 0.90 0.33 1.00 0.52 0.06 1.00 2 62 Metastasis BAP1 oncogenic mutation 0.90 0.24 1.00 0.81 0.14 1.00 2 62 Metastasis BRAF oncogenic mutation 0.90 0.24 1.00 0.52 0.06 1.00 2 62 Metastasis CDK4 amplification 0.90 0.21 1.00 0.35 0.05 1.00 2 62 Metastasis KMT2D oncogenic alterations: deletion/mutation 0.90 0.57 1.00 0.35 0.05 1.00 2 62 Metastasis MDM2 amplification 0.89 0.57 1.00 0.43 0.15 1.00 6 58 Metastasis CCNE1 oncogenic alterations: amplification/mutation 0.89 0.33 1.00 0.64 0.12 1.00 3 61 Metastasis KMT2D oncogenic mutation 0.88 0.31 1.00 0.26 0.04 1.00 2 62 Metastasis MDM2 oncogenic alterations: amplification/mutation 0.88 0.61 1.00 0.45 0.16 1.00 6 58 Metastasis CCNE1 amplification 0.87 0.29 1.00 0.57 0.10 1.00 3 61 Metastasis ERBB3 oncogenic alterations: amplification/mutation 0.86 0.19 1.00 0.39 0.07 1.00 3 61 Metastasis BAP1 oncogenic alterations: deletion/mutation 0.85 0.13 1.00 0.73 0.11 1.00 2 62 Metastasis TERT oncogenic mutation 0.82 0.59 0.75 0.68 0.14 0.98 4 60 Metastasis TERT oncogenic alterations: amplification/mutation 0.81 0.48 0.80 0.66 0.17 0.97 5 59 Metastasis GNAS amplification 0.81 0.17 1.00 0.66 0.09 1.00 2 62 Metastasis TGF beta pathway 0.80 0.42 0.90 0.52 0.26 0.97 10 54 Metastasis CDKN2A (p16INK4a) deletion 0.79 0.50 0.83 0.48 0.14 0.97 6 58 Metastasis CDKN2A (p14ARF) deletion 0.78 0.42 0.83 0.47 0.14 0.96 6 58 Metastasis PBRM1 oncogenic mutation 0.77 0.28 1.00 0.28 0.12 1.00 6 58 Metastasis CDKN2B oncogenic alterations: deletion/mutation 0.77 0.39 0.80 0.49 0.12 0.97 5 59 Metastasis CDKN2B deletion 0.76 0.39 0.80 0.44 0.11 0.96 5 59 Metastasis PIK3CA oncogenic alterations: amplification/mutation 0.76 0.42 0.83 0.34 0.12 0.95 6 58 Metastasis PIK3CA oncogenic mutation 0.76 0.47 0.83 0.36 0.12 0.95 6 58 Metastasis NFE2L2 oncogenic alterations: amplification/mutation 0.76 0.09 1.00 0.68 0.09 1.00 2 62 Metastasis MYC amplification 0.75 0.30 0.83 0.71 0.23 0.98 6 58 Table S9.8. Biomarkers detected in Melanoma Tumor Site Biomarker AUC AP Sensitivity Specificity PPV NPV Positive Negative Total Primary GNA11 oncogenic alterations: amplification/mutation 0.97 0.56 1.00 0.73 0.09 1.00 3 118 Primary GNA11 oncogenic mutation 0.96 0.52 1.00 0.81 0.12 1.00 3 118 Primary RECQL4 amplification 0.95 0.49 1.00 0.54 0.07 1.00 4 117 Primary BAP1 oncogenic alterations: deletion/mutation 0.94 0.33 1.00 0.56 0.05 1.00 3 118 Primary AGO2 amplification 0.94 0.47 1.00 0.52 0.08 1.00 4 98 Primary PREX2 amplification 0.94 0.61 1.00 0.48 0.06 1.00 3 99 Primary SF3B1 oncogenic mutation 0.93 0.51 1.00 0.60 0.19 1.00 10 111 Primary SOX17 amplification 0.92 0.44 1.00 0.73 0.09 1.00 3 118 Primary LYN amplification 0.92 0.54 1.00 0.36 0.05 1.00 3 99 Primary CRKL amplification 0.92 0.23 1.00 0.80 0.15 1.00 4 117 Primary SF3B1 oncogenic alterations: amplification/mutation 0.92 0.50 1.00 0.64 0.20 1.00 10 111 Primary YAP1 oncogenic alterations: amplification/mutation 0.91 0.38 1.00 0.80 0.21 1.00 6 115 Primary YAP1 amplification 0.91 0.27 1.00 0.57 0.11 1.00 6 115 Primary MYC oncogenic alterations: amplification/mutation 0.90 0.25 1.00 0.61 0.06 1.00 3 118 Primary PTPRD oncogenic mutation 0.89 0.19 1.00 0.67 0.09 1.00 4 117 Primary BAP1 oncogenic mutation 0.88 0.14 1.00 0.43 0.04 1.00 3 118 Primary TERT oncogenic alterations: amplification/mutation 0.88 0.84 0.94 0.59 0.62 0.93 51 70 Primary PRDM14 amplification 0.88 0.42 1.00 0.68 0.11 1.00 4 98 Primary CTNNB1 oncogenic alterations: amplification/mutation 0.87 0.22 1.00 0.56 0.07 1.00 4 117 Primary CTNNB1 oncogenic mutation 0.86 0.19 1.00 0.43 0.06 1.00 4 117 Primary MYC amplification 0.86 0.39 1.00 0.70 0.08 1.00 3 118 Primary TP53 oncogenic mutation 0.86 0.45 0.93 0.55 0.23 0.98 15 106 Primary ATM oncogenic mutation 0.85 0.17 1.00 0.44 0.04 1.00 3 118 Primary TP53 oncogenic alterations: deletion/mutation 0.85 0.48 0.93 0.54 0.22 0.98 15 106 Primary LZTR1 amplification 0.85 0.17 1.00 0.54 0.08 1.00 2 50 Primary TERT oncogenic mutation 0.85 0.76 0.94 0.61 0.62 0.94 49 72 Primary NF1 oncogenic alterations: deletion/mutation 0.84 0.36 1.00 0.47 0.24 1.00 17 104 Primary RAC1 oncogenic mutation 0.82 0.22 1.00 0.34 0.04 1.00 3 118 Primary ATM oncogenic alterations: deletion/mutation 0.82 0.13 1.00 0.39 0.05 1.00 4 117 Primary RB1 oncogenic alterations: deletion/mutation 0.81 0.08 1.00 0.40 0.04 1.00 3 118 Primary NF1 oncogenic mutation 0.81 0.32 1.00 0.42 0.19 1.00 15 106 Primary PTEN oncogenic alterations: deletion/mutation 0.81 0.39 1.00 0.53 0.15 1.00 9 112 Primary ATRX oncogenic alterations: deletion/mutation 0.80 0.10 0.75 0.67 0.07 0.99 4 117 Primary RB1 oncogenic mutation 0.79 0.07 1.00 0.47 0.05 1.00 3 118 Primary TMB-H 0.79 0.67 0.93 0.33 0.45 0.89 43 73 Primary PTPRD oncogenic alterations: deletion/mutation 0.78 0.09 1.00 0.60 0.08 1.00 4 117 Primary SMARCA2 oncogenic alterations: deletion/mutation 0.78 0.12 1.00 0.64 0.10 1.00 2 50 Primary BRAF oncogenic alterations: amplification/mutation 0.77 0.49 1.00 0.31 0.32 1.00 30 91 Primary BRCA1/2 germline/somatic mutation/deletion or fusion 0.76 0.42 1.00 0.51 0.37 1.00 13 45 Primary ATRX oncogenic mutation 0.76 0.09 0.75 0.68 0.07 0.99 4 117 Primary CDKN2B oncogenic alterations: deletion/mutation 0.76 0.33 0.79 0.68 0.31 0.95 19 102 Primary BRAF oncogenic mutation 0.76 0.50 0.97 0.33 0.32 0.97 30 91 Primary EP300 amplification 0.75 0.23 0.75 0.50 0.05 0.98 4 117 Metastasis RPS6KB2 amplification 0.96 0.57 1.00 0.71 0.08 1.00 5 203 Metastasis GNAQ oncogenic alterations: amplification/mutation 0.96 0.48 1.00 0.81 0.16 1.00 7 201 Metastasis GNAQ oncogenic mutation 0.95 0.50 1.00 0.78 0.13 1.00 7 201 Metastasis ELOC amplification 0.93 0.21 1.00 0.46 0.04 1.00 5 203 Metastasis NBN amplification 0.91 0.19 1.00 0.49 0.05 1.00 6 202 Metastasis RAD21 amplification 0.90 0.18 1.00 0.46 0.06 1.00 7 201 Metastasis SF3B1 oncogenic alterations: amplification/mutation 0.89 0.33 0.92 0.74 0.19 0.99 13 195 Metastasis SF3B1 oncogenic mutation 0.89 0.35 0.92 0.67 0.16 0.99 13 195 Metastasis RECQL4 amplification 0.87 0.27 1.00 0.40 0.06 1.00 8 200 Metastasis RTEL1 amplification 0.86 0.13 1.00 0.64 0.07 1.00 4 155 Metastasis PREX2 amplification 0.86 0.20 1.00 0.32 0.05 1.00 5 154 Metastasis BRAF amplification 0.86 0.29 0.80 0.72 0.07 0.99 5 203 Metastasis PRDM14 amplification 0.86 0.18 1.00 0.50 0.06 1.00 5 154 Metastasis AGO2 amplification 0.85 0.23 1.00 0.35 0.06 1.00 6 153 Metastasis CTNNB1 oncogenic alterations: amplification/mutation 0.82 0.22 0.93 0.42 0.11 0.99 15 193 Metastasis CTNNB1 oncogenic mutation 0.82 0.23 1.00 0.36 0.11 1.00 15 193 Metastasis MYC oncogenic alterations: amplification/mutation 0.82 0.22 0.89 0.46 0.07 0.99 9 199 Metastasis TP53 oncogenic mutation 0.81 0.60 0.89 0.39 0.25 0.94 38 170 Metastasis FGF3 amplification 0.81 0.38 0.91 0.38 0.08 0.99 11 197 Metastasis FGF4 amplification 0.80 0.40 1.00 0.29 0.07 1.00 11 197 Metastasis MYC amplification 0.80 0.20 0.89 0.56 0.08 0.99 9 199 Metastasis KIT amplification 0.80 0.14 0.86 0.64 0.08 0.99 7 201 Metastasis FGF4 oncogenic alterations: amplification/mutation 0.80 0.37 1.00 0.30 0.07 1.00 11 197 Metastasis FGF3 oncogenic alterations: amplification/mutation 0.79 0.37 0.91 0.40 0.08 0.99 11 197 Metastasis TP53 oncogenic alterations: deletion/mutation 0.79 0.59 0.87 0.38 0.24 0.93 39 169 Metastasis PAK1 amplification 0.77 0.31 1.00 0.31 0.06 1.00 9 199 Metastasis B2M deletion 0.77 0.07 1.00 0.58 0.06 1.00 5 203 Metastasis TERT oncogenic mutation 0.77 0.73 0.86 0.51 0.62 0.80 99 109 Metastasis PAK1 oncogenic alterations: amplification/mutation 0.76 0.30 1.00 0.29 0.06 1.00 9 199 Metastasis PTEN oncogenic alterations: deletion/mutation 0.76 0.22 0.93 0.37 0.10 0.99 14 194 Metastasis CCNQ oncogenic alterations: deletion/mutation 0.76 0.29 0.80 0.25 0.03 0.97 5 154 Table S9.9. Biomarkers detected in Non-Small Cell Lung Cancer Tumor Site Biomarker AUC AP Sensitivity Specificity PPV NPV Positive Negative Total Primary SOX2 amplification 0.96 0.40 0.86 0.93 0.22 1.00 21 882 Primary PRKCI amplification 0.92 0.23 0.88 0.81 0.09 1.00 16 742 Primary FGFR1 amplification 0.90 0.10 1.00 0.64 0.06 1.00 19 884 Primary FGFR1 oncogenic alterations: amplification/mutation 0.89 0.09 1.00 0.69 0.06 1.00 19 884 Primary RB1 oncogenic alterations: deletion/mutation 0.89 0.23 1.00 0.51 0.07 1.00 34 869 Primary EGFR oncogenic mutation 0.88 0.67 0.94 0.58 0.37 0.97 187 716 Primary RB1 oncogenic mutation 0.87 0.22 0.97 0.56 0.08 1.00 33 870 Primary PD-L1 &gt; 50% positive-stained tumor cells 0.87 0.67 0.91 0.61 0.30 0.97 64 342 Primary STK11 oncogenic mutation 0.87 0.56 0.81 0.73 0.26 0.97 94 809 Primary STK11 oncogenic alterations: deletion/mutation 0.87 0.56 0.84 0.72 0.26 0.97 97 806 Primary EGFR oncogenic alterations: amplification/mutation 0.86 0.67 0.92 0.53 0.36 0.96 201 702 Primary FGF3 amplification 0.85 0.24 0.77 0.66 0.05 0.99 22 881 Primary FGF4 amplification 0.85 0.19 0.82 0.66 0.06 0.99 22 881 Primary TP53 oncogenic alterations: deletion/mutation 0.85 0.80 0.90 0.62 0.65 0.89 395 508 Primary CCND1 amplification 0.85 0.18 0.96 0.58 0.06 1.00 23 880 Primary CCND1 oncogenic alterations: amplification/mutation 0.84 0.20 0.88 0.54 0.05 0.99 24 879 Primary TP53 oncogenic mutation 0.84 0.79 0.90 0.62 0.65 0.88 395 508 Primary FGF3 oncogenic alterations: amplification/mutation 0.84 0.20 0.77 0.65 0.05 0.99 22 881 Primary FGF4 oncogenic alterations: amplification/mutation 0.84 0.20 0.77 0.65 0.05 0.99 22 881 Primary FGF19 oncogenic alterations: amplification/mutation 0.84 0.19 0.86 0.62 0.05 0.99 22 881 Primary FGF19 amplification 0.84 0.20 0.86 0.64 0.06 0.99 22 881 Primary KMT2D oncogenic mutation 0.84 0.20 0.88 0.56 0.05 0.99 24 879 Primary KMT2D oncogenic alterations: deletion/mutation 0.84 0.27 0.88 0.55 0.05 0.99 25 878 Primary FOXA1 amplification 0.83 0.09 1.00 0.36 0.03 1.00 19 884 Primary MET oncogenic mutation 0.83 0.22 0.91 0.56 0.07 0.99 34 869 Primary KEAP1 oncogenic mutation 0.83 0.26 0.93 0.45 0.08 0.99 45 858 Primary KRAS oncogenic mutation 0.83 0.68 0.94 0.42 0.40 0.95 263 640 Primary KEAP1 oncogenic alterations: deletion/mutation 0.82 0.25 0.87 0.50 0.08 0.99 45 858 Primary KRAS oncogenic alterations: amplification/mutation 0.82 0.69 0.92 0.43 0.41 0.93 269 634 Primary CDKN2A (p16INK4a) deletion 0.81 0.22 0.81 0.70 0.18 0.98 69 834 Primary BRCA1 germline/somatic point mutation/deletion or fusion 0.81 0.46 0.90 0.57 0.28 0.97 21 114 Primary CDKN2A (p14ARF) deletion 0.81 0.21 0.81 0.66 0.17 0.98 69 834 Primary MET oncogenic alterations: amplification/mutation 0.81 0.20 0.90 0.48 0.08 0.99 42 861 Primary CDKN2B deletion 0.80 0.20 0.76 0.67 0.16 0.97 70 833 Primary SMARCA4 oncogenic alterations: deletion/mutation 0.80 0.23 0.89 0.38 0.04 0.99 28 875 Primary FOXA1 oncogenic alterations: amplification/mutation 0.80 0.07 0.90 0.41 0.03 0.99 20 883 Primary BRCA1/2 germline/somatic mutation/deletion or fusion 0.80 0.59 0.93 0.48 0.40 0.95 41 112 Primary SMARCA4 oncogenic mutation 0.79 0.17 0.85 0.43 0.04 0.99 27 876 Primary BRCA2 germline/somatic point mutation/deletion or fusion 0.78 0.40 0.95 0.44 0.25 0.98 22 115 Primary CDK4 oncogenic alterations: amplification/mutation 0.78 0.16 0.90 0.48 0.06 0.99 30 873 Primary CTNNB1 oncogenic mutation 0.77 0.17 0.88 0.55 0.05 0.99 26 877 Primary NKX2-1 oncogenic alterations: amplification/mutation 0.77 0.08 0.92 0.38 0.04 0.99 26 877 Primary NFKBIA amplification 0.76 0.08 0.83 0.47 0.04 0.99 24 879 Primary PTEN oncogenic alterations: deletion/mutation 0.76 0.13 0.92 0.38 0.04 0.99 25 878 Primary RTK pathway 0.76 0.74 0.90 0.40 0.56 0.83 417 486 Primary CTNNB1 oncogenic alterations: amplification/mutation 0.76 0.18 0.85 0.53 0.05 0.99 26 877 Primary PD-L1 Negative 0.76 0.72 0.90 0.37 0.53 0.82 240 300 Primary CDK4 amplification 0.76 0.15 0.83 0.48 0.05 0.99 30 873 Primary PD-L1 &gt; 1% positive-stained tumor cells 0.75 0.77 0.91 0.36 0.61 0.79 284 258 Metastasis SETD2 oncogenic mutation 0.86 0.17 1.00 0.25 0.03 1.00 9 381 Metastasis STK11 oncogenic mutation 0.86 0.39 0.85 0.75 0.24 0.98 33 357 Metastasis STK11 oncogenic alterations: deletion/mutation 0.86 0.37 0.88 0.68 0.21 0.98 34 356 Metastasis SETDB1 amplification 0.85 0.18 1.00 0.32 0.05 1.00 4 123 Metastasis CTNNB1 oncogenic alterations: amplification/mutation 0.84 0.10 1.00 0.50 0.04 1.00 8 382 Metastasis CTNNB1 oncogenic mutation 0.84 0.09 1.00 0.51 0.04 1.00 8 382 Metastasis SETD2 oncogenic alterations: deletion/mutation 0.84 0.14 1.00 0.43 0.04 1.00 9 381 Metastasis FGF3 amplification 0.82 0.13 0.92 0.40 0.05 0.99 12 378 Metastasis CDKN2B oncogenic alterations: deletion/mutation 0.82 0.42 0.92 0.46 0.21 0.97 53 337 Metastasis CDKN2B deletion 0.81 0.40 0.92 0.45 0.21 0.97 53 337 Metastasis SDHA amplification 0.81 0.21 0.89 0.43 0.07 0.99 19 371 Metastasis PD-L1 &gt; 50% positive-stained tumor cells 0.81 0.54 0.97 0.32 0.30 0.98 40 130 Metastasis IKZF1 amplification 0.81 0.18 0.75 0.70 0.07 0.99 12 378 Metastasis FGF3 oncogenic alterations: amplification/mutation 0.81 0.13 0.83 0.43 0.04 0.99 12 378 Metastasis NTRK1 oncogenic alterations: amplification/mutation 0.80 0.11 0.78 0.71 0.06 0.99 9 381 Metastasis MGA oncogenic alterations: deletion/mutation 0.80 0.10 1.00 0.37 0.05 1.00 13 377 Metastasis PRKCI amplification 0.80 0.19 0.88 0.58 0.05 0.99 8 306 Metastasis NTRK1 amplification 0.79 0.09 0.78 0.63 0.05 0.99 9 381 Metastasis MET amplification 0.79 0.21 0.92 0.37 0.05 0.99 13 377 Metastasis H3C14 amplification 0.79 0.11 0.91 0.58 0.06 1.00 11 363 Metastasis CDKN2A (p16INK4a) deletion 0.79 0.37 0.88 0.45 0.21 0.96 56 334 Metastasis FGF4 amplification 0.79 0.12 0.92 0.45 0.05 0.99 13 377 Metastasis CDKN2A (p14ARF) deletion 0.79 0.39 0.93 0.44 0.22 0.97 56 334 Metastasis FGF19 amplification 0.79 0.13 0.85 0.36 0.04 0.99 13 377 Metastasis RIT1 amplification 0.78 0.08 0.80 0.59 0.05 0.99 10 380 Metastasis CCND1 amplification 0.78 0.11 0.92 0.31 0.04 0.99 13 377 Metastasis FGF19 oncogenic alterations: amplification/mutation 0.78 0.11 0.92 0.35 0.05 0.99 13 377 Metastasis FGF4 oncogenic alterations: amplification/mutation 0.78 0.11 0.85 0.41 0.05 0.99 13 377 Metastasis PTPRD oncogenic alterations: deletion/mutation 0.78 0.17 1.00 0.33 0.03 1.00 9 381 Metastasis KMT2D oncogenic mutation 0.77 0.34 1.00 0.33 0.03 1.00 9 381 Metastasis BRCA1/2 germline/somatic mutation/deletion or fusion 0.77 0.76 0.86 0.58 0.69 0.79 28 26 Metastasis CCND1 oncogenic alterations: amplification/mutation 0.77 0.11 0.92 0.28 0.04 0.99 13 377 Metastasis IL7R amplification 0.77 0.08 0.91 0.47 0.05 0.99 11 379 Metastasis MGA oncogenic mutation 0.77 0.08 1.00 0.27 0.04 1.00 13 377 Metastasis KMT2D oncogenic alterations: deletion/mutation 0.77 0.22 0.90 0.28 0.03 0.99 10 380 Metastasis SMAD4 oncogenic mutation 0.76 0.14 0.91 0.40 0.04 0.99 11 379 Metastasis NKX2-1 oncogenic alterations: amplification/mutation 0.76 0.17 0.93 0.32 0.10 0.98 29 361 Metastasis KEAP1 oncogenic alterations: deletion/mutation 0.76 0.22 0.89 0.46 0.14 0.98 36 354 Metastasis H3C13 amplification 0.76 0.07 0.90 0.54 0.05 0.99 10 364 Metastasis NFKBIA amplification 0.76 0.16 0.88 0.40 0.09 0.98 24 366 Table S9.10. Biomarkers detected in Ovarian Cancer Tumor Site Biomarker AUC AP Sensitivity Specificity PPV NPV Positive Negative Total Primary CTNNB1 oncogenic alterations: amplification/mutation 0.99 0.82 1.00 0.75 0.13 1.00 8 209 Primary CTNNB1 oncogenic mutation 0.99 0.79 1.00 0.78 0.15 1.00 8 209 Primary KMT2B oncogenic alterations: deletion/mutation 0.97 0.36 1.00 0.93 0.24 1.00 4 192 Primary KMT2B oncogenic mutation 0.97 0.37 0.75 0.96 0.27 0.99 4 192 Primary TP53 oncogenic mutation 0.96 0.97 0.97 0.82 0.91 0.94 143 74 Primary TP53 oncogenic alterations: deletion/mutation 0.96 0.97 0.96 0.82 0.91 0.91 143 74 Primary CTCF oncogenic alterations: deletion/mutation 0.96 0.39 1.00 0.60 0.06 1.00 5 212 Primary RASA1 oncogenic alterations: deletion/mutation 0.94 0.35 1.00 0.52 0.07 1.00 7 210 Primary BRAF oncogenic mutation 0.93 0.71 0.86 0.69 0.08 0.99 7 210 Primary PTEN oncogenic alterations: deletion/mutation 0.93 0.60 0.90 0.53 0.08 0.99 10 207 Primary DNAJB1 amplification 0.92 0.35 1.00 0.66 0.08 1.00 6 203 Primary CARM1 amplification 0.92 0.16 1.00 0.61 0.05 1.00 4 192 Primary PTEN oncogenic mutation 0.92 0.67 0.90 0.81 0.18 0.99 10 207 Primary PIK3CA oncogenic mutation 0.91 0.48 1.00 0.32 0.15 1.00 23 194 Primary RASA1 oncogenic mutation 0.91 0.40 1.00 0.51 0.05 1.00 5 212 Primary KRAS oncogenic mutation 0.91 0.63 0.96 0.78 0.39 0.99 27 190 Primary Fragment of genome altered ≥ 30% 0.90 0.99 0.97 0.60 0.96 0.67 95 10 Primary BRAF oncogenic alterations: amplification/mutation 0.89 0.64 1.00 0.50 0.07 1.00 8 209 Primary TMB-H 0.89 0.50 0.82 0.69 0.12 0.99 11 203 Primary BRD4 amplification 0.89 0.44 0.86 0.68 0.08 0.99 7 210 Primary PIK3R1 oncogenic mutation 0.89 0.60 0.91 0.56 0.10 0.99 11 206 Primary UPF1 amplification 0.89 0.21 0.75 0.83 0.09 0.99 4 192 Primary ARID1A oncogenic alterations: deletion/mutation 0.88 0.62 0.94 0.62 0.29 0.98 31 186 Primary BRD4 oncogenic alterations: amplification/mutation 0.88 0.34 1.00 0.58 0.07 1.00 7 210 Primary ARAF deletion 0.87 0.23 0.86 0.68 0.08 0.99 7 210 Primary NF1 fusion 0.87 0.17 1.00 0.59 0.05 1.00 5 212 Primary ARID1A oncogenic mutation 0.87 0.63 0.90 0.58 0.26 0.97 30 187 Primary ELF3 amplification 0.87 0.19 0.80 0.82 0.10 0.99 5 191 Primary Genome instability ≥ 20% 0.87 0.96 0.94 0.55 0.90 0.69 85 20 Primary AR deletion 0.87 0.09 0.80 0.78 0.08 0.99 5 212 Primary CRLF2 deletion 0.86 0.27 1.00 0.76 0.12 1.00 7 210 Primary AKT2 oncogenic alterations: amplification/mutation 0.86 0.42 0.92 0.50 0.11 0.99 13 204 Primary NOTCH3 amplification 0.86 0.26 0.86 0.70 0.09 0.99 7 210 Primary MED12 deletion 0.86 0.15 0.86 0.78 0.12 0.99 7 210 Primary AMER1 oncogenic alterations: deletion/mutation 0.86 0.10 1.00 0.68 0.07 1.00 5 212 Primary TERT oncogenic mutation 0.86 0.15 0.80 0.75 0.07 0.99 5 212 Primary AKT2 amplification 0.86 0.31 1.00 0.49 0.11 1.00 13 204 Primary KEAP1 amplification 0.85 0.22 0.83 0.61 0.06 0.99 6 211 Primary RECQL4 amplification 0.85 0.25 0.92 0.56 0.11 0.99 12 205 Primary AMER1 deletion 0.85 0.12 0.80 0.69 0.06 0.99 5 212 Primary RBM10 oncogenic alterations: deletion/mutation 0.85 0.13 0.88 0.67 0.09 0.99 8 209 Primary RBM10 deletion 0.85 0.14 0.75 0.73 0.10 0.99 8 209 Primary GATA1 deletion 0.85 0.18 0.75 0.72 0.09 0.99 8 209 Primary PIK3CA oncogenic alterations: amplification/mutation 0.85 0.43 1.00 0.28 0.16 1.00 27 190 Primary EIF1AX deletion 0.84 0.26 1.00 0.72 0.12 1.00 8 209 Primary CALR amplification 0.83 0.34 0.86 0.64 0.08 0.99 7 202 Primary CEBPA amplification 0.83 0.26 1.00 0.41 0.06 1.00 7 202 Primary SDHA amplification 0.83 0.27 0.83 0.68 0.07 0.99 6 211 Primary PIK3R1 oncogenic alterations: deletion/mutation 0.83 0.48 1.00 0.35 0.09 1.00 13 204 Primary DNMT1 amplification 0.83 0.15 0.83 0.67 0.07 0.99 6 211 Primary RB1 oncogenic mutation 0.82 0.28 0.80 0.54 0.04 0.99 5 212 Primary MCL1 amplification 0.82 0.07 1.00 0.46 0.04 1.00 5 212 Primary DUSP4 deletion 0.82 0.17 0.83 0.78 0.11 0.99 6 190 Primary TERT oncogenic alterations: amplification/mutation 0.82 0.31 0.89 0.50 0.07 0.99 9 208 Primary ARID1B oncogenic alterations: deletion/mutation 0.81 0.41 1.00 0.42 0.06 1.00 8 209 Primary BABAM1 amplification 0.81 0.12 1.00 0.44 0.07 1.00 8 188 Primary Tetraploidy 0.81 0.82 0.96 0.54 0.75 0.91 55 39 Primary ERF deletion 0.81 0.32 1.00 0.61 0.05 1.00 4 192 Primary MTAP deletion 0.80 0.38 1.00 0.42 0.07 1.00 4 86 Primary ARID1B oncogenic mutation 0.80 0.23 0.86 0.22 0.04 0.98 7 210 Primary KDM6A oncogenic alterations: deletion/mutation 0.80 0.17 1.00 0.39 0.05 1.00 7 210 Primary MCL1 oncogenic alterations: amplification/mutation 0.80 0.07 1.00 0.36 0.04 1.00 5 212 Primary ARHGAP35 oncogenic alterations: amplification/mutation 0.80 0.18 0.80 0.75 0.16 0.98 5 85 Primary Whole genome doubling 0.79 0.64 0.94 0.46 0.43 0.94 16 37 Primary MTAP oncogenic alterations: deletion/mutation 0.79 0.42 1.00 0.42 0.07 1.00 4 86 Primary CCNE1 amplification 0.78 0.22 1.00 0.43 0.17 1.00 23 194 Primary RB1 oncogenic alterations: deletion/mutation 0.78 0.28 0.91 0.56 0.10 0.99 11 206 Primary RRAGC amplification 0.78 0.23 0.75 0.46 0.03 0.99 4 192 Primary KRAS oncogenic alterations: amplification/mutation 0.78 0.55 0.81 0.51 0.25 0.93 36 181 Primary NF1 oncogenic mutation 0.78 0.25 0.89 0.50 0.07 0.99 9 208 Primary NKX3-1 oncogenic alterations: deletion/mutation 0.77 0.09 0.80 0.71 0.06 0.99 5 212 Primary AGO2 amplification 0.77 0.21 0.91 0.55 0.11 0.99 11 185 Primary STK40 amplification 0.77 0.07 1.00 0.55 0.06 1.00 6 211 Primary MAP3K1 oncogenic alterations: deletion/mutation 0.77 0.08 1.00 0.21 0.03 1.00 6 211 Primary SLX4 deletion 0.77 0.09 0.75 0.66 0.04 0.99 4 192 Primary ETV6 amplification 0.76 0.28 0.75 0.60 0.07 0.98 8 209 Primary RAD52 amplification 0.76 0.41 0.80 0.54 0.08 0.98 10 207 Primary CCNE1 oncogenic alterations: amplification/mutation 0.75 0.20 0.96 0.45 0.17 0.99 23 194 Primary CDKN2A (p14ARF) deletion 0.75 0.42 0.80 0.51 0.07 0.98 10 207 Primary BRCA2 oncogenic alterations: deletion/mutation 0.75 0.14 0.80 0.60 0.05 0.99 5 212 52 Table S9.10. Biomarkers detected in Ovarian Cancer (continued) Tumor Site Biomarker AUC AP Sensitivity Specificity PPV NPV Positive Negative Total Metastasis SPRTN amplification 1.00 1.00 1.00 0.84 0.12 1.00 2 86 Metastasis RBM10 deletion 0.98 0.41 1.00 0.74 0.08 1.00 5 227 Metastasis MTAP oncogenic alterations: deletion/mutation 0.96 0.60 1.00 0.33 0.03 1.00 2 86 Metastasis TP53 oncogenic alterations: deletion/mutation 0.95 0.99 0.94 0.77 0.95 0.73 193 39 Metastasis AR deletion 0.95 0.23 1.00 0.79 0.09 1.00 5 227 Metastasis TP53 oncogenic mutation 0.94 0.99 0.93 0.77 0.95 0.70 193 39 Metastasis PGBD5 amplification 0.94 0.58 1.00 0.77 0.09 1.00 2 86 Metastasis KDM5C deletion 0.94 0.29 0.86 0.82 0.13 0.99 7 225 Metastasis GATA1 deletion 0.93 0.22 1.00 0.73 0.07 1.00 5 227 Metastasis ARAF deletion 0.92 0.26 1.00 0.69 0.08 1.00 6 226 Metastasis ARID1A oncogenic mutation 0.92 0.49 0.88 0.64 0.08 0.99 8 224 Metastasis MTAP deletion 0.92 0.32 1.00 0.26 0.03 1.00 2 86 Metastasis ARID1A oncogenic alterations: deletion/mutation 0.91 0.47 0.88 0.64 0.08 0.99 8 224 Metastasis GNA11 deletion 0.91 0.31 0.80 0.83 0.10 0.99 5 227 Metastasis KDM6A deletion 0.90 0.19 0.80 0.81 0.09 0.99 5 227 Metastasis CRLF2 deletion 0.90 0.25 0.86 0.72 0.09 0.99 7 225 Metastasis KDM5C oncogenic alterations: deletion/mutation 0.89 0.19 0.75 0.77 0.10 0.99 8 224 Metastasis CDKN2B deletion 0.89 0.29 1.00 0.48 0.07 1.00 9 223 Metastasis BABAM1 amplification 0.89 0.12 1.00 0.43 0.04 1.00 5 206 Metastasis KRAS oncogenic mutation 0.88 0.58 0.88 0.81 0.25 0.99 16 216 Metastasis CDKN2B oncogenic alterations: deletion/mutation 0.87 0.23 1.00 0.43 0.07 1.00 9 223 Metastasis CDKN2A (p16INK4a) deletion 0.87 0.31 1.00 0.34 0.06 1.00 9 223 Metastasis AMER1 deletion 0.86 0.12 0.83 0.73 0.08 0.99 6 226 Metastasis PLCG2 deletion 0.86 0.08 1.00 0.76 0.08 1.00 5 227 Metastasis CDKN2A (p14ARF) deletion 0.86 0.22 1.00 0.33 0.06 1.00 9 223 Metastasis NF1 fusion 0.84 0.11 1.00 0.51 0.04 1.00 5 227 Metastasis Genome instability ≥ 20% 0.84 0.97 0.93 0.55 0.93 0.55 123 20 Metastasis ZFHX3 oncogenic alterations: deletion/mutation 0.84 0.08 1.00 0.41 0.04 1.00 5 227 Metastasis NF1 deletion 0.84 0.11 1.00 0.66 0.09 1.00 8 224 Metastasis STK11 deletion 0.83 0.16 1.00 0.62 0.05 1.00 5 227 Metastasis PPP2R1A oncogenic mutation 0.82 0.16 0.88 0.74 0.11 0.99 8 224 Metastasis PIK3CA oncogenic mutation 0.82 0.32 1.00 0.37 0.14 1.00 22 210 Metastasis TERT oncogenic mutation 0.81 0.26 0.75 0.69 0.08 0.99 8 224 Metastasis EIF1AX deletion 0.80 0.22 0.83 0.71 0.14 0.99 12 220 Metastasis Fragment of genome altered ≥ 30% 0.80 0.98 0.91 0.46 0.94 0.33 130 13 Metastasis PIK3R1 oncogenic alterations: deletion/mutation 0.80 0.07 1.00 0.59 0.06 1.00 6 226 Metastasis KMT2D oncogenic alterations: deletion/mutation 0.80 0.09 0.80 0.57 0.04 0.99 5 227 Metastasis MCL1 oncogenic alterations: amplification/mutation 0.79 0.13 1.00 0.34 0.03 1.00 5 227 Metastasis CARM1 amplification 0.79 0.11 0.88 0.68 0.10 0.99 8 203 Metastasis SMARCA4 amplification 0.79 0.09 0.86 0.58 0.06 0.99 7 225 Metastasis RB1 oncogenic alterations: deletion/mutation 0.78 0.11 1.00 0.41 0.08 1.00 11 221 Metastasis CDK12 oncogenic alterations: deletion/mutation 0.78 0.11 0.83 0.29 0.03 0.99 6 226 Metastasis AMER1 oncogenic alterations: deletion/mutation 0.78 0.09 0.83 0.66 0.06 0.99 6 226 Metastasis TCF3 deletion 0.78 0.09 0.80 0.62 0.04 0.99 5 221 Metastasis BCOR oncogenic alterations: deletion/mutation 0.77 0.08 0.80 0.63 0.04 0.99 5 227 Metastasis TGF beta pathway 0.77 0.15 0.75 0.58 0.06 0.98 8 224 Metastasis FGFR2 oncogenic alterations: amplification/mutation 0.77 0.08 1.00 0.22 0.03 1.00 5 227 Metastasis GAB2 oncogenic alterations: amplification/mutation 0.77 0.07 1.00 0.47 0.04 1.00 2 86 Metastasis MCL1 amplification 0.76 0.12 1.00 0.39 0.03 1.00 5 227 Metastasis RIT1 amplification 0.76 0.17 1.00 0.47 0.04 1.00 5 227 Metastasis MAP2K4 deletion 0.76 0.07 0.83 0.54 0.05 0.99 6 226 Metastasis KDM6A oncogenic alterations: deletion/mutation 0.76 0.11 1.00 0.28 0.04 1.00 6 226 Metastasis Tetraploidy 0.76 0.80 0.92 0.35 0.69 0.75 79 51 Table S9.11. Biomarkers detected in Pancreatic Cancer Tumor Site Biomarker AUC AP Sensitivity Specificity PPV NPV Positive Negative Total Primary MEN1 oncogenic mutation 0.97 0.63 1.00 0.93 0.47 1.00 14 231 Primary MEN1 oncogenic alterations: deletion/mutation 0.97 0.59 1.00 0.93 0.45 1.00 14 231 Primary MTAP oncogenic alterations: deletion/mutation 0.93 0.37 1.00 0.78 0.20 1.00 3 55 Primary MTAP deletion 0.92 0.34 1.00 0.85 0.27 1.00 3 55 Primary TMB-H 0.91 0.60 0.83 0.63 0.05 0.99 6 233 Primary GNAS oncogenic alterations: amplification/mutation 0.88 0.45 1.00 0.37 0.07 1.00 11 234 Primary KRAS oncogenic mutation 0.88 0.95 0.91 0.69 0.91 0.67 191 54 Primary KRAS oncogenic alterations: amplification/mutation 0.87 0.95 0.90 0.67 0.90 0.64 191 54 Primary GNAS oncogenic mutation 0.87 0.48 1.00 0.22 0.06 1.00 11 234 Primary TP53 oncogenic alterations: deletion/mutation 0.86 0.91 0.88 0.63 0.80 0.76 153 92 Primary PIK3CA oncogenic mutation 0.86 0.44 1.00 0.58 0.06 1.00 7 238 Primary TP53 oncogenic mutation 0.85 0.90 0.90 0.64 0.81 0.79 153 92 Primary PIK3CA oncogenic alterations: amplification/mutation 0.85 0.41 1.00 0.61 0.08 1.00 8 237 Primary SMAD4 deletion 0.84 0.08 1.00 0.63 0.05 1.00 5 240 Primary CDKN2B deletion 0.83 0.23 0.79 0.68 0.13 0.98 14 231 Primary HRD pathway 0.82 0.30 1.00 0.31 0.05 1.00 9 236 Primary CDKN2A (p16INK4a) deletion 0.79 0.23 0.88 0.67 0.16 0.99 16 229 Primary RNF43 oncogenic mutation 0.77 0.24 1.00 0.31 0.05 1.00 9 236 Metastasis TSC2 oncogenic mutation 0.98 0.54 1.00 0.52 0.05 1.00 5 212 Metastasis MEN1 oncogenic mutation 0.96 0.58 0.94 0.91 0.50 0.99 18 199 Metastasis MEN1 oncogenic alterations: deletion/mutation 0.96 0.59 0.94 0.90 0.46 0.99 18 199 Metastasis TSC2 oncogenic alterations: deletion/mutation 0.93 0.38 1.00 0.54 0.06 1.00 6 211 Metastasis KRAS oncogenic alterations: amplification/mutation 0.92 0.96 0.82 0.83 0.92 0.67 152 65 Metastasis KRAS oncogenic mutation 0.91 0.96 0.82 0.82 0.91 0.66 152 65 Metastasis CTNNB1 oncogenic mutation 0.91 0.30 1.00 0.21 0.03 1.00 6 211 Metastasis AGO2 amplification 0.87 0.15 1.00 0.31 0.04 1.00 5 176 Metastasis CTNNB1 oncogenic alterations: amplification/mutation 0.87 0.25 1.00 0.33 0.04 1.00 6 211 Metastasis MYC oncogenic alterations: amplification/mutation 0.85 0.42 0.91 0.29 0.06 0.98 11 206 Metastasis MYC amplification 0.84 0.33 0.91 0.27 0.06 0.98 11 206 Metastasis KMT2D oncogenic mutation 0.81 0.11 1.00 0.37 0.04 1.00 6 211 Metastasis TP53 oncogenic mutation 0.79 0.82 0.88 0.55 0.75 0.75 130 87 Metastasis TP53 oncogenic alterations: deletion/mutation 0.79 0.81 0.88 0.55 0.75 0.76 130 87 Metastasis KRAS amplification 0.77 0.07 1.00 0.45 0.04 1.00 5 212 Metastasis MTAP deletion 0.76 0.33 0.80 0.64 0.24 0.96 10 69 Metastasis MTAP oncogenic alterations: deletion/mutation 0.76 0.40 0.90 0.55 0.23 0.97 10 69 Metastasis KMT2D oncogenic alterations: deletion/mutation 0.75 0.23 0.83 0.40 0.04 0.99 6 211 Table S9.12. Biomarkers detected in Prostate Cancer Tumor Site Biomarker AUC AP Sensitivity Specificity PPV NPV Positive Negative Total Primary PREX2 amplification 0.97 0.49 1.00 0.64 0.06 1.00 7 296 Primary PRDM14 amplification 0.94 0.43 1.00 0.70 0.10 1.00 10 293 Primary NBN amplification 0.94 0.48 1.00 0.66 0.06 1.00 8 376 Primary APC oncogenic mutation 0.92 0.41 1.00 0.54 0.06 1.00 10 374 Primary RECQL4 amplification 0.91 0.40 0.89 0.72 0.07 1.00 9 375 Primary AGO2 amplification 0.90 0.49 0.86 0.76 0.08 1.00 7 296 Primary TMB-H 0.90 0.39 1.00 0.68 0.07 1.00 9 368 Primary APC oncogenic alterations: deletion/mutation 0.89 0.44 1.00 0.58 0.07 1.00 11 373 Primary MYC amplification 0.87 0.26 0.87 0.68 0.10 0.99 15 369 Primary ELOC amplification 0.86 0.30 0.92 0.68 0.08 1.00 12 372 Primary MYC oncogenic alterations: amplification/mutation 0.85 0.26 0.81 0.67 0.10 0.99 16 368 Primary SPOP oncogenic mutation 0.80 0.46 0.98 0.29 0.17 0.99 50 334 Primary CTNNB1 oncogenic alterations: amplification/mutation 0.79 0.09 0.90 0.59 0.06 1.00 10 374 Primary PTEN deletion 0.79 0.16 0.75 0.60 0.09 0.98 20 364 Primary SPOP oncogenic alterations: deletion/mutation 0.79 0.42 0.96 0.27 0.16 0.98 50 334 Primary RNF43 oncogenic alterations: deletion/mutation 0.78 0.20 1.00 0.53 0.05 1.00 9 375 Primary RTK pathway 0.78 0.29 0.78 0.66 0.19 0.97 36 348 Primary TP53 oncogenic alterations: deletion/mutation 0.76 0.45 0.77 0.65 0.40 0.90 90 294 Metastasis DIS3 oncogenic alterations: deletion/mutation 0.86 0.11 1.00 0.63 0.06 1.00 7 290 Metastasis ETV6 deletion 0.85 0.24 1.00 0.40 0.03 1.00 6 291 Metastasis CDKN1B oncogenic alterations: deletion/mutation 0.84 0.14 1.00 0.24 0.05 1.00 11 286 Metastasis DIS3 deletion 0.83 0.20 1.00 0.52 0.05 1.00 7 290 Metastasis GATA1 amplification 0.82 0.15 1.00 0.46 0.04 1.00 7 290 Metastasis RB1 deletion 0.82 0.26 1.00 0.33 0.10 1.00 20 277 Metastasis NKX3-1 oncogenic alterations: deletion/mutation 0.81 0.23 1.00 0.21 0.08 1.00 19 278 Metastasis ZRSR2 amplification 0.81 0.13 0.86 0.65 0.06 0.99 7 290 Metastasis SOX17 amplification 0.81 0.09 1.00 0.40 0.04 1.00 8 289 Metastasis CYSLTR2 deletion 0.81 0.23 1.00 0.46 0.08 1.00 10 214 Metastasis ETV6 oncogenic alterations: deletion/mutation 0.80 0.07 1.00 0.36 0.03 1.00 6 291 Metastasis DUSP4 deletion 0.80 0.29 1.00 0.32 0.10 1.00 16 208 Metastasis TGF beta pathway 0.79 0.13 1.00 0.20 0.03 1.00 7 290 Metastasis FGFR1 deletion 0.79 0.16 0.88 0.56 0.05 0.99 8 289 Metastasis RPS6KB2 amplification 0.78 0.08 0.83 0.34 0.03 0.99 6 291 Metastasis PLCG2 deletion 0.78 0.23 1.00 0.34 0.06 1.00 13 284 Metastasis RBM10 amplification 0.77 0.06 1.00 0.40 0.03 1.00 6 291 Metastasis AKT1 oncogenic mutation 0.77 0.07 1.00 0.24 0.03 1.00 6 291 Metastasis EIF1AX amplification 0.77 0.10 0.83 0.62 0.04 0.99 6 291 Metastasis TP53 fusion 0.77 0.20 1.00 0.28 0.03 1.00 7 290 Metastasis RB1 oncogenic mutation 0.77 0.14 0.80 0.61 0.10 0.98 15 282 Metastasis PREX2 amplification 0.77 0.17 0.92 0.22 0.06 0.98 12 212 Metastasis H3C13 amplification 0.76 0.14 0.80 0.47 0.05 0.98 10 270 Metastasis AMER1 amplification 0.76 0.14 0.87 0.49 0.08 0.99 15 282 Metastasis SPOP oncogenic alterations: deletion/mutation 0.76 0.46 0.85 0.42 0.15 0.96 33 264 Metastasis FGF19 oncogenic alterations: amplification/mutation 0.75 0.12 0.90 0.35 0.05 0.99 10 287 Metastasis AR amplification 0.75 0.53 0.86 0.40 0.34 0.89 77 220 Table S9.13. Biomarkers detected in Renal Cell Carcinoma Tumor Site Biomarker AUC AP Sensitivity Specificity PPV NPV Positive Negative Total Primary TSC2 oncogenic alterations: deletion/mutation 0.99 0.71 1.00 0.93 0.29 1.00 5 168 Primary CRLF2 deletion 0.98 0.57 1.00 0.93 0.27 1.00 4 169 Primary TSC2 oncogenic mutation 0.98 0.70 1.00 0.90 0.24 1.00 5 168 Primary CDKN2A (p14ARF) deletion 0.96 0.55 0.83 0.92 0.28 0.99 6 167 Primary CDKN2A (p16INK4a) deletion 0.96 0.53 0.83 0.92 0.26 0.99 6 167 Primary CDKN2B oncogenic alterations: deletion/mutation 0.95 0.52 0.80 0.90 0.20 0.99 5 168 Primary VHL oncogenic mutation 0.87 0.78 0.97 0.72 0.70 0.97 69 104 Primary VHL oncogenic alterations: deletion/mutation 0.87 0.77 0.93 0.73 0.70 0.94 69 104 Primary PBRM1 oncogenic mutation 0.85 0.49 0.83 0.66 0.34 0.95 30 143 Primary TERT oncogenic mutation 0.84 0.13 1.00 0.47 0.05 1.00 5 168 Primary PTEN oncogenic alterations: deletion/mutation 0.84 0.15 1.00 0.61 0.07 1.00 5 168 Primary PBRM1 oncogenic alterations: deletion/mutation 0.84 0.48 0.80 0.68 0.34 0.94 30 143 Primary BAP1 oncogenic alterations: deletion/mutation 0.82 0.33 0.86 0.52 0.13 0.98 14 159 Primary SETD2 oncogenic alterations: deletion/mutation 0.81 0.36 1.00 0.42 0.15 1.00 16 157 Primary BAP1 oncogenic mutation 0.80 0.25 0.86 0.48 0.13 0.97 14 159 Primary SETD2 oncogenic mutation 0.79 0.29 0.94 0.46 0.15 0.99 16 157 Primary mTOR pathway 0.77 0.32 0.96 0.52 0.28 0.99 28 145 Primary TERT oncogenic alterations: amplification/mutation 0.77 0.25 0.83 0.52 0.06 0.99 6 167 Metastasis RB1 oncogenic alterations: deletion/mutation 0.96 0.64 1.00 0.85 0.18 1.00 2 59 Metastasis FBXW7 oncogenic alterations: deletion/mutation 0.93 0.27 1.00 0.73 0.11 1.00 2 59 Metastasis PIK3CA oncogenic mutation 0.83 0.42 1.00 0.21 0.08 1.00 4 57 Metastasis SMARCB1 oncogenic alterations: deletion/mutation 0.83 0.30 1.00 0.44 0.06 1.00 2 59 Metastasis PTEN oncogenic mutation 0.81 0.33 1.00 0.43 0.18 1.00 7 54 Metastasis VHL oncogenic alterations: deletion/mutation 0.80 0.70 0.92 0.67 0.66 0.92 25 36 Metastasis PBRM1 oncogenic mutation 0.80 0.67 0.89 0.53 0.44 0.92 18 43 Metastasis VHL oncogenic mutation 0.80 0.73 0.96 0.47 0.56 0.94 25 36 Metastasis PTEN oncogenic alterations: deletion/mutation 0.80 0.34 0.86 0.39 0.15 0.95 7 54 Metastasis TP53 oncogenic mutation 0.79 0.28 1.00 0.36 0.15 1.00 6 55 Metastasis PIK3CA oncogenic alterations: amplification/mutation 0.79 0.25 1.00 0.33 0.10 1.00 4 57 Metastasis TP53 oncogenic alterations: deletion/mutation 0.78 0.30 1.00 0.33 0.14 1.00 6 55 Table S9.14. Biomarkers detected in Thyroid Cancer Tumor Site Biomarker AUC AP Sensitivity Specificity PPV NPV Positive Negative Total Primary RB1 oncogenic alterations: deletion/mutation 0.99 0.58 1.00 0.78 0.12 1.00 2 68 Primary RB1 oncogenic mutation 0.97 0.45 1.00 0.93 0.29 1.00 2 68 Primary MSI-H/dMMR 0.97 0.67 1.00 0.83 0.17 1.00 2 59 Primary MSI-H vs MSS 0.95 0.33 1.00 0.90 0.25 1.00 2 59 Primary TP53 oncogenic alterations: deletion/mutation 0.91 0.83 0.92 0.60 0.34 0.97 13 57 Primary BRAF oncogenic mutation 0.91 0.93 0.88 0.58 0.64 0.85 32 38 Primary TMB-H 0.91 0.19 1.00 0.84 0.15 1.00 2 68 Primary BRAF oncogenic alterations: amplification/mutation 0.91 0.93 0.88 0.71 0.72 0.87 32 38 Primary TP53 oncogenic mutation 0.90 0.77 0.92 0.81 0.50 0.98 12 58 Primary CDKN2A (p14ARF) deletion 0.87 0.37 1.00 0.52 0.16 1.00 6 64 Primary CDKN2A (p16INK4a) deletion 0.86 0.41 0.83 0.58 0.16 0.97 6 64 Primary CDKN2B deletion 0.86 0.38 0.83 0.48 0.13 0.97 6 64 Primary CDKN2B oncogenic alterations: deletion/mutation 0.84 0.40 0.83 0.55 0.15 0.97 6 64 Primary ARID1A oncogenic mutation 0.82 0.13 1.00 0.40 0.05 1.00 2 68 Primary ZFHX3 oncogenic mutation 0.81 0.10 1.00 0.28 0.04 1.00 2 68 Primary ARID1A oncogenic alterations: deletion/mutation 0.80 0.11 1.00 0.63 0.07 1.00 2 68 Primary mTOR pathway 0.78 0.49 1.00 0.22 0.28 1.00 16 54 Primary NRAS oncogenic alterations: amplification/mutation 0.76 0.46 0.80 0.63 0.27 0.95 10 60 Primary NRAS oncogenic mutation 0.75 0.42 0.80 0.68 0.30 0.95 10 60 Metastasis DAXX oncogenic mutation 1.00 1.00 1.00 0.64 0.09 1.00 4 110 Metastasis DAXX oncogenic alterations: deletion/mutation 1.00 1.00 1.00 0.78 0.14 1.00 4 110 Metastasis NF1 oncogenic mutation 0.94 0.24 1.00 0.50 0.05 1.00 3 111 Metastasis CDKN2A (p14ARF) deletion 0.93 0.45 1.00 0.37 0.08 1.00 6 108 Metastasis NF1 oncogenic alterations: deletion/mutation 0.93 0.23 1.00 0.56 0.06 1.00 3 111 Metastasis CDKN2A (p16INK4a) deletion 0.92 0.43 1.00 0.45 0.09 1.00 6 108 Metastasis CDKN2B deletion 0.91 0.38 1.00 0.31 0.07 1.00 6 108 Metastasis BRAF oncogenic alterations: amplification/mutation 0.90 0.89 0.85 0.76 0.72 0.88 48 66 Metastasis CDKN2B oncogenic alterations: deletion/mutation 0.90 0.41 1.00 0.40 0.08 1.00 6 108 Metastasis BRAF oncogenic mutation 0.89 0.88 0.88 0.71 0.69 0.89 48 66 Metastasis TERT oncogenic alterations: amplification/mutation 0.89 0.85 0.94 0.68 0.71 0.93 52 62 Metastasis TERT oncogenic mutation 0.88 0.84 0.88 0.75 0.73 0.89 49 65 Metastasis PIK3CA oncogenic mutation 0.83 0.19 1.00 0.28 0.07 1.00 6 108 Metastasis TMB-H 0.81 0.11 0.75 0.72 0.09 0.99 4 110 Metastasis TP53 oncogenic alterations: deletion/mutation 0.77 0.53 0.79 0.50 0.18 0.94 14 100 Metastasis PTEN oncogenic alterations: deletion/mutation 0.77 0.07 1.00 0.51 0.05 1.00 3 111 Metastasis NTRK3 fusion 0.77 0.21 1.00 0.28 0.04 1.00 3 111 Table S9.15. Biomarkers detected in Soft Tissue Sarcoma Tumor Site Biomarker AUC AP Sensitivity Specificity PPV NPV Positive Negative Total Primary WT1 fusion 0.99 0.83 0.90 0.97 0.43 1.00 10 346 Primary SDHC amplification 0.94 0.29 1.00 0.47 0.05 1.00 10 346 Primary TMB-H 0.89 0.19 0.88 0.66 0.06 1.00 8 338 Primary JUN oncogenic alterations: amplification/mutation 0.89 0.39 1.00 0.58 0.06 1.00 10 346 Primary RB1 deletion 0.89 0.22 0.92 0.73 0.11 1.00 13 343 Primary CYSLTR2 deletion 0.89 0.26 0.92 0.70 0.11 1.00 13 306 Primary MDM2 oncogenic alterations: amplification/mutation 0.88 0.76 0.85 0.70 0.44 0.94 78 278 Primary MDM2 amplification 0.88 0.76 0.83 0.76 0.50 0.94 78 278 Primary CDK4 oncogenic alterations: amplification/mutation 0.88 0.74 0.76 0.86 0.58 0.93 72 284 Primary JUN amplification 0.88 0.40 0.90 0.68 0.07 1.00 10 346 Primary TP53 fusion 0.87 0.21 0.88 0.79 0.09 1.00 8 348 Primary BIRC3 amplification 0.87 0.11 1.00 0.30 0.03 1.00 8 348 Primary CDK4 amplification 0.87 0.73 0.77 0.82 0.52 0.94 71 285 Primary TP53 deletion 0.87 0.33 0.85 0.70 0.19 0.98 27 329 Primary RB1 oncogenic alterations: deletion/mutation 0.87 0.29 0.84 0.72 0.18 0.98 25 331 Primary TP53 oncogenic alterations: deletion/mutation 0.87 0.57 0.85 0.74 0.46 0.95 74 282 Primary TNFAIP3 amplification 0.84 0.17 0.93 0.52 0.07 0.99 14 342 Primary ATRX oncogenic alterations: deletion/mutation 0.84 0.34 0.89 0.61 0.11 0.99 19 337 Primary TERT oncogenic mutation 0.84 0.43 0.89 0.40 0.08 0.99 19 337 Primary DNA damage response 0.83 0.74 0.94 0.47 0.45 0.94 113 243 Primary YAP1 amplification 0.82 0.11 1.00 0.50 0.06 1.00 11 345 Primary NCOR1 amplification 0.82 0.24 0.78 0.76 0.08 0.99 9 347 Primary TEK deletion 0.81 0.08 1.00 0.56 0.05 1.00 7 312 Primary IFNGR1 amplification 0.81 0.12 0.75 0.78 0.07 0.99 8 348 Primary ATRX oncogenic mutation 0.80 0.14 0.82 0.58 0.06 0.99 11 345 Primary MTAP deletion 0.80 0.16 0.80 0.65 0.14 0.98 10 147 Primary CDKN2A (p16INK4a) deletion 0.79 0.31 0.76 0.69 0.23 0.96 38 318 Primary YAP1 oncogenic alterations: amplification/mutation 0.79 0.09 1.00 0.34 0.05 1.00 11 345 Primary NF1 oncogenic mutation 0.77 0.19 0.75 0.67 0.10 0.98 16 340 Primary RB1 oncogenic mutation 0.77 0.08 0.77 0.59 0.07 0.99 13 343 Primary TERT oncogenic alterations: amplification/mutation 0.76 0.34 0.97 0.30 0.14 0.99 38 318 Primary PDGFRA oncogenic alterations: amplification/mutation 0.76 0.09 0.89 0.50 0.04 0.99 9 347 Primary PTEN oncogenic alterations: deletion/mutation 0.76 0.17 0.75 0.61 0.08 0.98 16 340 Metastasis SMARCB1 oncogenic alterations: deletion/mutation 1.00 1.00 1.00 0.58 0.07 1.00 3 103 Metastasis WT1 fusion 0.99 0.92 1.00 0.97 0.70 1.00 7 99 Metastasis ATRX oncogenic mutation 0.99 0.73 1.00 0.53 0.08 1.00 4 102 Metastasis SMARCB1 deletion 0.98 0.68 1.00 0.44 0.05 1.00 3 103 Metastasis BCOR fusion 0.95 0.32 1.00 0.84 0.16 1.00 3 103 Metastasis MYC amplification 0.89 0.15 1.00 0.85 0.17 1.00 3 103 Metastasis ATRX oncogenic alterations: deletion/mutation 0.88 0.29 1.00 0.51 0.11 1.00 6 100 Metastasis NF1 oncogenic alterations: deletion/mutation 0.87 0.22 0.75 0.71 0.09 0.99 4 102 Metastasis CDKN2B oncogenic alterations: deletion/mutation 0.85 0.36 1.00 0.66 0.26 1.00 11 95 Metastasis TEK deletion 0.84 0.17 1.00 0.48 0.07 1.00 3 83 Metastasis MSI2 amplification 0.83 0.10 1.00 0.33 0.03 1.00 2 84 Metastasis CDKN2B deletion 0.82 0.26 0.91 0.72 0.27 0.99 11 95 Metastasis MAP2K4 amplification 0.81 0.10 1.00 0.65 0.08 1.00 3 103 Metastasis RICTOR oncogenic alterations: amplification/mutation 0.81 0.09 1.00 0.56 0.06 1.00 3 103 Metastasis CDKN2A (p14ARF) deletion 0.81 0.31 0.83 0.67 0.24 0.97 12 94 Metastasis NCOR1 amplification 0.81 0.09 1.00 0.66 0.08 1.00 3 103 Metastasis TP53 deletion 0.79 0.29 0.90 0.59 0.19 0.98 10 96 Metastasis CDKN2A (p16INK4a) deletion 0.79 0.33 0.92 0.62 0.26 0.98 13 93 Metastasis RB1 oncogenic alterations: deletion/mutation 0.78 0.27 0.80 0.54 0.15 0.96 10 96 Metastasis RB1 deletion 0.77 0.29 1.00 0.55 0.10 1.00 5 101 56 Table S10: Performance Metrics for Biomarker Prediction on the TCGA validation cohort. Metrics include Area Under the Curve (AUC), Average Precision (AP), Sensitivity, Specificity, Positive Predictive Value (PPV), and Negative Predictive Value (NPV). Sample counts are provided for each biomarker, indicating the number of positive, negative, and total samples. The performance of biomarkers in 20 TCGA projects that are associated with 12 out of the 15 most common cancer types are summarized in the following sub-tables S10.1 -S10.12.</p><p>Biomarkers associated with ovarian cancer (TCGA-OV), pancreatic cancer (TCGA-PAAD), and melanoma (TCGA-SKCM, TCGA-UVM) did not pass the criteria for high-performing biomarkers.</p><p>Table S10.1. Biomarkers detected in Bladder Cancer (TCGA-BLCA) Biomarker AUC AP Sensitivity Specificity PPV NPV Positive Negative Total H3C12 amplification 0.98 0.56 1.00 0.33 0.06 1.00 76 79 H3C2 amplification 0.98 0.56 1.00 0.21 0.05 1.00 76 79 H3C10 amplification 0.97 0.67 1.00 0.29 0.05 1.00 76 79 H3C7 amplification 0.96 0.61 1.00 0.26 0.05 1.00 76 79 H3C4 amplification 0.96 0.59 1.00 0.22 0.05 1.00 76 79 H3C8 amplification 0.95 0.34 1.00 0.26 0.05 1.00 76 79 MDC1 amplification 0.94 0.32 1.00 0.72 0.12 1.00 76 79 H3C11 amplification 0.93 0.72 1.00 0.49 0.07 1.00 76 79 MYD88 amplification 0.93 0.21 1.00 0.51 0.05 1.00 77 79 H2BC5 amplification 0.93 0.29 1.00 0.26 0.05 1.00 76 79 H3C6 amplification 0.92 0.47 1.00 0.28 0.05 1.00 76 79 H3C1 amplification 0.90 0.25 1.00 0.38 0.06 1.00 76 79 CBL oncogenic alterations: deletion/mutation 0.88 0.16 1.00 0.57 0.06 1.00 77 79 MLH1 amplification 0.87 0.18 1.00 0.53 0.05 1.00 77 79 NFE2L2 oncogenic mutation 0.87 0.46 1.00 0.20 0.06 1.00 75 79 E2F3 amplification 0.86 0.57 1.00 0.23 0.20 1.00 66 79 PAK1 oncogenic alterations: amplification/mutation 0.85 0.21 1.00 0.37 0.04 1.00 76 78 BRCA1 germline/somatic point mutation/deletion or fusion 0.84 0.17 1.00 0.77 0.19 1.00 75 79 GRIN2A amplification 0.84 0.11 1.00 0.77 0.10 1.00 77 79 TCF7L2 oncogenic alterations: deletion/mutation 0.83 0.11 1.00 0.25 0.03 1.00 77 79 SUZ12 amplification 0.83 0.10 1.00 0.62 0.06 1.00 77 79 VEGFA amplification 0.83 0.23 1.00 0.33 0.07 1.00 75 79 INPPL1 amplification 0.83 0.21 1.00 0.28 0.07 1.00 75 79 PTEN oncogenic mutation 0.82 0.10 1.00 0.39 0.04 1.00 77 79 FGFR3 oncogenic alterations: amplification/mutation 0.81 0.55 0.91 0.37 0.19 0.96 68 79 TENT5C amplification 0.80 0.18 1.00 0.26 0.05 1.00 76 79 FGFR oncogenic mutation 0.80 0.49 0.86 0.46 0.14 0.97 68 75 VEGFA oncogenic alterations: amplification/mutation 0.80 0.15 1.00 0.39 0.08 1.00 75 79 ERBB3 oncogenic alterations: amplification/mutation 0.78 0.09 1.00 0.27 0.04 1.00 73 75 SOCS1 amplification 0.78 0.08 1.00 0.73 0.09 1.00 77 79 SETDB1 amplification 0.77 0.29 1.00 0.28 0.17 1.00 69 79 CBL deletion 0.76 0.15 1.00 0.25 0.03 1.00 77 79 Table S10.2. Biomarkers detected in Breast Cancer (TCGA-BRCA) Biomarker AUC AP Sensitivity Specificity PPV NPV Positive Negative Total CDKN1A amplification 0.99 0.59 1.00 0.29 0.03 1.00 4 186 PIM1 amplification 0.96 0.29 1.00 0.42 0.04 1.00 5 185 ER 0.92 0.97 0.93 0.79 0.93 0.77 147 47 FBXW7 oncogenic mutation 0.90 0.13 1.00 0.20 0.03 1.00 4 184 CDH1 oncogenic alterations: deletion/mutation 0.90 0.51 0.85 0.86 0.42 0.98 20 165 TP53 oncogenic alterations: deletion/mutation 0.89 0.80 0.89 0.71 0.64 0.91 70 119 TP53 oncogenic mutation 0.88 0.79 0.90 0.71 0.64 0.92 70 119 KMT2B amplification 0.87 0.15 1.00 0.51 0.04 1.00 4 186 Fragment of genome altered ≥ 30% 0.87 0.83 0.83 0.68 0.67 0.84 87 114 TERT oncogenic alterations: amplification/mutation 0.85 0.13 1.00 0.52 0.04 1.00 4 185 ERBB2 amplification 0.84 0.40 0.82 0.54 0.15 0.97 17 173 PTPRT amplification 0.84 0.45 1.00 0.37 0.04 1.00 5 185 ETV6 amplification 0.83 0.29 0.80 0.68 0.06 0.99 5 184 PR 0.83 0.86 0.97 0.53 0.77 0.91 121 74 EGFR oncogenic alterations: amplification/mutation 0.83 0.14 1.00 0.40 0.04 1.00 4 184 ARID5B amplification 0.82 0.11 1.00 0.56 0.05 1.00 4 186 GATA3 oncogenic mutation 0.82 0.35 1.00 0.37 0.17 1.00 21 167 CCNE1 amplification 0.81 0.07 1.00 0.28 0.03 1.00 4 186 ERBB2 oncogenic alterations: amplification/mutation 0.80 0.41 0.89 0.41 0.14 0.97 18 169 CDK12 amplification 0.80 0.31 0.88 0.42 0.12 0.97 16 174 EED amplification 0.79 0.06 1.00 0.28 0.03 1.00 4 185 AKT1 oncogenic mutation 0.78 0.36 0.75 0.68 0.05 0.99 4 185 GATA3 oncogenic alterations: deletion/mutation 0.78 0.28 1.00 0.35 0.17 1.00 21 160 PRDM14 amplification 0.78 0.19 0.92 0.39 0.10 0.99 13 177 AXIN1 amplification 0.78 0.18 0.89 0.33 0.06 0.98 9 180 MAP3K1 oncogenic mutation 0.78 0.29 1.00 0.21 0.08 1.00 12 176 FGFR2 oncogenic alterations: amplification/mutation 0.77 0.08 1.00 0.28 0.04 1.00 5 183 SMARCE1 amplification 0.77 0.15 0.89 0.41 0.07 0.99 9 181 TRAF7 amplification 0.77 0.13 0.89 0.22 0.05 0.97 9 181 FBXW7 deletion 0.77 0.14 1.00 0.28 0.03 1.00 4 183 NCOA3 amplification 0.77 0.14 1.00 0.28 0.04 1.00 6 184 CCNE1 oncogenic alterations: amplification/mutation 0.77 0.05 1.00 0.33 0.03 1.00 4 186 E2F3 amplification 0.77 0.06 1.00 0.33 0.03 1.00 4 186 TOP1 amplification 0.76 0.26 0.80 0.58 0.05 0.99 5 185 FGFR2 amplification 0.76 0.05 1.00 0.45 0.04 1.00 4 186 DICER1 amplification 0.76 0.07 1.00 0.37 0.03 1.00 4 185 WWTR1 amplification 0.75 0.07 1.00 0.25 0.03 1.00 4 186 EIF4A2 amplification 0.75 0.05 1.00 0.37 0.03 1.00 4 186 HER2 Amplification 0.75 0.46 0.96 0.21 0.23 0.95 23 94 Table S10.3. Biomarkers detected in Colorectal Cancer (TCGA-COAD, TCGA-READ) Biomarker AUC AP Sensitivity Specificity PPV NPV Positive Negative Total BLM oncogenic mutation 0.99 0.58 1.00 0.42 0.04 1.00 2 83 BLM oncogenic alterations: deletion/mutation 0.99 0.58 1.00 0.49 0.05 1.00 2 81 ZFHX3 oncogenic mutation 0.99 0.75 1.00 0.75 0.09 1.00 2 80 KMT2D oncogenic mutation 0.98 0.45 1.00 0.90 0.20 1.00 2 81 HLA-B deletion/mutation 0.97 0.65 1.00 0.63 0.11 1.00 4 84 ZFHX3 oncogenic alterations: deletion/mutation 0.97 0.64 1.00 0.59 0.06 1.00 2 80 MSI-H/dMMR 0.97 0.92 0.88 0.86 0.56 0.97 16 81 MCL1 amplification 0.97 0.75 1.00 0.42 0.06 1.00 3 86 ZNRF3 oncogenic alterations: deletion/mutation 0.97 0.62 1.00 0.83 0.12 1.00 2 86 ZNRF3 oncogenic mutation 0.97 0.33 1.00 0.88 0.17 1.00 2 86 KMT2D oncogenic alterations: deletion/mutation 0.96 0.33 1.00 0.91 0.22 1.00 2 81 CASP8 oncogenic alterations: deletion/mutation 0.96 0.29 1.00 0.78 0.10 1.00 2 87 PTCH1 oncogenic alterations: deletion/mutation 0.96 0.38 1.00 0.87 0.15 1.00 2 84 PTCH1 oncogenic mutation 0.96 0.31 1.00 0.88 0.17 1.00 2 84 RNF43 oncogenic mutation 0.96 0.29 1.00 0.74 0.08 1.00 2 84 GRIN2A oncogenic alterations: deletion/mutation 0.96 0.31 1.00 0.62 0.06 1.00 2 81 ELF3 amplification 0.95 0.53 1.00 0.64 0.09 1.00 3 86 MSI-H vs MSS 0.95 0.91 0.88 0.90 0.64 0.97 16 81 RAD21 amplification 0.94 0.24 1.00 0.22 0.03 1.00 2 87 RNF43 oncogenic alterations: deletion/mutation 0.93 0.21 1.00 0.71 0.08 1.00 2 84 TMB-H 0.93 0.87 0.93 0.71 0.37 0.98 14 76 RIT1 oncogenic alterations: amplification/mutation 0.93 0.30 1.00 0.67 0.10 1.00 3 85 KMT2B oncogenic alterations: deletion/mutation 0.92 0.33 1.00 0.67 0.07 1.00 2 79 SDHC amplification 0.92 0.55 1.00 0.79 0.14 1.00 3 86 NOTCH3 oncogenic alterations: amplification/mutation 0.92 0.35 1.00 0.47 0.09 1.00 4 81 CASP8 oncogenic mutation 0.92 0.17 1.00 0.82 0.11 1.00 2 87 MDM4 amplification 0.92 0.30 1.00 0.70 0.10 1.00 3 86 NOTCH3 oncogenic alterations: deletion/mutation 0.92 0.48 1.00 0.30 0.07 1.00 4 81 PAX5 oncogenic alterations: deletion/mutation 0.91 0.46 1.00 0.33 0.05 1.00 3 85 CDH1 oncogenic mutation 0.91 0.21 1.00 0.26 0.05 1.00 3 84 KMT2B oncogenic mutation 0.91 0.24 1.00 0.71 0.08 1.00 2 79 NUF2 amplification 0.91 0.34 1.00 0.53 0.07 1.00 3 86 PARP1 amplification 0.90 0.23 1.00 0.77 0.13 1.00 3 86 KMT2A oncogenic alterations: deletion/mutation 0.90 0.29 1.00 0.72 0.12 1.00 3 79 IKBKE amplification 0.90 0.54 1.00 0.69 0.10 1.00 3 86 ATRX oncogenic mutation 0.90 0.59 1.00 0.26 0.05 1.00 3 82 KMT2A oncogenic mutation 0.89 0.21 1.00 0.77 0.14 1.00 3 79 SETDB1 amplification 0.89 0.53 1.00 0.65 0.09 1.00 3 86 PAX5 oncogenic mutation 0.89 0.44 1.00 0.60 0.08 1.00 3 85 NOTCH3 oncogenic mutation 0.89 0.41 1.00 0.52 0.09 1.00 4 81 GRIN2A oncogenic mutation 0.88 0.55 1.00 0.73 0.08 1.00 2 81 CDC73 amplification 0.88 0.31 1.00 0.56 0.07 1.00 3 86 ETV6 oncogenic mutation 0.86 0.29 1.00 0.64 0.06 1.00 2 85 BRCA2 amplification 0.86 0.15 1.00 0.30 0.03 1.00 2 86 MGA oncogenic mutation 0.84 0.60 1.00 0.35 0.09 1.00 5 81 TP53 oncogenic alterations: deletion/mutation 0.84 0.87 0.80 0.87 0.89 0.77 49 39 SRC oncogenic alterations: amplification/mutation 0.84 0.39 0.75 0.79 0.36 0.95 12 77 PPM1D oncogenic alterations: amplification/mutation 0.83 0.13 1.00 0.49 0.06 1.00 3 86 ERBB2 amplification 0.83 0.26 1.00 0.45 0.10 1.00 5 84 SETD2 oncogenic alterations: deletion/mutation 0.83 0.69 1.00 0.45 0.07 1.00 3 78 BRCA2 oncogenic alterations: deletion/mutation 0.82 0.36 1.00 0.34 0.09 1.00 5 80 SOX9 oncogenic mutation 0.82 0.45 0.91 0.21 0.14 0.94 11 78 SMARCB1 oncogenic alterations: deletion/mutation 0.82 0.15 1.00 0.21 0.04 1.00 3 84 FAT1 oncogenic mutation 0.82 0.51 1.00 0.29 0.08 1.00 5 77 GNAS amplification 0.82 0.30 0.82 0.64 0.24 0.96 11 78 SETD2 oncogenic mutation 0.81 0.69 1.00 0.34 0.05 1.00 3 79 B2M oncogenic mutation 0.81 0.11 1.00 0.77 0.13 1.00 3 86 ASXL1 oncogenic mutation 0.80 0.35 1.00 0.31 0.07 1.00 4 83 FLT1 oncogenic alterations: amplification/mutation 0.80 0.37 1.00 0.33 0.12 1.00 7 78 KRAS oncogenic alterations: amplification/mutation 0.80 0.77 0.90 0.38 0.56 0.82 41 47 XPO1 oncogenic alterations: amplification/mutation 0.80 0.10 1.00 0.33 0.03 1.00 2 86 TP63 oncogenic alterations: deletion/mutation 0.79 0.10 1.00 0.55 0.05 1.00 2 85 B2M oncogenic alterations: deletion/mutation 0.79 0.21 0.75 0.71 0.11 0.98 4 85 CDC73 oncogenic alterations: deletion/mutation 0.79 0.28 1.00 0.58 0.06 1.00 2 81 FLT1 amplification 0.79 0.39 1.00 0.30 0.11 1.00 7 82 AURKA oncogenic alterations: amplification/mutation 0.79 0.27 0.80 0.65 0.22 0.96 10 79 BRAF oncogenic mutation 0.78 0.48 0.80 0.58 0.20 0.96 10 78 BRAF oncogenic alterations: amplification/mutation 0.78 0.44 0.80 0.62 0.21 0.96 10 78 SOX9 oncogenic alterations: deletion/mutation 0.78 0.47 0.92 0.22 0.15 0.94 12 77 ARID1A oncogenic mutation 0.78 0.31 0.91 0.31 0.16 0.96 11 78 ARID2 oncogenic mutation 0.78 0.40 1.00 0.23 0.04 1.00 3 84 DNMT3B amplification 0.78 0.23 0.78 0.76 0.27 0.97 9 80 KRAS oncogenic mutation 0.78 0.75 0.88 0.33 0.52 0.76 40 48 BCL2L1 amplification 0.77 0.30 0.80 0.63 0.22 0.96 10 79 ETV6 oncogenic alterations: deletion/mutation 0.76 0.09 1.00 0.25 0.03 1.00 2 85 MSH2 oncogenic mutation 0.76 0.15 1.00 0.54 0.05 1.00 2 85 APC oncogenic mutation 0.75 0.88 0.86 0.47 0.85 0.50 66 19</p><p>Table S10.4. Biomarkers detected in Endometrial Cancer (TCGA-UCEC, TCGA-UCS) Biomarker AUC AP Sensitivity Specificity PPV NPV Positive Negative Total EZH2 oncogenic mutation 1.00 1.00 1.00 0.85 0.13 1.00 2 84 PALB2 oncogenic alterations: deletion/mutation 0.99 0.83 1.00 0.81 0.11 1.00 2 84 EZH2 oncogenic alterations: amplification/mutation 0.99 0.58 1.00 0.67 0.07 1.00 2 81 KDM5C oncogenic alterations: deletion/mutation 0.99 0.75 1.00 0.36 0.04 1.00 2 77 ERCC3 oncogenic mutation 0.98 0.50 1.00 0.60 0.06 1.00 2 86 RET oncogenic mutation 0.98 0.50 1.00 0.76 0.09 1.00 2 82 EZH2 oncogenic alterations: deletion/mutation 0.98 0.70 1.00 0.78 0.10 1.00 2 81 ERF amplification 0.98 0.45 1.00 0.61 0.05 1.00 2 89 KDM5C oncogenic mutation 0.97 0.45 1.00 0.53 0.05 1.00 2 80 PRDM1 oncogenic mutation 0.97 0.64 1.00 0.85 0.14 1.00 2 82 PALB2 oncogenic mutation 0.96 0.61 1.00 0.78 0.10 1.00 2 87 RET oncogenic alterations: amplification/mutation 0.96 0.61 1.00 0.39 0.04 1.00 2 79 DNMT3B amplification 0.96 0.27 1.00 0.78 0.09 1.00 2 90 ERCC2 amplification 0.94 0.24 1.00 0.74 0.08 1.00 2 89 TGFBR1 oncogenic mutation 0.94 0.23 1.00 0.88 0.17 1.00 2 84 FOXP1 oncogenic alterations: deletion/mutation 0.94 0.32 1.00 0.65 0.12 1.00 4 82 PREX2 amplification 0.94 0.21 1.00 0.40 0.04 1.00 2 90 CD79A amplification 0.93 0.20 1.00 0.61 0.05 1.00 2 89 H3C13 amplification 0.93 0.61 1.00 0.30 0.09 1.00 6 86 TET2 oncogenic mutation 0.93 0.35 1.00 0.62 0.11 1.00 4 82 GRIN2A oncogenic alterations: deletion/mutation 0.93 0.72 1.00 0.77 0.15 1.00 3 74 SPEN oncogenic mutation 0.93 0.30 1.00 0.64 0.12 1.00 4 83 GRIN2A oncogenic mutation 0.93 0.61 1.00 0.78 0.15 1.00 3 78 PTEN oncogenic alterations: deletion/mutation 0.93 0.97 0.97 0.54 0.85 0.87 66 24 MYCN oncogenic mutation 0.93 0.18 1.00 0.72 0.07 1.00 2 88 AKT2 amplification 0.92 0.24 1.00 0.74 0.12 1.00 3 88 SPEN oncogenic alterations: deletion/mutation 0.92 0.32 1.00 0.59 0.11 1.00 4 79 CIC amplification 0.92 0.23 1.00 0.58 0.05 1.00 2 89 AXL amplification 0.92 0.18 1.00 0.80 0.10 1.00 2 89 POLD1 oncogenic alterations: deletion/mutation 0.91 0.17 1.00 0.67 0.07 1.00 2 82 TGFBR1 oncogenic alterations: deletion/mutation 0.91 0.24 1.00 0.77 0.10 1.00 2 81 PIK3R3 oncogenic mutation 0.91 0.22 1.00 0.66 0.09 1.00 3 88 RAD50 oncogenic mutation 0.91 0.37 1.00 0.66 0.18 1.00 6 82 PRDM1 oncogenic alterations: deletion/mutation 0.91 0.56 1.00 0.70 0.08 1.00 2 79 TET2 oncogenic alterations: deletion/mutation 0.91 0.50 1.00 0.61 0.11 1.00 4 79 TP53BP1 oncogenic alterations: deletion/mutation 0.91 0.28 1.00 0.59 0.11 1.00 4 80 RAD50 oncogenic alterations: deletion/mutation 0.91 0.34 1.00 0.52 0.14 1.00 6 79 SETDB1 amplification 0.91 0.44 1.00 0.41 0.11 1.00 6 86 CCNE1 amplification 0.91 0.57 0.91 0.75 0.33 0.98 11 81 PTEN oncogenic mutation 0.91 0.96 0.92 0.57 0.83 0.76 63 28 ERF oncogenic mutation 0.91 0.15 1.00 0.72 0.07 1.00 2 90 CCNE1 oncogenic alterations: amplification/mutation 0.91 0.58 1.00 0.70 0.33 1.00 11 74 PARP1 oncogenic alterations: deletion/mutation 0.91 0.17 1.00 0.57 0.06 1.00 2 79 MCL1 amplification 0.91 0.37 1.00 0.42 0.11 1.00 6 86 ERCC3 oncogenic alterations: deletion/mutation 0.90 0.31 1.00 0.64 0.06 1.00 2 83 AXL oncogenic alterations: amplification/mutation 0.90 0.23 1.00 0.75 0.10 1.00 2 77 KMT2B amplification 0.90 0.27 1.00 0.75 0.15 1.00 4 87 EPHA7 oncogenic alterations: deletion/mutation 0.90 0.29 1.00 0.33 0.07 1.00 4 81 POLD1 oncogenic mutation 0.90 0.15 1.00 0.63 0.06 1.00 2 86 KMT2A oncogenic mutation 0.90 0.54 1.00 0.47 0.15 1.00 7 76 TP53 oncogenic alterations: deletion/mutation 0.90 0.84 0.85 0.83 0.74 0.91 33 58 PPM1D oncogenic mutation 0.90 0.31 1.00 0.55 0.14 1.00 6 85 TP53 oncogenic mutation 0.90 0.82 0.84 0.82 0.71 0.91 32 61 KMT2A oncogenic alterations: deletion/mutation 0.89 0.72 0.86 0.62 0.18 0.98 7 73 FOXP1 oncogenic mutation 0.89 0.28 1.00 0.71 0.14 1.00 4 85 ESR1 oncogenic mutation 0.89 0.22 1.00 0.52 0.09 1.00 4 85 BRCA2 oncogenic mutation 0.89 0.64 0.90 0.71 0.29 0.98 10 76 FOXP1 oncogenic alterations: amplification/mutation 0.89 0.21 1.00 0.38 0.07 1.00 4 82 KEAP1 amplification 0.88 0.18 1.00 0.63 0.08 1.00 3 89 NSD2 amplification 0.88 0.12 1.00 0.80 0.10 1.00 2 90 RAD21 amplification 0.88 0.12 1.00 0.37 0.03 1.00 2 90 TET1 oncogenic mutation 0.88 0.28 1.00 0.28 0.08 1.00 5 80 EPHA7 oncogenic mutation 0.88 0.59 1.00 0.62 0.11 1.00 4 85 MCL1 oncogenic alterations: amplification/mutation 0.88 0.38 1.00 0.43 0.11 1.00 6 82 SDHA amplification 0.88 0.13 1.00 0.56 0.05 1.00 2 90 PIK3R2 amplification 0.88 0.43 1.00 0.67 0.09 1.00 3 89 SUFU oncogenic mutation 0.88 0.12 1.00 0.70 0.07 1.00 2 89 ANKRD11 oncogenic mutation 0.88 0.16 1.00 0.63 0.09 1.00 3 78 RTEL1 amplification 0.87 0.38 0.80 0.83 0.21 0.99 5 87 ASXL1 amplification 0.87 0.29 0.80 0.74 0.15 0.98 5 87 60 Table S10.4. Biomarkers detected in Endometrial Cancer (TCGA-UCEC, TCGA-UCS) (continued) Biomarker AUC AP Sensitivity Specificity PPV NPV Positive Negative Total TMB-H 0.87 0.88 0.79 0.84 0.80 0.83 42 51 TRIP13 amplification 0.87 0.11 1.00 0.41 0.04 1.00 2 90 ERCC4 oncogenic alterations: deletion/mutation 0.87 0.13 1.00 0.69 0.08 1.00 2 78 NSD1 oncogenic mutation 0.87 0.35 1.00 0.62 0.26 1.00 10 74 SRC amplification 0.87 0.38 0.75 0.80 0.14 0.99 4 88 POLE oncogenic mutation 0.87 0.42 1.00 0.55 0.24 1.00 11 78 TERT amplification 0.87 0.13 1.00 0.73 0.08 1.00 2 90 RICTOR amplification 0.87 0.12 1.00 0.58 0.05 1.00 2 90 PARP1 oncogenic mutation 0.87 0.12 1.00 0.68 0.07 1.00 2 82 BCL2L1 amplification 0.86 0.25 0.80 0.79 0.18 0.99 5 87 MLH1 oncogenic mutation 0.86 0.25 1.00 0.55 0.07 1.00 3 86 BRCA2 oncogenic alterations: deletion/mutation 0.86 0.56 0.80 0.68 0.26 0.96 10 73 FGFR3 amplification 0.86 0.17 1.00 0.68 0.06 1.00 2 90 MLH1 oncogenic alterations: deletion/mutation 0.86 0.42 1.00 0.49 0.07 1.00 3 83 BRCA2 germline/somatic point mutation/deletion or fusion 0.86 0.53 0.94 0.50 0.29 0.97 17 78 TP53BP1 oncogenic mutation 0.86 0.18 1.00 0.70 0.14 1.00 4 83 JAK3 amplification 0.86 0.34 1.00 0.62 0.13 1.00 5 87 PIK3R3 oncogenic alterations: deletion/mutation 0.85 0.15 1.00 0.74 0.12 1.00 3 82 KMT2C oncogenic mutation 0.85 0.43 1.00 0.49 0.16 1.00 7 72 SOX2 amplification 0.85 0.24 0.86 0.73 0.21 0.98 7 85 NOTCH2 oncogenic alterations: amplification/mutation 0.85 0.30 1.00 0.20 0.12 1.00 8 70 PRKCI amplification 0.85 0.35 1.00 0.67 0.27 1.00 10 82 MSH6 oncogenic alterations: deletion/mutation 0.85 0.27 1.00 0.68 0.24 1.00 8 77 CEBPA amplification 0.85 0.37 1.00 0.63 0.14 1.00 5 86 NF1 oncogenic alterations: deletion/mutation 0.85 0.32 1.00 0.51 0.21 1.00 9 69 BRCA1/2 germline/somatic mutation/deletion or fusion 0.85 0.41 0.92 0.76 0.35 0.98 12 83 NF1 oncogenic mutation 0.85 0.36 1.00 0.57 0.21 1.00 9 76 PIK3CA amplification 0.85 0.29 1.00 0.33 0.14 1.00 9 83 FOXO1 oncogenic alterations: deletion/mutation 0.85 0.12 1.00 0.56 0.05 1.00 2 81 MSH6 oncogenic mutation 0.85 0.29 0.88 0.74 0.25 0.98 8 80 MGA oncogenic alterations: deletion/mutation 0.85 0.49 1.00 0.43 0.23 1.00 12 70 EP300 oncogenic mutation 0.84 0.21 0.75 0.67 0.11 0.98 4 72 PTPRD oncogenic mutation 0.84 0.21 1.00 0.65 0.18 1.00 6 80 PTCH1 oncogenic alterations: deletion/mutation 0.84 0.49 0.91 0.59 0.24 0.98 11 75 DCUN1D1 amplification 0.84 0.27 0.86 0.71 0.19 0.98 7 85 SF3B1 oncogenic mutation 0.84 0.13 1.00 0.69 0.07 1.00 2 80 NOTCH2 oncogenic mutation 0.84 0.10 1.00 0.44 0.04 1.00 2 79 BRCA1 oncogenic mutation 0.84 0.12 1.00 0.54 0.07 1.00 3 81 BRCA1 germline/somatic point mutation/deletion or fusion 0.84 0.49 0.92 0.59 0.24 0.98 12 83 YES1 amplification 0.84 0.15 1.00 0.49 0.06 1.00 3 89 MSI-H vs MSS 0.83 0.78 0.86 0.64 0.60 0.88 37 58 PMS1 oncogenic alterations: deletion/mutation 0.83 0.16 1.00 0.65 0.09 1.00 3 82 RAD52 amplification 0.83 0.28 1.00 0.26 0.03 1.00 2 89 CHEK1 oncogenic alterations: deletion/mutation 0.83 0.10 1.00 0.40 0.04 1.00 2 86 MYCN oncogenic alterations: amplification/mutation 0.83 0.18 1.00 0.36 0.07 1.00 4 83 SF3B1 oncogenic alterations: amplification/mutation 0.83 0.10 1.00 0.48 0.05 1.00 2 77 ATR oncogenic alterations: deletion/mutation 0.83 0.36 0.89 0.56 0.20 0.98 9 73 CASP8 oncogenic mutation 0.83 0.29 0.89 0.60 0.20 0.98 9 82 ARID5B oncogenic mutation 0.83 0.35 0.89 0.55 0.19 0.98 9 78 MRE11 oncogenic mutation 0.83 0.21 0.75 0.55 0.07 0.98 4 87 PDGFRA oncogenic mutation 0.83 0.09 1.00 0.57 0.05 1.00 2 82 ATR oncogenic mutation 0.83 0.33 0.89 0.48 0.17 0.97 9 77 CASP8 oncogenic alterations: deletion/mutation 0.83 0.32 0.80 0.62 0.21 0.96 10 78 TET1 oncogenic alterations: deletion/mutation 0.83 0.18 1.00 0.38 0.09 1.00 5 77 RB1 oncogenic mutation 0.83 0.14 1.00 0.28 0.03 1.00 2 80 NCOR1 oncogenic mutation 0.82 0.13 1.00 0.47 0.07 1.00 3 80 BRCA1 oncogenic alterations: deletion/mutation 0.82 0.12 1.00 0.51 0.07 1.00 3 78 NSD1 oncogenic alterations: deletion/mutation 0.82 0.39 1.00 0.41 0.19 1.00 10 71 EP300 oncogenic alterations: deletion/mutation 0.82 0.18 0.75 0.71 0.13 0.98 4 68 MGA oncogenic mutation 0.82 0.37 0.92 0.58 0.26 0.98 12 73 ARID1B oncogenic alterations: deletion/mutation 0.82 0.14 1.00 0.64 0.12 1.00 4 81 CTR9 oncogenic alterations: deletion/mutation 0.82 0.11 1.00 0.32 0.04 1.00 2 78 PBRM1 oncogenic alterations: deletion/mutation 0.82 0.26 0.83 0.61 0.14 0.98 6 79 PBRM1 oncogenic mutation 0.82 0.26 0.83 0.73 0.19 0.98 6 83 CDC73 oncogenic alterations: deletion/mutation 0.81 0.20 1.00 0.24 0.03 1.00 2 82 MSI-H/dMMR 0.81 0.75 0.86 0.59 0.57 0.87 37 58 ETV6 oncogenic mutation 0.81 0.09 1.00 0.63 0.06 1.00 2 86 ASXL2 oncogenic mutation 0.81 0.09 1.00 0.67 0.07 1.00 2 83 NSD1 oncogenic alterations: amplification/mutation 0.81 0.41 1.00 0.25 0.16 1.00 10 71 APC oncogenic mutation 0.81 0.45 0.90 0.55 0.21 0.98 10 76 SLX4 oncogenic mutation 0.81 0.17 1.00 0.47 0.11 1.00 5 79 PIK3CB oncogenic mutation 0.80 0.20 1.00 0.40 0.04 1.00 2 82 NSD3 amplification 0.80 0.10 1.00 0.67 0.09 1.00 3 88 KDM5A oncogenic alterations: amplification/mutation 0.80 0.20 1.00 0.24 0.03 1.00 2 76 Table S10.4. Biomarkers detected in Endometrial Cancer (TCGA-UCEC, TCGA-UCS) (continued) Biomarker AUC AP Sensitivity Specificity PPV NPV Positive Negative Total TP63 amplification 0.80 0.15 1.00 0.66 0.15 1.00 5 86 PRDM14 amplification 0.80 0.10 1.00 0.51 0.06 1.00 3 89 IL7R amplification 0.80 0.13 1.00 0.62 0.08 1.00 3 89 PTCH1 oncogenic mutation 0.80 0.33 0.82 0.68 0.26 0.96 11 77 PPM1D amplification 0.80 0.07 1.00 0.41 0.04 1.00 2 90 EIF4A2 amplification 0.80 0.14 1.00 0.71 0.17 1.00 5 86 MAP3K13 amplification 0.80 0.20 0.75 0.78 0.25 0.97 8 83 APC oncogenic alterations: deletion/mutation 0.80 0.43 0.90 0.30 0.15 0.96 10 73 BRD4 oncogenic alterations: amplification/mutation 0.80 0.22 0.75 0.75 0.14 0.98 4 77 CTNNB1 oncogenic mutation 0.79 0.61 0.90 0.52 0.36 0.95 20 67 PMS1 oncogenic mutation 0.79 0.13 1.00 0.38 0.05 1.00 3 85 NOTCH3 amplification 0.79 0.21 0.75 0.61 0.08 0.98 4 88 CTNNB1 oncogenic alterations: amplification/mutation 0.79 0.60 0.90 0.52 0.37 0.94 20 65 FAT1 oncogenic alterations: deletion/mutation 0.78 0.51 0.93 0.38 0.26 0.96 15 64 BCL6 amplification 0.78 0.16 0.80 0.77 0.17 0.99 5 86 ZFHX3 oncogenic mutation 0.78 0.47 0.80 0.52 0.28 0.92 15 65 BRD4 amplification 0.78 0.21 0.75 0.76 0.12 0.99 4 88 NFE2L2 oncogenic mutation 0.78 0.33 1.00 0.26 0.07 1.00 5 85 ATRX oncogenic mutation 0.78 0.24 0.89 0.66 0.24 0.98 9 73 SMARCA4 amplification 0.78 0.15 0.80 0.66 0.12 0.98 5 87 KMT2B oncogenic mutation 0.78 0.55 0.83 0.53 0.23 0.95 12 70 CIC oncogenic mutation 0.78 0.21 1.00 0.26 0.06 1.00 4 85 PRKCI oncogenic alterations: amplification/mutation 0.78 0.31 0.90 0.41 0.17 0.97 10 74 KDM5A amplification 0.78 0.15 1.00 0.20 0.03 1.00 2 89 CTCF oncogenic mutation 0.78 0.52 0.96 0.47 0.39 0.97 23 64 KMT2C oncogenic alterations: deletion/mutation 0.77 0.34 1.00 0.33 0.15 1.00 8 67 PTPRT amplification 0.77 0.07 1.00 0.61 0.05 1.00 2 90 FGFR3 oncogenic alterations: amplification/mutation 0.77 0.12 1.00 0.49 0.07 1.00 3 79 YES1 oncogenic alterations: amplification/mutation 0.77 0.11 1.00 0.42 0.06 1.00 3 81 BARD1 oncogenic mutation 0.77 0.09 1.00 0.67 0.09 1.00 3 87 LYN amplification 0.77 0.12 1.00 0.51 0.06 1.00 3 89 MTOR oncogenic mutation 0.76 0.38 0.83 0.50 0.11 0.97 6 78 CDC73 oncogenic mutation 0.76 0.07 1.00 0.46 0.04 1.00 2 85 FAT1 oncogenic mutation 0.76 0.51 1.00 0.43 0.25 1.00 13 69 RUNX1 oncogenic mutation 0.76 0.07 1.00 0.56 0.05 1.00 2 88 ATRX oncogenic alterations: deletion/mutation 0.76 0.23 0.89 0.54 0.20 0.97 9 70 MRE11 oncogenic alterations: deletion/mutation 0.76 0.12 1.00 0.33 0.07 1.00 4 84 ATM oncogenic mutation 0.76 0.30 0.92 0.55 0.27 0.97 13 71 INPP4B oncogenic mutation 0.76 0.14 0.80 0.57 0.11 0.98 5 80 RECQL oncogenic alterations: deletion/mutation 0.75 0.09 1.00 0.58 0.05 1.00 2 83 RUNX1 oncogenic alterations: deletion/mutation 0.75 0.07 1.00 0.34 0.03 1.00 2 85 NBN amplification 0.75 0.40 1.00 0.22 0.04 1.00 3 89 MYC oncogenic alterations: amplification/mutation 0.75 0.12 1.00 0.56 0.10 1.00 4 80 NOTCH2 oncogenic alterations: deletion/mutation 0.75 0.08 1.00 0.26 0.04 1.00 2 70 FANCA oncogenic mutation 0.75 0.07 1.00 0.60 0.06 1.00 2 82 Table S10.5. Biomarkers detected in Esophagogastric Cancer (TCGA-ESCA, TCGA-STAD) Biomarker AUC AP Sensitivity Specificity PPV NPV Positive Negative Total BMPR1A oncogenic mutation 0.99 0.58 1.00 0.38 0.03 1.00 2 91 B2M oncogenic mutation 0.99 0.59 1.00 0.94 0.38 1.00 3 90 MEN1 oncogenic alterations: deletion/mutation 0.98 0.48 1.00 0.22 0.04 1.00 3 88 B2M oncogenic alterations: deletion/mutation 0.97 0.44 1.00 0.83 0.17 1.00 3 89 PIK3C2G amplification 0.97 0.42 1.00 0.29 0.03 1.00 2 91 ARID1B oncogenic mutation 0.97 0.66 1.00 0.47 0.06 1.00 3 89 CDH1 oncogenic mutation 0.96 0.56 1.00 0.84 0.22 1.00 4 86 CDH1 oncogenic alterations: deletion/mutation 0.96 0.63 1.00 0.86 0.29 1.00 5 84 MEN1 oncogenic mutation 0.96 0.32 1.00 0.25 0.04 1.00 3 89 KMT2B oncogenic mutation 0.94 0.54 1.00 0.53 0.13 1.00 6 83 CTNNB1 amplification 0.94 0.58 1.00 0.25 0.03 1.00 2 91 BLM amplification 0.94 0.38 1.00 0.26 0.07 1.00 5 88 KMT2D oncogenic mutation 0.94 0.65 1.00 0.70 0.19 1.00 5 74 MGA oncogenic alterations: deletion/mutation 0.93 0.26 1.00 0.29 0.05 1.00 3 86 CDC73 oncogenic alterations: deletion/mutation 0.93 0.25 1.00 0.38 0.04 1.00 2 88 KMT2D oncogenic alterations: deletion/mutation 0.93 0.64 1.00 0.74 0.24 1.00 6 73 NFE2L2 oncogenic alterations: amplification/mutation 0.93 0.21 1.00 0.88 0.15 1.00 2 89 MSI-H vs MSS 0.92 0.82 0.79 0.75 0.35 0.95 14 80 KMT2B oncogenic alterations: deletion/mutation 0.92 0.52 1.00 0.41 0.13 1.00 7 80 MSI-H/dMMR 0.92 0.83 1.00 0.47 0.25 1.00 14 80 BLM oncogenic alterations: deletion/mutation 0.92 0.32 1.00 0.46 0.04 1.00 2 83 BLM oncogenic mutation 0.91 0.56 1.00 0.62 0.06 1.00 2 89 NOTCH1 oncogenic mutation 0.91 0.15 1.00 0.85 0.13 1.00 2 88 BCOR oncogenic mutation 0.91 0.17 1.00 0.21 0.03 1.00 2 90 SOX9 oncogenic alterations: deletion/mutation 0.90 0.47 1.00 0.62 0.08 1.00 3 87 KRAS oncogenic mutation 0.90 0.42 1.00 0.58 0.20 1.00 9 83 PTP4A1 amplification 0.90 0.15 1.00 0.40 0.04 1.00 2 91 NOTCH1 oncogenic alterations: amplification/mutation 0.90 0.16 1.00 0.60 0.05 1.00 2 87 EP300 oncogenic mutation 0.90 0.14 1.00 0.75 0.08 1.00 2 87 HLA-B deletion/mutation 0.89 0.45 1.00 0.30 0.09 1.00 6 84 GNAS amplification 0.89 0.13 1.00 0.30 0.03 1.00 2 91 BARD1 oncogenic mutation 0.89 0.43 0.75 0.93 0.33 0.99 4 88 RARA amplification 0.89 0.50 1.00 0.24 0.07 1.00 5 88 FBXW7 deletion 0.89 0.54 1.00 0.54 0.05 1.00 2 91 BARD1 oncogenic alterations: deletion/mutation 0.89 0.21 1.00 0.71 0.14 1.00 4 87 MGA oncogenic mutation 0.88 0.18 1.00 0.34 0.05 1.00 3 87 INPPL1 amplification 0.88 0.29 1.00 0.48 0.10 1.00 5 87 KMT2C oncogenic mutation 0.87 0.42 0.88 0.70 0.23 0.98 8 77 TMB-H 0.87 0.77 0.88 0.51 0.27 0.95 16 77 BRCA1/2 germline/somatic mutation/deletion or fusion 0.87 0.24 1.00 0.55 0.11 1.00 5 89 KRAS oncogenic alterations: amplification/mutation 0.86 0.51 1.00 0.43 0.27 1.00 16 76 PPM1D oncogenic alterations: amplification/mutation 0.86 0.54 1.00 0.41 0.04 1.00 2 90 FAT1 oncogenic mutation 0.86 0.11 1.00 0.38 0.04 1.00 2 86 FGF4 amplification 0.86 0.74 1.00 0.40 0.21 1.00 13 80 INPP4B amplification 0.86 0.13 1.00 0.26 0.03 1.00 2 90 KDM5C oncogenic mutation 0.85 0.14 1.00 0.70 0.10 1.00 3 86 TP53 oncogenic alterations: deletion/mutation 0.85 0.87 0.94 0.51 0.70 0.88 50 41 FGF4 oncogenic alterations: amplification/mutation 0.85 0.73 0.92 0.33 0.18 0.96 13 79 TP53 oncogenic mutation 0.85 0.87 0.90 0.60 0.72 0.83 49 42 KMT2A oncogenic alterations: deletion/mutation 0.83 0.20 1.00 0.59 0.06 1.00 2 83 ERBB2 amplification 0.82 0.44 1.00 0.42 0.16 1.00 9 84 MDM2 oncogenic alterations: amplification/mutation 0.82 0.23 0.75 0.70 0.10 0.98 4 86 GNAS oncogenic alterations: amplification/mutation 0.82 0.11 1.00 0.48 0.06 1.00 3 88 FGF3 oncogenic alterations: amplification/mutation 0.81 0.71 0.93 0.26 0.19 0.95 14 77 BRCA1 germline/somatic point mutation/deletion or fusion 0.81 0.17 1.00 0.25 0.07 1.00 5 89 FGF3 amplification 0.80 0.70 0.93 0.30 0.19 0.96 14 79 DCUN1D1 amplification 0.80 0.33 1.00 0.31 0.12 1.00 8 85 CDKN2B oncogenic alterations: deletion/mutation 0.80 0.36 1.00 0.33 0.17 1.00 11 82 CDKN2B deletion 0.80 0.35 1.00 0.38 0.18 1.00 11 82 PTPRT oncogenic mutation 0.79 0.10 1.00 0.20 0.04 1.00 3 80 YES1 amplification 0.79 0.07 1.00 0.73 0.07 1.00 2 91 PTEN oncogenic mutation 0.79 0.35 0.75 0.47 0.06 0.98 4 88 MDM2 amplification 0.79 0.22 0.75 0.74 0.12 0.99 4 89 CDKN2A (p16INK4a) deletion 0.79 0.40 1.00 0.46 0.25 1.00 14 79 FGF19 amplification 0.78 0.66 0.93 0.29 0.20 0.96 15 78 CDKN2A (p14ARF) deletion 0.78 0.41 1.00 0.34 0.21 1.00 14 79 KMT2C oncogenic alterations: deletion/mutation 0.78 0.25 0.89 0.41 0.15 0.97 9 75 RAF1 amplification 0.77 0.10 1.00 0.63 0.11 1.00 4 89 IRS2 amplification 0.76 0.13 1.00 0.27 0.04 1.00 3 90 CTNNB1 oncogenic mutation 0.76 0.19 0.75 0.34 0.05 0.97 4 88 CCND1 amplification 0.76 0.58 0.87 0.22 0.18 0.89 15 78 CCND1 oncogenic alterations: amplification/mutation 0.76 0.63 0.93 0.27 0.20 0.95 15 77 CDK12 amplification 0.75 0.22 1.00 0.37 0.10 1.00 6 87 Table S10.6. Biomarkers detected in Glioma (TCGA-GBM, TCGA-LGG) Biomarker AUC AP Sensitivity Specificity PPV NPV Positive Negative Total GRIN2A oncogenic alterations: deletion/mutation 0.97 0.56 1.00 0.68 0.07 1.00 3 136 IDH1 oncogenic mutation 0.94 0.92 0.91 0.81 0.84 0.89 76 68 IDH1 oncogenic alterations: amplification/mutation 0.93 0.93 0.92 0.76 0.81 0.89 76 67 TP53 oncogenic alterations: deletion/mutation 0.93 0.93 0.95 0.64 0.66 0.95 60 83 TP53 oncogenic mutation 0.93 0.92 0.95 0.64 0.64 0.95 58 86 XRCC2 amplification 0.93 0.29 1.00 0.49 0.07 1.00 6 166 FUBP1 oncogenic alterations: deletion/mutation 0.93 0.48 1.00 0.54 0.10 1.00 7 134 CIC oncogenic mutation 0.93 0.56 0.78 0.87 0.48 0.96 18 118 ATRX oncogenic mutation 0.92 0.73 1.00 0.37 0.30 1.00 29 108 ATRX oncogenic alterations: deletion/mutation 0.92 0.70 1.00 0.47 0.36 1.00 31 105 EZH2 oncogenic alterations: amplification/mutation 0.91 0.38 1.00 0.47 0.08 1.00 6 137 FUBP1 oncogenic mutation 0.91 0.37 1.00 0.57 0.11 1.00 7 136 EZH2 amplification 0.91 0.44 1.00 0.45 0.06 1.00 6 166 EGFR amplification 0.90 0.78 0.93 0.67 0.46 0.97 40 132 KMT2C amplification 0.90 0.39 1.00 0.23 0.05 1.00 6 166 STAG2 oncogenic alterations: deletion/mutation 0.90 0.17 1.00 0.70 0.07 1.00 3 134 EGFR oncogenic alterations: amplification/mutation 0.90 0.79 0.91 0.70 0.56 0.95 44 106 CDKN2B oncogenic alterations: deletion/mutation 0.89 0.83 0.91 0.72 0.62 0.94 53 104 NF1 oncogenic mutation 0.89 0.31 1.00 0.67 0.17 1.00 9 133 PTEN oncogenic alterations: deletion/mutation 0.87 0.51 0.88 0.73 0.40 0.97 24 118 NF1 oncogenic alterations: deletion/mutation 0.87 0.31 0.90 0.76 0.23 0.99 10 130 BCOR oncogenic mutation 0.87 0.20 1.00 0.65 0.09 1.00 5 139 CDKN2A (p14ARF) deletion 0.86 0.75 0.89 0.66 0.53 0.93 53 119 CDKN2A (p16INK4a) deletion 0.86 0.74 0.87 0.67 0.54 0.92 53 119 MTAP oncogenic alterations: deletion/mutation 0.86 0.71 0.83 0.65 0.47 0.91 42 111 RB1 oncogenic mutation 0.86 0.32 0.75 0.78 0.09 0.99 4 138 CDKN2B deletion 0.85 0.76 0.87 0.67 0.54 0.92 53 119 RTK pathway 0.84 0.88 0.92 0.41 0.71 0.77 86 56 PTEN oncogenic mutation 0.84 0.38 0.81 0.69 0.25 0.97 16 125 NOTCH1 oncogenic mutation 0.83 0.33 0.80 0.70 0.09 0.99 5 138 CCND2 amplification 0.82 0.24 0.86 0.55 0.07 0.99 7 165 EGFR oncogenic mutation 0.82 0.33 0.81 0.66 0.24 0.96 16 124 MTAP deletion 0.82 0.59 0.79 0.65 0.42 0.90 42 130 MDM2 oncogenic alterations: amplification/mutation 0.81 0.20 0.83 0.69 0.10 0.99 6 137 SMO oncogenic alterations: amplification/mutation 0.81 0.14 1.00 0.24 0.05 1.00 6 137 PDCD1 deletion 0.81 0.12 0.75 0.83 0.10 0.99 4 168 PTEN deletion 0.81 0.20 0.88 0.65 0.11 0.99 8 164 RAD21 amplification 0.81 0.20 0.75 0.54 0.04 0.99 4 168 ARID1A oncogenic mutation 0.80 0.08 1.00 0.37 0.03 1.00 3 139 MDM2 amplification 0.80 0.29 0.83 0.63 0.08 0.99 6 166 KIT amplification 0.79 0.21 1.00 0.32 0.08 1.00 10 162 FAT1 deletion 0.79 0.10 0.80 0.50 0.05 0.99 5 167 NOTCH1 oncogenic alterations: deletion/mutation 0.79 0.25 0.80 0.49 0.05 0.99 5 135 CDK4 oncogenic alterations: amplification/mutation 0.78 0.40 0.81 0.66 0.23 0.97 16 128 FAT1 oncogenic alterations: deletion/mutation 0.78 0.11 1.00 0.25 0.05 1.00 5 133 GLI1 oncogenic alterations: amplification/mutation 0.78 0.18 0.78 0.64 0.13 0.98 9 132 PDGFRA amplification 0.78 0.31 0.93 0.33 0.11 0.98 14 158 GLI1 amplification 0.78 0.16 0.78 0.56 0.09 0.98 9 163 DNA damage response 0.77 0.70 0.91 0.35 0.50 0.85 58 80 PDGFRA oncogenic alterations: amplification/mutation 0.77 0.28 0.93 0.26 0.12 0.97 14 128 RB1 oncogenic alterations: deletion/mutation 0.76 0.30 0.78 0.50 0.10 0.97 9 132 Table S10.7. Biomarkers detected in Hepatobiliary Cancer (TCGA-CHOL, TCGA-LIHC) Biomarker AUC AP Sensitivity Specificity PPV NPV Positive Negative Total DNAJB1 fusion 1.00 1.00 1.00 0.99 0.67 1.00 2 88 FGFR2 oncogenic alterations: amplification/mutation 0.99 0.58 1.00 0.87 0.15 1.00 2 85 FGFR oncogenic mutation 0.95 0.36 1.00 0.89 0.17 1.00 2 88 ALOX12B deletion 0.93 0.57 1.00 0.29 0.03 1.00 2 86 FLCN deletion 0.93 0.19 1.00 0.52 0.05 1.00 2 85 IDH1 oncogenic alterations: amplification/mutation 0.92 0.58 0.80 0.95 0.50 0.99 5 82 GPS2 deletion 0.88 0.17 1.00 0.36 0.04 1.00 2 86 EPHA3 amplification 0.88 0.13 1.00 0.40 0.04 1.00 2 86 BRIP1 amplification 0.88 0.30 1.00 0.23 0.03 1.00 2 86 FLCN oncogenic alterations: deletion/mutation 0.86 0.29 1.00 0.74 0.08 1.00 2 85 MYC oncogenic alterations: amplification/mutation 0.86 0.39 1.00 0.44 0.19 1.00 10 78 NCOR1 amplification 0.86 0.12 1.00 0.76 0.09 1.00 2 83 TP53 oncogenic alterations: deletion/mutation 0.84 0.76 0.77 0.80 0.71 0.84 35 54 RAD21 amplification 0.83 0.37 0.90 0.64 0.24 0.98 10 78 ARID2 oncogenic alterations: deletion/mutation 0.83 0.24 1.00 0.27 0.05 1.00 3 84 SMYD3 amplification 0.82 0.36 1.00 0.22 0.09 1.00 6 82 APC oncogenic mutation 0.82 0.08 1.00 0.40 0.04 1.00 2 86 MYC amplification 0.81 0.35 0.90 0.51 0.19 0.98 10 78 PIK3CA oncogenic mutation 0.80 0.10 1.00 0.51 0.04 1.00 2 88 NCOR1 deletion 0.80 0.14 1.00 0.39 0.06 1.00 3 83 PREX2 amplification 0.79 0.34 0.80 0.46 0.08 0.97 5 83 ELOC amplification 0.79 0.38 0.83 0.46 0.10 0.97 6 82 AURKB deletion 0.78 0.10 1.00 0.26 0.03 1.00 2 86 H3C13 amplification 0.78 0.31 1.00 0.20 0.12 1.00 9 79 NTRK1 oncogenic alterations: amplification/mutation 0.78 0.30 1.00 0.23 0.13 1.00 9 78 RIT1 amplification 0.78 0.37 1.00 0.20 0.12 1.00 9 79 YES1 amplification 0.77 0.15 1.00 0.21 0.03 1.00 2 86 MCL1 oncogenic alterations: amplification/mutation 0.77 0.31 1.00 0.22 0.13 1.00 9 79 CDKN2B deletion 0.76 0.13 1.00 0.49 0.11 1.00 5 83 NUF2 amplification 0.76 0.39 1.00 0.33 0.13 1.00 8 80 65 Table S10.8. Biomarkers detected in Non-Small Cell Lung Cancer (TCGA-LUAD, TCGA-LUSC) Biomarker AUC AP Sensitivity Specificity PPV NPV Positive Negative Total STK11 oncogenic alterations: deletion/mutation 0.94 0.51 1.00 0.64 0.16 1.00 12 169 GNAS amplification 0.94 0.19 1.00 0.28 0.03 1.00 4 179 STK11 oncogenic mutation 0.94 0.46 1.00 0.75 0.22 1.00 12 169 CDK4 oncogenic alterations: amplification/mutation 0.87 0.19 1.00 0.52 0.06 1.00 5 176 CDK4 amplification 0.87 0.28 1.00 0.53 0.06 1.00 5 178 RTEL1 amplification 0.87 0.29 0.83 0.43 0.05 0.99 6 177 KRAS oncogenic mutation 0.86 0.44 0.96 0.67 0.29 0.99 23 159 NSD1 deletion 0.86 0.10 1.00 0.68 0.07 1.00 4 177 CCND2 amplification 0.83 0.10 1.00 0.22 0.03 1.00 4 178 TP63 amplification 0.82 0.49 1.00 0.31 0.24 1.00 33 150 DCUN1D1 amplification 0.82 0.60 0.88 0.59 0.38 0.94 40 143 MAP3K13 amplification 0.82 0.54 0.94 0.51 0.31 0.97 35 148 PIK3CA amplification 0.82 0.49 0.94 0.50 0.32 0.97 36 147 SOX2 amplification 0.81 0.56 0.95 0.50 0.35 0.97 40 143 KMT2D oncogenic alterations: deletion/mutation 0.81 0.26 0.94 0.26 0.12 0.97 16 149 EPHA3 deletion 0.81 0.07 1.00 0.56 0.05 1.00 4 178 KMT2C oncogenic alterations: deletion/mutation 0.80 0.19 1.00 0.21 0.06 1.00 8 152 EIF4A2 amplification 0.80 0.44 0.97 0.51 0.30 0.99 33 150 NSD1 oncogenic mutation 0.80 0.20 1.00 0.51 0.04 1.00 4 173 BCL6 oncogenic alterations: amplification/mutation 0.80 0.48 0.91 0.53 0.30 0.96 32 146 BCL6 amplification 0.80 0.43 0.94 0.55 0.31 0.98 32 151 TP53 oncogenic mutation 0.80 0.90 0.96 0.42 0.82 0.77 134 48 KRAS oncogenic alterations: amplification/mutation 0.79 0.49 0.82 0.64 0.29 0.95 28 154 PIK3CA oncogenic alterations: amplification/mutation 0.79 0.44 1.00 0.30 0.33 1.00 46 135 GNAS oncogenic alterations: amplification/mutation 0.78 0.07 1.00 0.22 0.03 1.00 4 178 CRKL amplification 0.78 0.06 1.00 0.23 0.03 1.00 4 177 AKT2 oncogenic alterations: amplification/mutation 0.77 0.22 0.91 0.29 0.08 0.98 11 169 TP53 oncogenic alterations: deletion/mutation 0.77 0.87 0.95 0.42 0.82 0.74 134 48 NFE2L2 oncogenic mutation 0.77 0.20 1.00 0.20 0.08 1.00 11 169 KMT2D oncogenic mutation 0.77 0.20 0.94 0.31 0.13 0.98 16 149 FGF19 oncogenic alterations: amplification/mutation 0.77 0.32 0.93 0.30 0.11 0.98 15 166 CCND1 oncogenic alterations: amplification/mutation 0.77 0.33 1.00 0.21 0.10 1.00 15 165 CCND1 amplification 0.77 0.35 1.00 0.21 0.10 1.00 15 168 ELF3 amplification 0.76 0.18 0.83 0.49 0.05 0.99 6 177 EPHB1 amplification 0.76 0.07 1.00 0.56 0.07 1.00 6 177 MET oncogenic alterations: amplification/mutation 0.76 0.07 0.75 0.64 0.05 0.99 4 175 WWTR1 amplification 0.76 0.18 0.92 0.58 0.14 0.99 13 170 RBM10 oncogenic mutation 0.76 0.15 1.00 0.54 0.10 1.00 9 171 IKZF1 amplification 0.76 0.32 0.83 0.32 0.04 0.98 6 177 FGF19 amplification 0.75 0.28 0.87 0.33 0.10 0.96 15 168 AKT2 amplification 0.75 0.17 0.90 0.40 0.08 0.99 10 173 GATA2 amplification 0.75 0.05 1.00 0.59 0.05 1.00 4 179 Table S10.9. Biomarkers detected in Prostate Cancer (TCGA-PRAD) Biomarker AUC AP Sensitivity Specificity PPV NPV Positive Negative Total FANCC amplification 0.92 0.20 1.00 0.25 0.03 1.00 2 79 BMPR1A oncogenic alterations: deletion/mutation 0.85 0.13 1.00 0.30 0.04 1.00 2 79 ERCC3 deletion 0.85 0.17 1.00 0.40 0.08 1.00 4 77 ZRSR2 amplification 0.84 0.16 1.00 0.69 0.11 1.00 3 78 PTCH1 amplification 0.84 0.11 1.00 0.30 0.04 1.00 2 79 MED12 oncogenic alterations: amplification/mutation 0.81 0.09 1.00 0.60 0.06 1.00 2 78 TBX3 amplification 0.81 0.53 1.00 0.23 0.03 1.00 2 79 SPOP oncogenic alterations: deletion/mutation 0.78 0.22 1.00 0.21 0.12 1.00 8 73 KMT2C fusion 0.76 0.11 1.00 0.38 0.04 1.00 2 79 SPOP oncogenic mutation 0.76 0.20 1.00 0.33 0.14 1.00 8 73 CDK12 oncogenic alterations: deletion/mutation 0.75 0.22 1.00 0.43 0.07 1.00 3 76 Table S11: MSK Development cohort counts (continued) train tune test patients samples slides patients samples slides patients samples slides Cancer Type Tumor Site Small Cell Lung Cancer Primary 124 125 134 38 38 40 39 41 Metastasis 116 124 133 38 39 39 27 29 Appendiceal Cancer Primary 110 110 119 35 35 37 21 21 Metastasis 130 132 143 42 47 48 33 35 Salivary Gland Cancer Primary 106 109 117 21 21 24 18 18 Metastasis 145 166 189 35 39 42 39 45 Mature B-Cell Neoplasms Primary 90 91 98 19 21 23 33 34 Metastasis 5 5 5 2 2 2 2 2 Nerve Sheath Tumor Primary 86 98 103 29 31 32 19 20 Metastasis 18 21 22 2 2 2 1 2 Gastrointestinal Neuroendocrine Tumor Primary 78 79 85 15 16 17 18 18 Metastasis 73 74 80 17 17 18 17 18 Small Bowel Cancer Primary 78 83 88 24 25 28 27 27 Metastasis 30 32 34 9 9 9 9 9 Anal Cancer Primary 68 70 76 15 15 15 25 25 Metastasis 36 36 39 13 14 18 7 7 Ampullary Cancer Primary 61 61 68 13 13 15 15 15 Metastasis 21 22 24 6 6 6 5 7 Sellar Tumor Primary 60 64 73 16 16 17 18 19 Metastasis 3 4 4 3 3 4 1 1 Retinoblastoma Primary 53 54 64 14 14 17 11 11 Metastasis 2 2 2 0 0 0 0 0 Adrenocortical Carcinoma Primary 47 48 51 6 6 6 5 5 Metastasis 25 26 26 3 3 3 2 2 Thymic Tumor Primary 40 40 40 8 8 8 10 11 Metastasis 23 25 27 4 5 8 6 6 Sex Cord Stromal Tumor Primary 40 40 42 7 7 8 6 6 Metastasis 30 32 36 8 8 8 7 8 Breast Sarcoma Primary 38 38 40 12 12 12 4 4 Metastasis 9 9 10 3 4 5 1 1 71 Table S11: MSK Development cohort counts (continued) train tune test patients samples slides patients samples slides patients samples slides Cancer Type Tumor Site Wilms Tumor Primary 37 44 53 7 9 10 6 7 Metastasis 10 13 15 5 5 6 4 5 Vaginal Cancer Primary 35 36 40 6 6 6 7 7 Metastasis 8 8 8 4 4 4 3 3 Embryonal Tumor Primary 35 40 51 8 10 10 5 6 Metastasis 4 4 5 1 1 1 0 0 Miscellaneous Brain Tumor Primary 34 35 37 8 8 9 6 6 Metastasis 3 3 3 0 0 0 1 1 Tubular Adenoma of the Colon Primary 27 28 31 9 10 10 3 4 Histiocytosis Primary 24 24 27 8 8 11 5 7 Metastasis 4 4 4 1 1 1 0 0 Miscellaneous Neuroepithelial Tumor Primary 21 21 21 3 3 3 4 4 Metastasis 2 2 2 1 1 1 1 1 Mature T and NK Neoplasms Primary 19 19 21  <ref type="table">S3</ref>). B: Estimated cost saving for PCR or NGS definitive screening test, using OmniScreen pre-screening, to enroll 500 patients with a mutation in a targeted gene and histology. Y-axis showed the estimated cost reduction (%) for molecular testing with OmniScreen pre-screening. The estimated amount ($) of cost reduction is annotated on top of each bar. X-axis indicated targeted genes that are commonly assessed by NGS or PCR clinically, and their published prevalence of gene alterations (%) in each cancer: BRAF in colorectal cancer (CRC) and melanoma, EGFR in non-small cell lung cancer (NSCLC), FGFR3 in bladder cancer, KRAS (estimated prevalence: 10% in non-smokers, 30% in smokers for NSCLC; 40% in CRC), and MET in NSCLC. C: Prediction of 5 canonical signaling pathways (TGF-β, RTK, HRD, mTOR, DDR), tumor mutation burden (TMB), microsatellite instability (MSI), and chromosomal instability measures: genome instability index (GI), fraction of genome altered (FGA), tetraploidy, whole genome doubling (WGD) and loss-of-heterozygosity (LOH). Blue boxes indicate high-performing biomarkers (Table <ref type="table">S3</ref>). </p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 :</head><label>1</label><figDesc>Figure 1: Pan-cancer digital biomarker identification from H&amp;E whole slide images (WSIs). A: The Om-niScreen workflow: H&amp;E WSIs from diverse tumor histologies are processed using Virchow2 to generate tile embeddings. These representations, along with genomic ground truth, serve as input to train an aggregator network for biomarker prediction. The use cases of biomarker predictions include genetic alteration prediction, genotype-phenotype correlation, treatment target prediction, and pathway and chromosomal instability phenotype detection. B: Sample counts across diverse cancer types in the dataset, split by train, tune and test.Remaining rare cancers account for 4% of all samples (category 'Other', not visualized). 3% of all samples do not have an associated cancer type (category 'Unknown', not visualized). Sample distributions are stratified by data cohort and tumor site.</figDesc><graphic coords="7,153.34,314.58,316.46,244.71" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2 :</head><label>2</label><figDesc>Figure 2: Pan-cancer digital biomarker prediction performance. A: An overview heatmap showing the prediction of 739 genetic alteration biomarkers with AUC &gt; 0.5, representing 320 genes across 43 cancers in the MSK test set. Biomarker labels included had more than 2 positive samples with a positive ratio &gt; 2%. Color coded by AUC. B: Heatmap of gene biomarkers, with AUC &gt; 0.5, identified from primary (P) and metastatic (M) cancers of the most common histologies. Blue boxes highlighted the top performing genes (N=47) in which the corresponding genetic alteration biomarkers (N=80) achieved an AUC &gt; 0.85, sensitivity &gt; 0.8 and specificity &gt; 0.3. C: Distribution of tumor area in MSK test set, split by tumor site. D: Change in AUC for biomarker prediction with respect to the increasing of tumor area within WSIs. E: Change in AUC for biomarker prediction with respect to the fraction of training data set. F: Distribution of biomarker prevalence (i.e., the ratio of positive samples) for high-performing biomarkers included in training data scale analysis.</figDesc><graphic coords="8,257.23,487.89,167.20,84.20" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Figure 4 :</head><label>4</label><figDesc>Figure 4: NSCLC EGFR panel prediction. A: ROC curve of EGFR oncogenic mutation prediction. × indicates the operating point at 90% sensitivity. Classification of binary predictions: true positives (TP), true negatives (TN), false positives (FP), false negatives (FN) were determined against ground truth confirmed by MSK-IMPACT sequencing. B: Euler diagram illustrating the the overlap of EGFR FP samples that are TP for other genes within the same pathways as EGFR in NSCLC, including KRAS (N=115), MET (N=23) and ALK/RET/ROS1 fusion (N=19).Examples of 1024 × 1024 regions in lung adenocarcinomas slides that were highly attended by OmniScreen during the prediction of EGFR oncogenic mutations, C: EGFR TPs, showing histologic patterns consistent with a likelihood of EGFR alteration, such as lepidic (ii), acinar (i), and papillary/micropapillary growth patterns were evident, as were moderate (i, ii) to high nuclear atypia; D: EGFR FPs, predicted with high EGFR mutation likelihood by OmniScreen, confirmed as EGFR wild type and harboring KRAS, MET, or ALK/ROS1/RET mutations. These cases predominantly exhibit acinar (KRAS: i, ii; MET: ii), papillary (MET: i; ALK/ROS/RET: ii), solid-type growth (ALK/ROS/RET: i) patterns, with moderate or greater (KRAS: ii; ALK/ROS/RET: i) nuclear pleomorphism and atypia.</figDesc><graphic coords="20,237.84,341.95,224.98,149.99" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Figure 5 :</head><label>5</label><figDesc>Figure 5: Comparing biomarker prediction performance (AUC) achieved by different models: conventional individually trained models (Single Label) within specific tumor types vs. OmniScreen. Selected biomarkers stratified into two groups: A: biomarkers (N=10) with ∆AUC (relative change in AUC between two models) &lt; 2%, and B: biomarkers (N=10) with ∆AUC &gt; 2%. Tumor types including: Breast Cancer (BC), Bladder Cancer (BLCA), Colorectal Cancer (CRC), Endometrial Cancer (EC), Esophagogastric Cancer (EGC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer (OC), Pancreatic Cancer (PC), Prostate Cancer (PCa), Renal Cell Carcinoma (RCC), Soft Tissue Sarcoma (STS), Thyroid Cancer (THCA). C: Correlation between AUC values obtained from the single-label models and OmniScreen. Fitted lines are shown for each group of biomarkers to highlight trends within the data. D: Comparison of biomarker prevalence distributions between two groups: biomarkers with ∆AUC &lt;2% and biomarkers with ∆AUC&gt; 2%.</figDesc><graphic coords="21,309.00,399.81,156.76,134.36" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><figDesc>Number of targeted enrolled patients: N target • Prevalence of a genomic alteration in a cancer: prevalence • Sensitivity, i.e., the AI model algorithm's true positive rate: sensitivity • Specificity, i.e., the AI model algorithm's true negative rate: specif icity • Cost of AI screening per patient: C AI • Cost of molecular testing per patient: C testing 1. Cost estimation for patient screening using a conventional molecular testing:</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_7"><head>Figure S4 :</head><label>S4</label><figDesc>Figure S4: Biomarker predictions in treatment targets and pathways. A: Heatmap showing the prediction of specific therapeutic hotspots in target genes (Y-axis) detected by OmniScreen across common cancer types at primary (P) and metastatic (M) lesions, with AUC &gt; 0.5. Blue boxes indicate high-performing therapeutic targets associated biomarkers (TableS3). B: Estimated cost saving for PCR or NGS definitive screening test, using OmniScreen pre-screening, to enroll 500 patients with a mutation in a targeted gene and histology. Y-axis showed the estimated cost reduction (%) for molecular testing with OmniScreen pre-screening. The estimated amount ($) of cost reduction is annotated on top of each bar. X-axis indicated targeted genes that are commonly assessed by NGS or PCR clinically, and their published prevalence of gene alterations (%) in each cancer: BRAF in colorectal cancer (CRC) and melanoma, EGFR in non-small cell lung cancer (NSCLC), FGFR3 in bladder cancer, KRAS (estimated prevalence: 10% in non-smokers, 30% in smokers for NSCLC; 40% in CRC), and MET in NSCLC. C: Prediction of 5 canonical signaling pathways (TGF-β, RTK, HRD, mTOR, DDR), tumor mutation burden (TMB), microsatellite instability (MSI), and chromosomal instability measures: genome instability index (GI), fraction of genome altered (FGA), tetraploidy, whole genome doubling (WGD) and loss-of-heterozygosity (LOH). Blue boxes indicate high-performing biomarkers (TableS3).</figDesc><graphic coords="78,182.79,463.28,173.55,138.84" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_8"><figDesc>Figure S5: Genotype-Phenotype associations. A: Comparison between the distribution of CDH1 prediction scores in breast lobular invasive carcinoma and in the other subtypes of breast cancers. B: Comparison between the distribution of IDH1 prediction scores in oligodendroglioma and in the other subtypes of glioma. Examples of 1024 × 1024 regions highly attended by OmniScreen during the prediction of genomic alterations, highlighting specific histologic phenotypic features. These include C: cases with VHL mutations confirmed as clear cell renal cell carcinoma, displaying the characteristic clear cell histology of renal cell carcinoma ((i) and (ii)); D: cases with RB1 loss identified as leiomyosarcomas, showing the characteristic spindle cells with eosinophilic cytoplasm in storiform or fasicular growth patterns characteristic of leiomyosarcomas (i), with perhaps higher concentration of nuclear atypia (ii). E: Cases with KMT2D mutations detected as lung squamous cell carcinomas, exhibiting moderate to high nuclear pleomorphism and atypia (i) along with features characteristic of squamous cell differentiation, such as intercellular bridges and focal keratinization (ii); F: colon adenocarcinomas with MSI-H/dMMR, characterized by poorly differentiated, medullary-like patterns of tumor growth with "pushing" borders, tumor infiltrating lymphocytes (TILs) ((i) and (ii)), and mucin production.</figDesc><graphic coords="79,147.62,405.49,147.31,147.31" type="bitmap" /></figure>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Figure <ref type="figure">S2</ref>: Genomic feature and binary biomarker label derivation. A: Overview of genomic features, including gene level alteration labels of 489 genes from the MSK-IMPACT panel, alterations in a group of genes participating in 5 canonical signaling pathways, genome instability: tumor mutation burden (TMB), microsatellite instability high (MSI-H) or defects in mismatch repair genes (dMMR), and chromosomal instability (CIN) measured by fraction of genome altered (FGA), loss-of-heterozygosity (LOH), genome instability index (GI), whole genome doubling (WGD), and tetraploidy. The alterations include mutations (SNVs/indels), copy number aberrations (amplification and deletion), and fusion events. The oncogenic status was determined based on OncoKB annotation. B: Summary table showing the number of labels in different label categories. </p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Cancer biomarkers: emerging trends and clinical implications for personalized treatment</title>
		<author>
			<persName><forename type="first">Antonio</forename><surname>Passaro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Maise</forename><surname>Al Bakir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Emily</forename><forename type="middle">G</forename><surname>Hamilton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Maximilian</forename><surname>Diehn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Fabrice</forename><surname>André</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sinchita</forename><surname>Roy-Chowdhuri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Giannis</forename><surname>Mountzios</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ignacio</forename><forename type="middle">I</forename><surname>Wistuba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Charles</forename><surname>Swanton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Solange</forename><surname>Peters</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">187</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1617" to="1635" />
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Tumor biomarkers for diagnosis, prognosis and targeted therapy</title>
		<author>
			<persName><forename type="first">Yue</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lei</forename><surname>Tao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jiahao</forename><surname>Qiu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jing</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Xinyu</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yu</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Xinyu</forename><surname>Tian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Xinqi</forename><surname>Guan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Xiaobo</forename><surname>Cen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yinglan</forename><surname>Zhao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Signal Transduction and Targeted Therapy</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">132</biblScope>
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Diagnostic and prognostic factors in patients with prostate cancer: a systematic review</title>
		<author>
			<persName><forename type="first">Katharina</forename><surname>Beyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lisa</forename><surname>Moris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Michael</forename><surname>Lardas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Anna</forename><surname>Haire</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Francesco</forename><surname>Barletta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Simone</forename><surname>Scuderi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Megan</forename><surname>Molnar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ronald</forename><surname>Herrera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Abdul</forename><surname>Rauf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Riccardo</forename><surname>Campi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMJ Open</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page">58267</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castrationresistant Prostate Cancer</title>
		<author>
			<persName><forename type="first">P</forename><surname>Ryon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Virginia</forename><surname>Graf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Joaquin</forename><surname>Fisher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ole</forename><forename type="middle">V</forename><surname>Mateo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Russell</forename><forename type="middle">W</forename><surname>Gjoerup</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Kira</forename><surname>Madison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hanna</forename><surname>Raskina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">James</forename><surname>Tukachinsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Rachel</forename><surname>Creeden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Richard Sp</forename><surname>Cunningham</surname></persName>
		</author>
		<author>
			<persName><surname>Huang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">European Urology</title>
		<imprint>
			<biblScope unit="volume">81</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="37" to="47" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<monogr>
		<title level="m" type="main">Adjuvant Olaparib for Patients with BRCA1-or BRCA2-Mutated Breast Cancer</title>
		<author>
			<persName><forename type="first">Judy</forename><forename type="middle">E</forename><surname>Andrew Nj Tutt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Bella</forename><surname>Garber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Giuseppe</forename><surname>Kaufman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Debora</forename><surname>Viale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Priya</forename><surname>Fumagalli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Richard</forename><forename type="middle">D</forename><surname>Rastogi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Evandro</forename><surname>Gelber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Anitra</forename><surname>De Azambuja</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Judith</forename><surname>Fielding</surname></persName>
		</author>
		<author>
			<persName><surname>Balmaña</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2021">2021</date>
			<publisher>New England Journal of Medicine</publisher>
			<biblScope unit="volume">384</biblScope>
			<biblScope unit="page" from="2394" to="2405" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline</title>
		<author>
			<persName><forename type="first">R</forename><surname>Scott E Eggener</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Andrew</forename><forename type="middle">J</forename><surname>Bryan Rumble</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Todd</forename><forename type="middle">M</forename><surname>Armstrong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Tony</forename><surname>Morgan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Philip</forename><surname>Crispino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Theodorus</forename><surname>Cornford</surname></persName>
		</author>
		<author>
			<persName><surname>Van Der</surname></persName>
		</author>
		<author>
			<persName><forename type="first">David</forename><forename type="middle">J</forename><surname>Kwast</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Alex</forename><forename type="middle">J</forename><surname>Grignon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Neeraj</forename><surname>Rai</surname></persName>
		</author>
		<author>
			<persName><surname>Agarwal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Clinical Oncology</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="issue">13</biblScope>
			<biblScope unit="page" from="1474" to="1494" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Circulating Tumor Cell Detection Technologies and Clinical Utility: Challenges and Opportunities</title>
		<author>
			<persName><forename type="first">Zeina</forename><surname>Habli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Walid</forename><surname>Alchamaa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Raya</forename><surname>Saab</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Humam</forename><surname>Kadara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Massoud</forename><forename type="middle">L</forename><surname>Khraiche</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancers</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page">1930</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Assessment of Circulating Nucleic Acids in Cancer: From Current Status to Future Perspectives and Potential Clinical Applications</title>
		<author>
			<persName><forename type="first">Gabriella</forename><surname>Cirmena</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Martina</forename><surname>Dameri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Francesco</forename><surname>Ravera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Piero</forename><surname>Fregatti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Alberto</forename><surname>Ballestrero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Gabriele</forename><surname>Zoppoli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancers</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">14</biblScope>
			<biblScope unit="page">3460</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Development and deployment of a histopathology-based deep learning algorithm for patient prescreening in a clinical trial</title>
		<author>
			<persName><forename type="first">Albert</forename><surname>Juan Ramon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Chaitanya</forename><surname>Parmar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Oscar</forename><forename type="middle">M</forename><surname>Carrasco-Zevallos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Carlos</forename><surname>Csiszer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">F</forename><surname>Stephen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Patricia</forename><surname>Yip</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Nicole</forename><forename type="middle">L</forename><surname>Raciti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Spyros</forename><surname>Stone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Michelle</forename><forename type="middle">M</forename><surname>Triantos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Patrick</forename><surname>Quiroz</surname></persName>
		</author>
		<author>
			<persName><surname>Crowley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature Communications</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">4690</biblScope>
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Applications of machine learning in drug discovery and development</title>
		<author>
			<persName><forename type="first">Jessica</forename><surname>Vamathevan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dominic</forename><surname>Clark</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Paul</forename><surname>Czodrowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ian</forename><surname>Dunham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Edgardo</forename><surname>Ferran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">George</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Bin</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Anant</forename><surname>Madabhushi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Parantu</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Michaela</forename><surname>Spitzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Shanrong</forename><surname>Zhao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature Reviews Drug Discovery</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="463" to="477" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Pan-cancer computational histopathology reveals mutations, tumor composition and prognosis</title>
		<author>
			<persName><forename type="first">Yu</forename><surname>Fu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Alexander</forename><forename type="middle">W</forename><surname>Jung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ramon</forename><surname>Viñas Torne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Santiago</forename><surname>Gonzalez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Harald</forename><surname>Vöhringer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Artem</forename><surname>Shmatko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lucy</forename><forename type="middle">R</forename><surname>Yates</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mercedes</forename><surname>Jimenez-Linan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Luiza</forename><surname>Moore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Moritz</forename><surname>Gerstung</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature cancer</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="800" to="810" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Pan-cancer image-based detection of clinically actionable genetic alterations</title>
		<author>
			<persName><forename type="first">Jakob</forename><surname>Nikolas Kather</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lara</forename><forename type="middle">R</forename><surname>Heij</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Heike</forename><forename type="middle">I</forename><surname>Grabsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Chiara</forename><surname>Loeffler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Amelie</forename><surname>Echle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sophie</forename><surname>Hannah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jeremias</forename><surname>Muti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jan</forename><forename type="middle">M</forename><surname>Krause</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Kai Aj</forename><surname>Niehues</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Peter</forename><surname>Sommer</surname></persName>
		</author>
		<author>
			<persName><surname>Bankhead</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature Cancer</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="789" to="799" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<monogr>
		<title level="m" type="main">Genetic mutation and biological pathway prediction based on whole slide images in breast carcinoma using deep learning</title>
		<author>
			<persName><forename type="first">Hui</forename><surname>Qu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mu</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Zhennan</forename><surname>Yan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">He</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Vinod</forename><forename type="middle">K</forename><surname>Rustgi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Shaoting</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Olivier</forename><surname>Gevaert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dimitris</forename><forename type="middle">N</forename><surname>Metaxas</surname></persName>
		</author>
		<imprint>
			<publisher>npj Precision Oncology</publisher>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">2021</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Prediction of recurrence risk in endometrial cancer with multimodal deep learning</title>
		<author>
			<persName><forename type="first">Sarah</forename><surname>Volinsky-Fremond</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Nanda</forename><surname>Horeweg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sonali</forename><surname>Andani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jurriaan Barkey</forename><surname>Wolf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Maxime</forename><forename type="middle">W</forename><surname>Lafarge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Cor</forename><forename type="middle">D</forename><surname>De Kroon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Gitte</forename><surname>Ørtoft</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Estrid</forename><surname>Høgdall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jouke</forename><surname>Dijkstra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jan</forename><forename type="middle">J</forename><surname>Jobsen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature Medicine</title>
		<imprint>
			<biblScope unit="page" from="1" to="12" />
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<monogr>
		<title level="m" type="main">H&amp;e-based computational biomarker enables universal egfr screening for lung adenocarcinoma</title>
		<author>
			<persName><forename type="first">Gabriele</forename><surname>Campanella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">David</forename><surname>Ho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ida</forename><surname>Häggström</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Anton</forename><forename type="middle">S</forename><surname>Becker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jason</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Chad</forename><surname>Vanderbilt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Thomas</forename><forename type="middle">J</forename><surname>Fuchs</surname></persName>
		</author>
		<idno type="arXiv">arXiv:2206.10573</idno>
		<imprint>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="report_type">arXiv preprint</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">A systematic pan-cancer study on deep learning-based prediction of multi-omic biomarkers from routine pathology images</title>
		<author>
			<persName><forename type="first">Julian</forename><surname>Salim Arslan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Cher</forename><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Debapriya</forename><surname>Bass</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Andre</forename><surname>Mehrotra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Shikha</forename><surname>Geraldes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Julius</forename><surname>Singhal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Xiusi</forename><surname>Hense</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Pandu</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Oscar</forename><surname>Raharja-Liu</surname></persName>
		</author>
		<author>
			<persName><surname>Maiques</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Communications Medicine</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">48</biblScope>
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">The Cancer Genome Atlas Pan-Cancer analysis project</title>
		<author>
			<persName><forename type="first">Eric</forename><forename type="middle">A</forename><surname>John N Weinstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Gordon</forename><forename type="middle">B</forename><surname>Collisson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Kenna</forename><forename type="middle">R</forename><surname>Mills</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Brad</forename><forename type="middle">A</forename><surname>Shaw</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Kyle</forename><surname>Ozenberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ilya</forename><surname>Ellrott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Chris</forename><surname>Shmulevich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Joshua</forename><forename type="middle">M</forename><surname>Sander</surname></persName>
		</author>
		<author>
			<persName><surname>Stuart</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature genetics</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1113" to="1120" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">The impact of site-specific digital histology signatures on deep learning model accuracy and bias</title>
		<author>
			<persName><forename type="first">James</forename><surname>Frederick M Howard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sara</forename><surname>Dolezal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jefree</forename><surname>Kochanny</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Heather</forename><surname>Schulte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lara</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dezheng</forename><surname>Heij</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Rita</forename><surname>Huo</surname></persName>
		</author>
		<author>
			<persName><surname>Nanda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jakob</forename><forename type="middle">N</forename><surname>Olufunmilayo I Olopade</surname></persName>
		</author>
		<author>
			<persName><surname>Kather</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature communications</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">4423</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Deep Learning-Based Prediction of Molecular Tumor Biomarkers from H&amp;E: A Practical Review</title>
		<author>
			<persName><forename type="first">D</forename><surname>Heather</surname></persName>
		</author>
		<author>
			<persName><surname>Couture</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Personalized Medicine</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page">2022</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">A foundation model for clinical-grade computational pathology and rare cancers detection</title>
		<author>
			<persName><forename type="first">Eugene</forename><surname>Vorontsov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Alican</forename><surname>Bozkurt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Adam</forename><surname>Casson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">George</forename><surname>Shaikovski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Michal</forename><surname>Zelechowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Kristen</forename><surname>Severson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Eric</forename><surname>Zimmermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">James</forename><surname>Hall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Neil</forename><surname>Tenenholtz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Nicolo</forename><surname>Fusi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature Medicine</title>
		<imprint>
			<biblScope unit="page" from="1" to="12" />
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<monogr>
		<title level="m" type="main">Virchow 2: Scaling Self-Supervised Mixed Magnification Models in Pathology</title>
		<author>
			<persName><forename type="first">Eric</forename><surname>Zimmermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Eugene</forename><surname>Vorontsov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Julian</forename><surname>Viret</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Adam</forename><surname>Casson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Michal</forename><surname>Zelechowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">George</forename><surname>Shaikovski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Neil</forename><surname>Tenenholtz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">James</forename><surname>Hall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Thomas</forename><surname>Fuchs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Nicolo</forename><surname>Fusi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Siqi</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Kristen</forename><surname>Severson</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">My Cancer Genome: a unified genomics and clinical trial portal</title>
		<author>
			<persName><forename type="first">Charles</forename><surname>Swanton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The Lancet Oncology</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="668" to="669" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">My Cancer Genome: Coevolution of Precision Oncology and a Molecular Oncology Knowledgebase</title>
		<author>
			<persName><forename type="first">Marilyn</forename><forename type="middle">E</forename><surname>Holt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Kathleen</forename><forename type="middle">F</forename><surname>Mittendorf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Michele</forename><surname>Lenoue-Newton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Neha</forename><forename type="middle">M</forename><surname>Jain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ingrid</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Christine</forename><forename type="middle">M</forename><surname>Lovly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Travis</forename><surname>Osterman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Christine</forename><surname>Micheel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mia</forename><surname>Levy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JCO Clinical Cancer Informatics</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="995" to="1004" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">Debyani</forename><surname>Chakravarty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jianjiong</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Shaun</forename><forename type="middle">M</forename><surname>Phillips</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ritika</forename><surname>Kundra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hui</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jing</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Joshua</forename><forename type="middle">E</forename><surname>Rudolph</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Rona</forename><surname>Yaeger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Tenley</forename><surname>Soumerai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Moriah</forename><forename type="middle">H</forename><surname>Nissan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Michael</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Steven</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Garth</forename><surname>Kundel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Zachary</forename><surname>Fell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Radhika</forename><surname>Heins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ritu</forename><surname>Chandramohan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Agnes</forename><surname>Somwar</surname></persName>
		</author>
		<author>
			<persName><surname>Viale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Vasilis</forename><surname>David M Hyman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Anthony</forename><surname>Syrgkanis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Shaun</forename><surname>Funnell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Armin</forename><surname>Badges</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Wei</forename><surname>Danesh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Nils</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><surname>Weinhold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Marlies</forename><surname>Samuel F Bakhoum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lillian</forename><surname>Verstoep</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Laura</forename><surname>Nichols</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jessie</forename><surname>Borsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jill</forename><forename type="middle">P</forename><surname>Foo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Michael</forename><surname>Mesirov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Gustavo</forename><surname>Peto</surname></persName>
		</author>
		<author>
			<persName><surname>Rossi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Emek</forename><surname>Michael C Wendl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dora</forename><surname>Demir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Craig</forename><forename type="middle">H</forename><surname>Dias-Santagata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Marc</forename><surname>Mermel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Alan</forename><surname>Ladanyi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Boris</forename><surname>Ashworth</surname></persName>
		</author>
		<author>
			<persName><surname>Reva</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JCO Precision Oncology</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="1" to="16" />
			<date type="published" when="2017">2017</date>
			<publisher>David B Solit, and Nikolaus Schultz. OncoKB: A Precision Oncology Knowledge Base</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Advancements in Cancer Treatment: A Decade of Progress</title>
		<author>
			<persName><forename type="first">Jonathan</forename><forename type="middle">R</forename><surname>Suehnholz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Amanda</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hannah</forename><forename type="middle">Y</forename><surname>Samuel K Jackson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Michael</forename><forename type="middle">J</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Daniela</forename><surname>Thompson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sophia</forename><forename type="middle">L</forename><surname>Rivera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Vikram</forename><surname>Martinez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Emily</forename><forename type="middle">J</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Katherine</forename><forename type="middle">L</forename><surname>Moore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jason</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><surname>Liu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Discovery</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="789" to="805" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Microsatellite instability in noncolorectal and nonendometrial malignancies in patients with Lynch syndrome</title>
		<author>
			<persName><forename type="first">Lisa</forename><surname>Elze</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Rachel</forename><forename type="middle">S</forename><surname>Van Der Post</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Janet</forename><forename type="middle">R</forename><surname>Vos</surname></persName>
		</author>
		<author>
			<persName><surname>Arjen R Mensenkamp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Mirjam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Iris</forename><forename type="middle">D</forename><surname>De Hullu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Nicoline</forename><surname>Nagtegaal</surname></persName>
		</author>
		<author>
			<persName><surname>Hoogerbrugge</surname></persName>
		</author>
		<author>
			<persName><surname>Richarda M De</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Marjolijn Jl</forename><surname>Voer</surname></persName>
		</author>
		<author>
			<persName><surname>Ligtenberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JNCI: Journal of the National Cancer Institute</title>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="853" to="860" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">A genomics-driven artificial intelligencebased model classifies breast invasive lobular carcinoma and discovers cdh1 inactivating mechanisms</title>
		<author>
			<persName><forename type="first">Fresia</forename><surname>Pareja</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Higinio</forename><surname>Dopeso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yi</forename><surname>Kan Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Andrea</forename><forename type="middle">M</forename><surname>Gazzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">David</forename><forename type="middle">N</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Monami</forename><surname>Banerjee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Pier</forename><surname>Selenica</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jan</forename><forename type="middle">H</forename><surname>Bernhard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Fatemeh</forename><surname>Derakhshan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Edaise</surname></persName>
		</author>
		<author>
			<persName><surname>Da Silva</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Research</title>
		<imprint>
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">IDH-mutant are distinct and aggressive</title>
		<author>
			<persName><forename type="first">Abigail</forename><forename type="middle">K</forename><surname>Suwala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Marius</forename><surname>Felix</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dennis</forename><surname>Friedel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Damian</forename><surname>Stichel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Daniel</forename><surname>Schrimpf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Felix</forename><surname>Hinz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ekkehard</forename><surname>Hewer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Leonille</forename><surname>Schweizer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hildegard</forename><surname>Dohmen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ute</forename><surname>Pohl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Neuropathologica</title>
		<imprint>
			<biblScope unit="volume">143</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="263" to="281" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<monogr>
		<title level="m" type="main">Genomic and epigenomic basis of breast invasive lobular carcinomas lacking CDH1 genetic alterations. npj Precision Oncology</title>
		<author>
			<persName><forename type="first">Higinio</forename><surname>Dopeso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Andrea</forename><forename type="middle">M</forename><surname>Gazzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Fatemeh</forename><surname>Derakhshan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">David</forename><forename type="middle">N</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Pier</forename><surname>Selenica</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sahar</forename><surname>Jalali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Arnaud</forename><surname>Da</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Cruz</forename><surname>Paula</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Antonio</forename><surname>Marra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Edaise</forename><forename type="middle">M</forename><surname>Da Silva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Thais</forename><surname>Basili</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2024">2024</date>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">33</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Biomarker tests for molecularly targeted therapies-the key to unlocking precision medicine</title>
		<author>
			<persName><forename type="first">H</forename><surname>Gary</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Harold</forename><forename type="middle">L</forename><surname>Lyman</surname></persName>
		</author>
		<author>
			<persName><surname>Moses</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">New England Journal of Medicine</title>
		<imprint>
			<biblScope unit="volume">375</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="4" to="6" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors</title>
		<author>
			<persName><forename type="first">Changxia</forename><surname>Shao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Gerald</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lingkang</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Scott</forename><surname>Pruitt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Emily</forename><surname>Castellanos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Garrett</forename><surname>Frampton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Tamara</forename><surname>Kenneth R Carson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Gaurav</forename><surname>Snow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">David</forename><surname>Singal</surname></persName>
		</author>
		<author>
			<persName><surname>Fabrizio</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA Network Open</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="2025109" to="e2025109" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology</title>
		<author>
			<persName><forename type="first">T</forename><surname>Donavan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Talia</forename><forename type="middle">N</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ahmet</forename><surname>Mitchell</surname></persName>
		</author>
		<author>
			<persName><surname>Zehir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ronak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ryma</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Aijazuddin</forename><surname>Benayed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Raghu</forename><surname>Syed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Zhen</forename><surname>Chandramohan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yu</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Helen</forename><forename type="middle">H</forename><surname>Won</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Sasinya</surname></persName>
		</author>
		<author>
			<persName><surname>Scott</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The Journal of molecular diagnostics</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="251" to="264" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Pan-trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions</title>
		<author>
			<persName><forename type="first">Ryma</forename><surname>Jaclyn F Hechtman</surname></persName>
		</author>
		<author>
			<persName><surname>Benayed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Alexander</forename><surname>David M Hyman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ahmet</forename><surname>Drilon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Denise</forename><surname>Zehir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Maria</forename><forename type="middle">E</forename><surname>Frosina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Snjezana</forename><surname>Arcila</surname></persName>
		</author>
		<author>
			<persName><forename type="first">David</forename><forename type="middle">S</forename><surname>Dogan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Marc</forename><surname>Klimstra</surname></persName>
		</author>
		<author>
			<persName><surname>Ladanyi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The American journal of surgical pathology</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1547" to="1551" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Diagnosis of known sarcoma fusions and novel fusion partners by targeted RNA sequencing with identification of a recurrent ACTB-FOSB fusion in pseudomyogenic hemangioendothelioma</title>
		<author>
			<persName><forename type="first">Guo</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ryma</forename><surname>Benayed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Caleb</forename><surname>Ho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Kerry</forename><surname>Mullaney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Purvil</forename><surname>Sukhadia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Kelly</forename><surname>Rios</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ryan</forename><surname>Berry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Brian</forename><forename type="middle">P</forename><surname>Rubin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Khedoudja</forename><surname>Nafa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lu</forename><surname>Wang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Modern Pathology</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="609" to="620" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Decoupled Weight Decay Regularization</title>
		<author>
			<persName><forename type="first">Ilya</forename><surname>Loshchilov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Frank</forename><surname>Hutter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">International Conference on Learning Representations</title>
		<imprint>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution</title>
		<author>
			<persName><forename type="first">Vincenzo</forename><surname>Di Nunno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lidia</forename><surname>Gatto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Alicia</forename><surname>Tosoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Stefania</forename><surname>Bartolini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Enrico</forename><surname>Franceschi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Frontiers in Oncology</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">1067252</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Brafv600e-mutant metastatic nsclc: disease overview and treatment landscape</title>
		<author>
			<persName><forename type="first">David</forename><surname>Planchard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Rachel</forename><forename type="middle">E</forename><surname>Sanborn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Marcelo</forename><forename type="middle">V</forename><surname>Negrao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Aria</forename><surname>Vaishnavi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Egbert</forename><forename type="middle">F</forename><surname>Smit</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">NPJ Precision Oncology</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">90</biblScope>
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Tumor heterogeneity in VHL drives metastasis in clear cell renal cell carcinoma</title>
		<author>
			<persName><forename type="first">Junhui</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ping</forename><surname>Tan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Moe</forename><surname>Ishihara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Nicholas</forename><forename type="middle">A</forename><surname>Bayley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Shiruyeh</forename><surname>Schokrpur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jeremy</forename><forename type="middle">G</forename><surname>Reynoso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yangjun</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Raymond</forename><forename type="middle">J</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Camelia</forename><surname>Dumitras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lu</forename><surname>Yang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Signal Transduction and Targeted Therapy</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">155</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">VHL mutation drives human clear cell renal cell carcinoma progression through PI3K/AKT-dependent cholesteryl ester accumulation</title>
		<author>
			<persName><forename type="first">Shuo</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Tinghe</forename><surname>Fang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yexuan</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Weichen</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Zhuoyang</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yaoyao</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Chi</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Shuai</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Zhuojun</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jia</forename><surname>Liu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ebiomedicine</title>
		<imprint>
			<biblScope unit="page">103</biblScope>
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">Kyung</forename><surname>Joo</surname></persName>
		</author>
		<author>
			<persName><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hyun</forename><surname>Woo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Kyoungbun</forename><surname>Paik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ji</forename><forename type="middle">Kon</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sang</forename><surname>Ryu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yong-Tae</forename><surname>Hyub Lee</surname></persName>
		</author>
		<author>
			<persName><surname>Kim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncotarget</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">30</biblScope>
			<biblScope unit="page">49796</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">FISH Diagnostic Assessment of MDM2 Amplification in Liposarcoma: Potential Pitfalls and Troubleshooting Recommendations</title>
		<author>
			<persName><forename type="first">Alessandro</forename><surname>Gambella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Luca</forename><surname>Bertero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Milena</forename><surname>Rondón-Lagos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ludovica</forename><surname>Verdun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Di</forename><surname>Cantogno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Nelson</forename><surname>Rangel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Chiara</forename><surname>Pitino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Andrea</forename><surname>Alessia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Luca</forename><surname>Ricci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Isabella</forename><surname>Mangherini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Paola</forename><surname>Castellano</surname></persName>
		</author>
		<author>
			<persName><surname>Cassoni</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">International Journal of Molecular Sciences</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">1342</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">MDM2 Amplified Sarcomas: A Literature Review</title>
		<author>
			<persName><forename type="first">Raf</forename><surname>Sciot</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diagnostics</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page">496</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<monogr>
		<title level="m" type="main">Multi-site desmoplastic small round cell tumors are genetically related and immune-cold</title>
		<author>
			<persName><forename type="first">Chia-Chin</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hannah</forename><forename type="middle">C</forename><surname>Beird</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Salah-Eddine</forename><surname>Lamhamedi-Cherradi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Melinda</forename><surname>Soeung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Davis</forename><surname>Ingram</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Danh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Robert</forename><forename type="middle">W</forename><surname>Truong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sandhya</forename><surname>Porter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Latasha</forename><surname>Krishnan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Curtis</forename><surname>Little</surname></persName>
		</author>
		<author>
			<persName><surname>Gumbs</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2022">2022</date>
			<publisher>npj Precision Oncology</publisher>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">21</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition</title>
		<author>
			<persName><forename type="first">Yuanwang</forename><surname>Pan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Han</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hai</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hua</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yueqiang</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yuan</forename><surname>Hao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Xinyuan</forename><surname>Tong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ayushi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Selim</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sittinon</forename><surname>Misirlioglu</surname></persName>
		</author>
		<author>
			<persName><surname>Tang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Cell</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="88" to="105" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">A predominant enhancer co-amplified with the SOX2 oncogene is necessary and sufficient for its expression in squamous cancer</title>
		<author>
			<persName><forename type="first">Yanli</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Zhong</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jin</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Dinesh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Katelyn</forename><forename type="middle">L</forename><surname>Ramadurai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Estrella</forename><surname>Mortenson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yifei</forename><surname>Aguilera-Jimenez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Xiaojun</forename><surname>Yan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Alison</forename><forename type="middle">M</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Katherine</forename><forename type="middle">E</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName><surname>Varley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature Communications</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">7139</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell Carcinoma</title>
		<author>
			<persName><forename type="first">Kazuaki</forename><surname>Takahashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Masataka</forename><surname>Takenaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Aikou</forename><surname>Okamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">David</forename><forename type="middle">Dl</forename><surname>Bowtell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Takashi</forename><surname>Kohno</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancers</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page">1769</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
